cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"I have processed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) to evaluate the tumor immune microenvironment and predict response to atezolizumab. The patient’s details are as follows: male, white, bladder tissue origin, and a tumor mutational burden of 18.0 mutations per megabase. Based on this information, could you provide an analysis predicting whether the patient is likely to respond to atezolizumab and explain the reasoning behind your assessment?","I have processed mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA) to evaluate the tumor immune microenvironment and predict response to atezolizumab. The patient’s details are as follows: male, white, bladder tissue origin, and a tumor mutational burden of 18.0 mutations per megabase. Based on this information, could you provide an analysis predicting whether the patient is likely to respond to atezolizumab and explain the reasoning behind your assessment? Analyze the tumor microenvironment’s transcriptomic profile with the COMPASS tool to forecast the patient’s treatment response. Specifically, assess markers associated with decreased immune function (including natural killer cells, exhausted T cells, and general B-cell activity) alongside markers that reflect enhanced immune function (such as macrophage activity, the IFNG signaling pathway, and indicators of genomic integrity). Then, integrate these markers with the COMPASS output to construct a well-supported, evidence-based assessment of the patient's likely treatment response, highlighting how each transcriptomic feature informs the overall interpretation of immune activity.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"Based on processed mRNA TPM data from a patient's tumor immune microenvironment, how would you assess the likelihood of response to Atezolizumab in a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) with a tumor mutational burden of 1.0 mutation per megabase? Please provide a detailed conclusion along with the supporting rationale for classifying the patient as a responder or non-responder.","Based on processed mRNA TPM data from a patient's tumor immune microenvironment, how would you assess the likelihood of response to Atezolizumab in a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) with a tumor mutational burden of 1.0 mutation per megabase? Please provide a detailed conclusion along with the supporting rationale for classifying the patient as a responder or non-responder. Evaluate the transcriptomic profile of the tumor microenvironment using the COMPASS tool to predict the patient's treatment response. Focus on both immune-suppressive markers (including those for natural killer cells, exhausted T cells, and overall B-cell activity) and immune-activating indicators (such as macrophage activity, the IFNG signaling pathway, and measures of genomic integrity). Then, integrate these data with the COMPASS output to deliver an evidence-based assessment of the likely treatment response, clearly explaining how each transcriptomic feature contributes to the overall interpretation of immune activity.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"I have processed mRNA TPM data that characterizes the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), and I would like to evaluate their predicted response to Atezolizumab. The patient is a white female with bladder tissue involvement, BLCA diagnosis, and a tumor mutational burden of 44.0 mutations per megabase. Based on these parameters, can you provide an assessment of whether the patient is likely to be a responder or non-responder to Atezolizumab, along with the rationale for your conclusion?","I have processed mRNA TPM data that characterizes the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), and I would like to evaluate their predicted response to Atezolizumab. The patient is a white female with bladder tissue involvement, BLCA diagnosis, and a tumor mutational burden of 44.0 mutations per megabase. Based on these parameters, can you provide an assessment of whether the patient is likely to be a responder or non-responder to Atezolizumab, along with the rationale for your conclusion? Use the COMPASS tool to assess the tumor microenvironment’s gene expression profile with the goal of predicting the patient’s treatment response. Review both immune-suppressive markers (for example, those indicating natural killer cell function, T cell exhaustion, and overall B-cell activity) as well as immune-activating signals (such as macrophage activity, IFNG pathway signaling, and indicators of genomic integrity). Then, combine these findings with the COMPASS output to provide a clear, evidence-based evaluation of treatment response, explaining the role each transcriptomic feature plays in the overall immune landscape.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"Given mRNA TPM data profiling the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you evaluate the predicted responsiveness to Atezolizumab? The patient in question is a  (F)emale, White individual with a tumor sample from a lymph node and a tumor mutational burden of 2.0 mutations per MB. Please provide a conclusion on whether this patient is likely to respond to Atezolizumab, along with detailed reasoning for your assessment.","Given mRNA TPM data profiling the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you evaluate the predicted responsiveness to Atezolizumab? The patient in question is a  (F)emale, White individual with a tumor sample from a lymph node and a tumor mutational burden of 2.0 mutations per MB. Please provide a conclusion on whether this patient is likely to respond to Atezolizumab, along with detailed reasoning for your assessment. Please use the COMPASS tool to analyze the tumor microenvironment’s gene expression profile to forecast the patient's treatment response. Begin by evaluating markers that indicate immune suppression (including those related to natural killer cell function, T cell exhaustion, and overall B-cell activity), as well as those suggesting immune activation (such as macrophage activity, IFNG pathway signaling, and markers of genomic integrity). Then, integrate these findings with the COMPASS output to deliver an evidence-based assessment of treatment response, highlighting how each transcriptomic feature influences the immune landscape.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"Based on the available mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma, along with the clinical parameters (male, White, bladder tissue involvement, and a tumor mutational burden of 8.0 mutations per megabase), how would you assess this patient’s predicted responsiveness to Atezolizumab? Please provide a conclusion on whether this patient is likely to be a responder or non-responder, and include the supporting scientific rationale for your assessment.","Based on the available mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma, along with the clinical parameters (male, White, bladder tissue involvement, and a tumor mutational burden of 8.0 mutations per megabase), how would you assess this patient’s predicted responsiveness to Atezolizumab? Please provide a conclusion on whether this patient is likely to be a responder or non-responder, and include the supporting scientific rationale for your assessment. Please employ the COMPASS tool to evaluate the tumor microenvironment's gene expression profile for predicting the patient's treatment response. Begin by assessing markers of immune suppression—including those related to natural killer cell function, T cell exhaustion, and B-cell activity—as well as markers of immune activation, such as macrophage activity, IFNG pathway signaling, and indicators of genomic integrity. Next, integrate these results with the COMPASS output to provide an evidence-based assessment, detailing how each transcriptomic feature affects the overall immune landscape and treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), and I would like to assess the predicted response to atezolizumab therapy. The patient's details are as follows: Female, White, bladder tissue involvement, BLCA diagnosis, and a tumor mutational burden of 6.0 mutations per megabase. Based on these data, could you please determine whether the patient is likely to be a responder or non-responder to atezolizumab, and provide the rationale for this assessment?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA), and I would like to assess the predicted response to atezolizumab therapy. The patient's details are as follows: Female, White, bladder tissue involvement, BLCA diagnosis, and a tumor mutational burden of 6.0 mutations per megabase. Based on these data, could you please determine whether the patient is likely to be a responder or non-responder to atezolizumab, and provide the rationale for this assessment? Use the COMPASS tool to assess the gene expression profile of the tumor microenvironment to predict treatment response. Start by evaluating markers associated with immune suppression—such as those indicating natural killer cell function, T cell exhaustion, and B-cell activity—and markers of immune activation, such as macrophage activity, IFNG pathway signaling, and measures of genomic integrity. Then, combine these results with the COMPASS output to produce an evidence-based evaluation that explains how each transcriptomic feature contributes to the overall immune landscape and influences treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"Based on the patient's mRNA TPM data reflecting the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following clinical details—male sex, white race, kidney tissue involvement, and a tumor mutational burden of 11.0 mutations per megabase—could you determine whether this patient is likely to respond to atezolizumab? Please include supporting clinical reasoning in your assessment.","Based on the patient's mRNA TPM data reflecting the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following clinical details—male sex, white race, kidney tissue involvement, and a tumor mutational burden of 11.0 mutations per megabase—could you determine whether this patient is likely to respond to atezolizumab? Please include supporting clinical reasoning in your assessment. Please use the COMPASS tool to evaluate the tumor microenvironment's gene expression profile for predicting the response to treatment. Begin by assessing markers of immune suppression (including indicators of natural killer cell function, T cell exhaustion, and B-cell activity) along with markers of immune activation (such as macrophage activity, IFNG pathway signaling, and genomic integrity measures). Next, integrate these findings with the overall COMPASS output to create a detailed, evidence-based report that explains how each transcriptomic feature contributes to the tumor’s immune landscape and affects treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"I have mRNA TPM expression data from a patient with bladder urothelial carcinoma. The patient is a white male with a bladder tumor and a tumor mutational burden of 18.0 mutations per megabase. Based on these data, could you assess whether the patient is likely to respond to Atezolizumab, and provide detailed reasoning to support your conclusion?","I have mRNA TPM expression data from a patient with bladder urothelial carcinoma. The patient is a white male with a bladder tumor and a tumor mutational burden of 18.0 mutations per megabase. Based on these data, could you assess whether the patient is likely to respond to Atezolizumab, and provide detailed reasoning to support your conclusion? Evaluate the tumor's gene expression profile using the COMPASS tool to predict treatment response. Begin by assessing immune suppression markers—including natural killer cell function, T cell exhaustion, and B-cell activity—and immune activation markers such as macrophage activity, IFNG pathway signaling, and genomic integrity. Then, combine these findings with the overall COMPASS output to develop a comprehensive, evidence-based report detailing how each transcriptomic feature shapes the tumor’s immune landscape and influences treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"I have analyzed the mRNA TPM data for a female patient with bladder urothelial carcinoma (BLCA), focusing on the tumor immune microenvironment. The patient is white, and the tumor tissue is from the bladder. Note that the tumor mutational burden data (FMOne mutation burden per MB) is not available. Based on the provided molecular and clinical details, can you determine whether the patient is predicted to respond to Atezolizumab, and please explain the reasoning behind this prediction?","I have analyzed the mRNA TPM data for a female patient with bladder urothelial carcinoma (BLCA), focusing on the tumor immune microenvironment. The patient is white, and the tumor tissue is from the bladder. Note that the tumor mutational burden data (FMOne mutation burden per MB) is not available. Based on the provided molecular and clinical details, can you determine whether the patient is predicted to respond to Atezolizumab, and please explain the reasoning behind this prediction? Begin by using the COMPASS tool to analyze the tumor's gene expression profile for predicting treatment response. First, review markers of immune suppression—specifically, indicators of natural killer cell activity, T cell exhaustion, and B-cell function—as well as markers of immune activation, including macrophage activity, IFNG pathway signaling, and measures of genomic integrity. Then, integrate these findings with the overall COMPASS output to create a detailed, evidence-backed report that explains how each transcriptomic feature contributes to the tumor’s immune environment and impacts treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"Based on processed mRNA TPM data assessing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma, how would you predict the patient's responsiveness to Atezolizumab (i.e., classify them as a responder or non-responder)? The available patient details are: Male, White, with missing data for tissue type and tumor mutational burden. Please provide a conclusion along with the supporting rationale.","Based on processed mRNA TPM data assessing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma, how would you predict the patient's responsiveness to Atezolizumab (i.e., classify them as a responder or non-responder)? The available patient details are: Male, White, with missing data for tissue type and tumor mutational burden. Please provide a conclusion along with the supporting rationale. Use the COMPASS tool to evaluate the tumor's gene expression profile with the goal of predicting treatment response. First, assess markers of immune suppression—specifically, natural killer cell activity, T cell exhaustion, and B-cell function—as well as markers of immune activation, which include macrophage activity, IFNG pathway signaling, and indicators of genomic integrity. Then, combine these results with the overall COMPASS analysis to prepare a detailed, evidence-based report that explains how each transcriptomic feature shapes the tumor’s immune environment and influences treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) to characterize the tumor immune microenvironment and assess the likelihood of response to Atezolizumab. The patient is a white male with tissue classified as kidney, a diagnosis of BLCA, and a tumor mutational burden of 2.0 FMOne mutations per MB. Could you provide a conclusion on whether this patient is expected to be a responder or non-responder to Atezolizumab, along with the supporting rationale?","I have analyzed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) to characterize the tumor immune microenvironment and assess the likelihood of response to Atezolizumab. The patient is a white male with tissue classified as kidney, a diagnosis of BLCA, and a tumor mutational burden of 2.0 FMOne mutations per MB. Could you provide a conclusion on whether this patient is expected to be a responder or non-responder to Atezolizumab, along with the supporting rationale? Utilize the COMPASS tool to analyze the tumor’s gene expression profile and predict treatment response. Begin by evaluating markers of immune suppression—such as natural killer cell activity, T cell exhaustion, and B-cell function—as well as markers of immune activation—including macrophage activity, IFNG pathway signaling, and genomic integrity indicators. Then, integrate these findings with the overall COMPASS analysis to produce a detailed, evidence-based report that describes how each transcriptomic feature influences the tumor’s immune environment and impacts treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient profile is as follows: male, white, with bladder tissue, and a tumor mutational burden of 8.0 mutations per MB. Could you provide an evaluation on whether this patient is predicted to respond to Atezolizumab, and explain the rationale behind this assessment?","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient profile is as follows: male, white, with bladder tissue, and a tumor mutational burden of 8.0 mutations per MB. Could you provide an evaluation on whether this patient is predicted to respond to Atezolizumab, and explain the rationale behind this assessment? Please use the COMPASS tool to examine the tumor's gene expression profile and forecast its response to treatment. Start by assessing immune suppression markers (such as natural killer cell activity, T cell exhaustion, and B-cell function) along with immune activation markers (including macrophage activity, IFNG pathway signaling, and indicators of genomic integrity). Then, combine these results with the overall COMPASS analysis to generate a comprehensive, evidence-based report that details how each transcriptomic feature affects the tumor's immune landscape and influences treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"Based on the patient’s mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), could you assess her likelihood of responding to atezolizumab? The patient is a White female, with tissue obtained from a lymph node, and her tumor mutational burden (FMOne mutations per MB) is not available. Please classify her as a responder or non-responder and provide the underlying rationale for your assessment.","Based on the patient’s mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), could you assess her likelihood of responding to atezolizumab? The patient is a White female, with tissue obtained from a lymph node, and her tumor mutational burden (FMOne mutations per MB) is not available. Please classify her as a responder or non-responder and provide the underlying rationale for your assessment. Please utilize the COMPASS tool to analyze the tumor’s gene expression profile and predict its treatment response. Begin by evaluating markers related to immune suppression (for example, natural killer cell activity, T-cell exhaustion, and B-cell function) as well as markers of immune activation (including macrophage function, interferon-gamma pathway signaling, and measures of genomic integrity). Next, integrate these findings with the overall COMPASS analysis to produce a detailed, evidence-based report that explains how each transcriptomic feature shapes the tumor’s immune microenvironment and affects treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"I have analyzed mRNA TPM data from a ureter tissue sample of a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 9 mutations per MB. Based on these data and considering Atezolizumab treatment, could you provide an assessment of this patient’s likelihood of being a responder, along with the supporting rationale for your conclusion?","I have analyzed mRNA TPM data from a ureter tissue sample of a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 9 mutations per MB. Based on these data and considering Atezolizumab treatment, could you provide an assessment of this patient’s likelihood of being a responder, along with the supporting rationale for your conclusion? Please use the COMPASS tool to assess the tumor’s gene expression profile in order to predict its response to treatment. Start by examining immune suppressive markers (such as natural killer cell activity, T-cell exhaustion, and B-cell function) alongside markers indicative of immune activation (including macrophage function, interferon-gamma signaling, and genomic integrity). Then, combine these results with the overall COMPASS analysis to generate a comprehensive, evidence-based report that details how each transcriptomic characteristic influences the tumor’s immune microenvironment and subsequent treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"A patient with Bladder Urothelial Carcinoma (BLCA), who is a white female with bladder tissue involvement and a tumor mutational burden of 4.0 mutations per megabase, has had her tumor immune microenvironment assessed using mRNA TPM data. Based on these molecular and clinical details, can you determine whether she is likely to respond to Atezolizumab, and please explain the supporting rationale?","A patient with Bladder Urothelial Carcinoma (BLCA), who is a white female with bladder tissue involvement and a tumor mutational burden of 4.0 mutations per megabase, has had her tumor immune microenvironment assessed using mRNA TPM data. Based on these molecular and clinical details, can you determine whether she is likely to respond to Atezolizumab, and please explain the supporting rationale? Use the COMPASS tool to analyze the tumor’s gene expression profile for treatment response prediction. Begin by evaluating immune suppressive markers (such as natural killer cell activity, T-cell exhaustion, and B-cell function) alongside immune activation indicators (including macrophage function, interferon-gamma signaling, and genomic integrity). Then, integrate these findings into the overall COMPASS analysis to produce a comprehensive, evidence-based report that explains how each transcriptomic factor influences the tumor’s immune microenvironment and its response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"Based on the processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), could you assess whether this patient is likely to respond to Atezolizumab therapy? The patient is a white male with a ureteral tumor and a tumor mutational burden of 32 mutations per megabase. Please provide a conclusion regarding responder status along with the supporting rationale.","Based on the processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), could you assess whether this patient is likely to respond to Atezolizumab therapy? The patient is a white male with a ureteral tumor and a tumor mutational burden of 32 mutations per megabase. Please provide a conclusion regarding responder status along with the supporting rationale. Use the COMPASS tool to assess the tumor's gene expression profile for predicting treatment response. Start by examining markers that indicate immune suppression (for example, natural killer cell activity, T-cell exhaustion, and B-cell function) as well as markers of immune activation (including macrophage function, interferon-gamma signaling, and genomic integrity). Then, incorporate these results into the overall COMPASS evaluation to create a comprehensive, evidence-based report detailing how each transcriptomic factor affects the tumor’s immune microenvironment and its potential response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma, and I would like to evaluate the predicted responsiveness to atezolizumab. The patient is a white male with a bladder tumor and a tumor mutational burden of 21 mutations per megabase. Based on these details, can you determine whether the patient is likely to respond to atezolizumab and provide a rationale for your conclusion?","I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma, and I would like to evaluate the predicted responsiveness to atezolizumab. The patient is a white male with a bladder tumor and a tumor mutational burden of 21 mutations per megabase. Based on these details, can you determine whether the patient is likely to respond to atezolizumab and provide a rationale for your conclusion? Please use the COMPASS tool to evaluate the tumor's gene expression profile. Begin by assessing markers of immunosuppression (such as natural killer cell activity, T-cell exhaustion, and B-cell function) alongside markers of immune activation (including macrophage function, interferon-gamma signaling, and genomic integrity). Then, integrate these findings into the overall COMPASS analysis to develop an evidence-based report that clearly outlines how each transcriptomic factor impacts the tumor's immune microenvironment and its potential response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"Given the patient's mRNA TPM data reflecting the tumor immune microenvironment for BLCA, along with the clinical details (male, white, kidney tissue origin, Bladder Urothelial Carcinoma diagnosis, and a tumor mutational burden of 10 mutations/MB), can you conclude whether this patient would be classified as a responder or non-responder to Atezolizumab? Please include your supporting rationale.","Given the patient's mRNA TPM data reflecting the tumor immune microenvironment for BLCA, along with the clinical details (male, white, kidney tissue origin, Bladder Urothelial Carcinoma diagnosis, and a tumor mutational burden of 10 mutations/MB), can you conclude whether this patient would be classified as a responder or non-responder to Atezolizumab? Please include your supporting rationale. Use the COMPASS tool to assess the tumor's gene expression profile. Start by evaluating immunosuppressive markers, including natural killer cell activity, T-cell exhaustion, and B-cell function, as well as markers of immune activation, such as macrophage function, interferon-gamma signaling, and genomic integrity. Then, incorporate these results into the overall COMPASS analysis to generate an evidence-based report that details the influence of each transcriptomic factor on the tumor's immune microenvironment and its potential response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"For a patient with bladder urothelial carcinoma (BLCA)—male, White, with bladder tissue and a tumor mutational burden of 38 mutations/MB—based on processed mRNA TPM data of the tumor immune microenvironment, would you classify this patient as a responder or non-responder to atezolizumab? Please include the clinical reasoning supporting your conclusion.","For a patient with bladder urothelial carcinoma (BLCA)—male, White, with bladder tissue and a tumor mutational burden of 38 mutations/MB—based on processed mRNA TPM data of the tumor immune microenvironment, would you classify this patient as a responder or non-responder to atezolizumab? Please include the clinical reasoning supporting your conclusion. Please use the COMPASS diagnostic tool to evaluate the tumor’s gene expression profile. Initially, assess immunosuppressive markers (natural killer cell activity, T-cell exhaustion, and B-cell function) alongside indicators of immune activation (macrophage function, interferon-gamma signaling, and genomic integrity). Then, integrate these findings into the overall COMPASS analysis to create an evidence-supported report that explains how each transcriptomic factor may affect the tumor’s immune microenvironment and its anticipated response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"Based on the mRNA TPM data for the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and given the following clinical details—female sex, white race, bladder tissue tumor origin, and a tumor mutational burden of 7.0 mutations per MB—can you determine whether this patient is more likely to respond to Atezolizumab, and provide the clinical reasoning behind that prediction?","Based on the mRNA TPM data for the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) and given the following clinical details—female sex, white race, bladder tissue tumor origin, and a tumor mutational burden of 7.0 mutations per MB—can you determine whether this patient is more likely to respond to Atezolizumab, and provide the clinical reasoning behind that prediction? Please use the COMPASS diagnostic tool to analyze the tumor’s gene expression profile. Begin by evaluating immunosuppressive markers (including natural killer cell activity, T-cell exhaustion, and B-cell function) as well as markers of immune activation (such as macrophage activity, interferon-gamma signaling, and indicators of genomic integrity). Then, incorporate these results into your overall COMPASS assessment and prepare a report detailing how each transcriptomic factor may influence the immune microenvironment and the tumor’s likely response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a bladder tumor and a tumor mutational burden of 5.0 (FMOne mutation burden per MB). Based on these clinical and molecular characteristics, could you assess the predicted responsiveness to Atezolizumab and provide your supporting rationale for classifying the patient as a responder or non-responder?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a bladder tumor and a tumor mutational burden of 5.0 (FMOne mutation burden per MB). Based on these clinical and molecular characteristics, could you assess the predicted responsiveness to Atezolizumab and provide your supporting rationale for classifying the patient as a responder or non-responder? Use the COMPASS diagnostic tool to evaluate the tumor’s gene expression profile. Start by assessing immunosuppressive markers—such as natural killer cell activity, T-cell exhaustion, and B-cell function—and immune activation markers, including macrophage activity, interferon-gamma signaling, and genomic integrity indicators. Then, integrate these findings into your overall COMPASS evaluation and prepare a detailed report that explains how each transcriptomic factor may affect the tumor’s immune microenvironment and its expected response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"I have a patient with Bladder Urothelial Carcinoma whose mRNA TPM data characterizes the tumor immune microenvironment. The patient is male, white, with bladder tissue involvement, and has a tumor mutational burden of 15 mutations per megabase. Could you please assess the likelihood of this patient responding to Atezolizumab and provide the rationale behind your conclusion based on these clinical parameters?","I have a patient with Bladder Urothelial Carcinoma whose mRNA TPM data characterizes the tumor immune microenvironment. The patient is male, white, with bladder tissue involvement, and has a tumor mutational burden of 15 mutations per megabase. Could you please assess the likelihood of this patient responding to Atezolizumab and provide the rationale behind your conclusion based on these clinical parameters? Please use the COMPASS diagnostic tool to assess the tumor’s gene expression profile. Begin by evaluating immunosuppressive markers—specifically natural killer cell activity, T-cell exhaustion, and B-cell function—as well as immune activation markers, such as macrophage activity, interferon-gamma signaling, and indicators of genomic integrity. Once these assessments are complete, integrate the findings into your overall COMPASS evaluation. Finally, prepare a detailed report that outlines how each transcriptomic factor may influence the tumor’s immune microenvironment and its anticipated response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"Given a male, white patient with Bladder Urothelial Carcinoma (BLCA) who has been profiled using mRNA TPM data of the tumor immune microenvironment (with kidney tissue as the source), and noting that the Tumor Mutational Burden data is unavailable, how would you assess the likelihood of responsiveness to Atezolizumab? Please provide your conclusion along with the supporting rationale for classifying this patient as a responder or non-responder.","Given a male, white patient with Bladder Urothelial Carcinoma (BLCA) who has been profiled using mRNA TPM data of the tumor immune microenvironment (with kidney tissue as the source), and noting that the Tumor Mutational Burden data is unavailable, how would you assess the likelihood of responsiveness to Atezolizumab? Please provide your conclusion along with the supporting rationale for classifying this patient as a responder or non-responder. Please utilize the COMPASS diagnostic tool to evaluate the tumor’s gene expression profile. Start by assessing immunosuppressive markers—including natural killer cell activity, signs of T-cell exhaustion, and B-cell function—as well as immune activation markers such as macrophage activity, interferon-gamma signaling, and measures of genomic integrity. Once these specific evaluations are completed, integrate the results into your overall COMPASS assessment. Finally, generate a comprehensive report that details the impact of each transcriptomic factor on the tumor’s immune microenvironment and its potential response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/181b63-ar-181b638.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data characterizing the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male, with a lung tissue sample, and the tumor mutational burden is unavailable. Based on this data, could you assess whether the patient is likely to respond to Atezolizumab and provide the rationale for your conclusion?","I have processed mRNA TPM data characterizing the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male, with a lung tissue sample, and the tumor mutational burden is unavailable. Based on this data, could you assess whether the patient is likely to respond to Atezolizumab and provide the rationale for your conclusion? Please use the COMPASS diagnostic tool to analyze the tumor's gene expression profile. Begin by evaluating immunosuppressive markers—such as natural killer cell activity, indicators of T-cell exhaustion, and B-cell function—as well as immune activation markers like macrophage activity, interferon-gamma signaling, and genomic integrity measures. After completing these specific assessments, incorporate your findings into the overall COMPASS evaluation. Finally, compile a detailed report that explains how each measured transcriptomic factor impacts the tumor’s immune microenvironment and its potential response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"Based on this patient's processed mRNA TPM data of the tumor immune microenvironment for bladder urothelial carcinoma, along with the following details—Sex: Male; Race: White; Tissue: Bladder; Disease: BLCA; and Tumor Mutational Burden: 18 mutations/MB—could you provide an assessment of the predicted responsiveness to Atezolizumab? Please include your reasoning in determining whether the patient is more likely to be a responder or a non-responder.","Based on this patient's processed mRNA TPM data of the tumor immune microenvironment for bladder urothelial carcinoma, along with the following details—Sex: Male; Race: White; Tissue: Bladder; Disease: BLCA; and Tumor Mutational Burden: 18 mutations/MB—could you provide an assessment of the predicted responsiveness to Atezolizumab? Please include your reasoning in determining whether the patient is more likely to be a responder or a non-responder. Please perform a gene expression analysis of the tumor using the COMPASS diagnostic tool. Begin by measuring immunosuppressive factors—such as natural killer cell activity, T-cell exhaustion markers, and B-cell functionality—as well as markers of immune activation, including macrophage activity, interferon-gamma signaling, and measures of genomic integrity. Once these assessments are completed, integrate your findings into the overall COMPASS evaluation. Finally, prepare a comprehensive report detailing how each transcriptomic factor contributes to the tumor's immune microenvironment and may influence its therapy response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"Based on mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), along with clinical attributes (male, Black or African American, ureter tissue sample, and a tumor mutational burden of 7.0 mutations per MB), how would you classify this patient’s predicted responsiveness to atezolizumab? Please provide your conclusion and explain the reasoning behind it.","Based on mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), along with clinical attributes (male, Black or African American, ureter tissue sample, and a tumor mutational burden of 7.0 mutations per MB), how would you classify this patient’s predicted responsiveness to atezolizumab? Please provide your conclusion and explain the reasoning behind it. Please use the COMPASS diagnostic tool to perform a comprehensive gene expression analysis of the tumor. Start by evaluating immunosuppressive parameters (including natural killer cell activity, markers of T-cell exhaustion, and B-cell functionality) as well as indicators of immune activation (such as macrophage activity, interferon-gamma signaling, and measures of genomic integrity). After completing these assessments, integrate the results into the overall COMPASS evaluation. Finally, prepare a detailed report that explains how each of these transcriptomic factors influences the tumor’s immune microenvironment and potentially affects its response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"Based on the mRNA TPM data of the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 19 mutations per MB, could you determine whether this patient is likely to respond to Atezolizumab, and please explain the reasoning behind your assessment?","Based on the mRNA TPM data of the tumor immune microenvironment for a male, white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 19 mutations per MB, could you determine whether this patient is likely to respond to Atezolizumab, and please explain the reasoning behind your assessment? Utilize the COMPASS diagnostic tool to conduct a detailed gene expression analysis of the tumor. Begin by assessing immunosuppressive markers—including natural killer cell activity, T-cell exhaustion indicators, and B-cell functionality—as well as indicators of immune activation, such as macrophage activity, interferon-gamma signaling, and genomic integrity. Once these evaluations are complete, integrate all findings into the overall COMPASS assessment. Finally, compile a comprehensive report that explains how each transcriptomic factor impacts the tumor’s immune microenvironment and its potential influence on therapy response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"For a male, Caucasian patient with Bladder Urothelial Carcinoma (bladder tissue) and a tumor mutational burden of 5.0 mutations/MB, can we determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale based on the mRNA TPM data representing the tumor immune microenvironment.","For a male, Caucasian patient with Bladder Urothelial Carcinoma (bladder tissue) and a tumor mutational burden of 5.0 mutations/MB, can we determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale based on the mRNA TPM data representing the tumor immune microenvironment. Please use the COMPASS diagnostic tool to perform a comprehensive gene expression assessment of the tumor. Start by evaluating immunosuppressive markers, including natural killer cell activity, indicators of T-cell exhaustion, and B-cell functionality. Also, assess markers of immune activation, such as macrophage activity, interferon-gamma signaling, and overall genomic integrity. Once these evaluations are complete, integrate all the data into the overall COMPASS assessment and generate a detailed report. This report should clearly describe how each transcriptomic factor influences the tumor’s immune microenvironment and its potential effect on the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"Based on mRNA TPM data from the patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you evaluate the predicted response to Atezolizumab? The patient is a white male with bladder tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 5.0 mutations per megabase. Please provide your conclusion on whether this patient is likely to be a responder or non-responder, including your supporting rationale.","Based on mRNA TPM data from the patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you evaluate the predicted response to Atezolizumab? The patient is a white male with bladder tissue involvement, a diagnosis of BLCA, and a tumor mutational burden of 5.0 mutations per megabase. Please provide your conclusion on whether this patient is likely to be a responder or non-responder, including your supporting rationale. Please use the COMPASS diagnostic tool to conduct a thorough assessment of tumor gene expression. Begin by examining immunosuppressive markers, such as natural killer cell activity, indications of T-cell exhaustion, and B-cell function. In addition, evaluate markers of immune activation, including macrophage activity, interferon-gamma signaling, and overall genomic integrity. After completing these analyses, compile the data into a comprehensive COMPASS assessment report that details how each transcriptomic factor may influence the tumor’s immune microenvironment and affect the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"Given mRNA TPM data from the tumor immune microenvironment of a male, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8 mutations per MB, can you determine if this patient is predicted to respond to Atezolizumab and provide the supporting rationale for your assessment?","Given mRNA TPM data from the tumor immune microenvironment of a male, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8 mutations per MB, can you determine if this patient is predicted to respond to Atezolizumab and provide the supporting rationale for your assessment? Use the COMPASS diagnostic tool to perform a detailed evaluation of tumor gene expression. First, assess immunosuppressive markers, including natural killer cell activity, indicators of T-cell exhaustion, and B-cell functionality. Next, examine markers of immune activation, such as macrophage activity, interferon-gamma signaling, and overall genomic integrity. Once these analyses are complete, compile the data into a comprehensive COMPASS assessment report that outlines how each transcriptomic factor might impact the tumor's immune microenvironment and influence the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled using mRNA TPM data. The patient is a white female with tumor tissue sampled from the ureter and a tumor mutational burden of 13.0 mutations per megabase. Based on this information, can you determine whether the patient is predicted to respond to atezolizumab, and please explain the rationale behind your conclusion?","I have a patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled using mRNA TPM data. The patient is a white female with tumor tissue sampled from the ureter and a tumor mutational burden of 13.0 mutations per megabase. Based on this information, can you determine whether the patient is predicted to respond to atezolizumab, and please explain the rationale behind your conclusion? Please use the COMPASS diagnostic tool to thoroughly evaluate tumor gene expression. Begin by assessing markers related to immunosuppression, including natural killer cell activity, signs of T-cell exhaustion, and B-cell function. Then evaluate markers of immune activation, such as macrophage activity, interferon-gamma signaling, and overall genomic integrity. After completing these analyses, compile a detailed COMPASS assessment report that describes how each transcriptomic marker may affect the tumor’s immune environment and potentially influence the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"Using mRNA TPM data that characterizes the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), please assess the predicted response to Atezolizumab. The patient is a 16.0 mutations per MB tumor mutational burden male of White race, with tissue derived from the kidney. Based on these details, would you classify this patient as a likely responder or non-responder, and what evidence supports your conclusion?","Using mRNA TPM data that characterizes the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), please assess the predicted response to Atezolizumab. The patient is a 16.0 mutations per MB tumor mutational burden male of White race, with tissue derived from the kidney. Based on these details, would you classify this patient as a likely responder or non-responder, and what evidence supports your conclusion? Use the COMPASS diagnostic tool to perform a comprehensive assessment of tumor gene expression. Start by evaluating immunosuppressive markers—including natural killer cell activity, indicators of T-cell exhaustion, and B-cell function. Then, assess markers of immune activation such as macrophage activity, interferon-gamma signaling, and genomic integrity. Finally, prepare a detailed report that outlines how each transcriptomic marker may influence the tumor's immune environment and affect the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"Based on mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA), with the following details: male, white, kidney tissue sample, and a tumor mutational burden of 2.0 mutations per megabase, how would you assess this patient’s predicted responsiveness to Atezolizumab, and what is the rationale for classifying them as a responder or non-responder?","Based on mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA), with the following details: male, white, kidney tissue sample, and a tumor mutational burden of 2.0 mutations per megabase, how would you assess this patient’s predicted responsiveness to Atezolizumab, and what is the rationale for classifying them as a responder or non-responder? Please use the COMPASS diagnostic tool to conduct a detailed evaluation of tumor gene expression. Begin by analyzing key immunosuppressive markers, including assessments of natural killer cell activity, T-cell exhaustion indices, and B-cell functionality. Next, examine markers linked to immune activation, such as macrophage activity, interferon-gamma signaling, and the overall genomic integrity. Finally, compile a comprehensive report that explains how each of these transcriptomic markers may impact the tumor’s immune microenvironment and influence the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"A patient presents with bladder urothelial carcinoma with available mRNA TPM data for the tumor immune microenvironment. The patient is a white female, and the tumor mutational burden data is unavailable (NaN). Based on this information, could you provide an evaluation of her likely response to Atezolizumab, including the supporting rationale for your assessment?","A patient presents with bladder urothelial carcinoma with available mRNA TPM data for the tumor immune microenvironment. The patient is a white female, and the tumor mutational burden data is unavailable (NaN). Based on this information, could you provide an evaluation of her likely response to Atezolizumab, including the supporting rationale for your assessment? Please use the COMPASS diagnostic tool to perform a comprehensive tumor gene expression evaluation. Start by analyzing key immunosuppressive markers, including assessments of natural killer cell activity, T-cell exhaustion, and B-cell functionality. Then, evaluate markers of immune activation, focusing on macrophage activity, interferon-gamma signaling, and the overall genomic integrity. Finally, prepare a detailed report explaining how each of these transcriptomic markers might affect the tumor’s immune microenvironment and influence the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"I have processed mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma. The patient is a 62-year-old white male, with bladder tissue involved and a tumor mutational burden of 7.0 mutations per megabase. Based on these clinical characteristics, can you provide an evidence-based conclusion on whether he is likely to respond to Atezolizumab, including your reasoning?","I have processed mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma. The patient is a 62-year-old white male, with bladder tissue involved and a tumor mutational burden of 7.0 mutations per megabase. Based on these clinical characteristics, can you provide an evidence-based conclusion on whether he is likely to respond to Atezolizumab, including your reasoning? Please use the COMPASS diagnostic tool to conduct a detailed transcriptomic analysis of the tumor. Begin by evaluating key immunosuppressive markers, including natural killer cell activity, T-cell exhaustion, and B-cell function. Next, assess markers of immune activation by examining macrophage activity, interferon-gamma signaling, and overall genomic integrity. Finally, compile a comprehensive report discussing how these transcriptomic findings might impact the tumor’s immune microenvironment and the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"For a patient with Bladder Urothelial Carcinoma characterized by a male, White demographic, bladder tissue origin, and a tumor mutational burden of 20 mutations per megabase, based on the processed mRNA TPM data of the tumor immune microenvironment, would you classify this patient as likely to respond to Atezolizumab? Please provide your assessment with supporting rationale.","For a patient with Bladder Urothelial Carcinoma characterized by a male, White demographic, bladder tissue origin, and a tumor mutational burden of 20 mutations per megabase, based on the processed mRNA TPM data of the tumor immune microenvironment, would you classify this patient as likely to respond to Atezolizumab? Please provide your assessment with supporting rationale. Please use the COMPASS diagnostic tool to perform a detailed transcriptomic analysis of the tumor. Start by evaluating immunosuppressive markers, including assessments of natural killer cell activity, T-cell exhaustion, and B-cell function. Then, shift focus to markers of immune activation by examining macrophage activity, interferon-gamma signaling pathways, and overall genomic integrity. Finally, compile a comprehensive report that explains how these transcriptomic findings might influence the tumor’s immune microenvironment and potentially affect the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"I have processed mRNA TPM data for a white female patient with bladder urothelial carcinoma (BLCA), and her tumor mutational burden is 5.0 mutations per MB. Could you please evaluate her predicted responsiveness to Atezolizumab and provide your reasoning for classifying her as a responder or non-responder?","I have processed mRNA TPM data for a white female patient with bladder urothelial carcinoma (BLCA), and her tumor mutational burden is 5.0 mutations per MB. Could you please evaluate her predicted responsiveness to Atezolizumab and provide your reasoning for classifying her as a responder or non-responder? Please use the COMPASS diagnostic tool to conduct an in-depth transcriptomic evaluation of the tumor. Begin by assessing immunosuppressive markers, focusing on natural killer cell activity, T-cell exhaustion, and B-cell functionality. Next, investigate markers of immune activation by analyzing macrophage activity, the interferon-gamma signaling pathway, and the overall genomic stability. Finally, compile a detailed report describing how these transcriptomic findings could impact the tumor’s immune microenvironment and potentially influence the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"Based on mRNA TPM data characterizing the tumor immune microenvironment of a male, white patient with bladder tissue diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 38 mutations per megabase, what is the predicted response to Atezolizumab? Please classify the patient as a responder or non-responder and provide the clinical rationale supporting this determination.","Based on mRNA TPM data characterizing the tumor immune microenvironment of a male, white patient with bladder tissue diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 38 mutations per megabase, what is the predicted response to Atezolizumab? Please classify the patient as a responder or non-responder and provide the clinical rationale supporting this determination. Please employ the COMPASS diagnostic tool to perform a comprehensive transcriptomic analysis of the tumor. Start by evaluating immunosuppressive markers, including natural killer cell activity, indicators of T-cell exhaustion, and B-cell functionality. Then, assess markers of immune activation by examining macrophage activity, the interferon-gamma signaling pathway, and overall genomic stability. Finally, prepare a detailed report that explains how these transcriptomic findings could affect the tumor's immune microenvironment and potentially influence the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"Based on mRNA TPM data of the tumor immune microenvironment from a patient with bladder urothelial carcinoma (BLCA), can you assess the likelihood of a positive response to Atezolizumab? The patient is a  white male with a kidney tissue sample and a tumor mutational burden of 6.0 mutations per megabase. Please include the rationale behind your assessment.","Based on mRNA TPM data of the tumor immune microenvironment from a patient with bladder urothelial carcinoma (BLCA), can you assess the likelihood of a positive response to Atezolizumab? The patient is a  white male with a kidney tissue sample and a tumor mutational burden of 6.0 mutations per megabase. Please include the rationale behind your assessment. Please use the COMPASS diagnostic tool to conduct a detailed transcriptomic analysis of the tumor. Begin by assessing immunosuppressive markers, specifically natural killer cell activity, signs of T-cell exhaustion, and B-cell function. Next, evaluate markers of immune activation by examining macrophage activity, the interferon-gamma signaling pathway, and overall genomic stability. Finally, compile a comprehensive report outlining how these transcriptomic findings could impact the tumor’s immune microenvironment and potentially affect the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"Based on the mRNA TPM data for this patient's tumor immune microenvironment in bladder urothelial carcinoma, along with the following details—Male, White, bladder tissue involvement, and a tumor mutational burden of 8.0 mutations per megabase—can you determine if this patient is likely to respond to Atezolizumab, and please provide your reasoning?","Based on the mRNA TPM data for this patient's tumor immune microenvironment in bladder urothelial carcinoma, along with the following details—Male, White, bladder tissue involvement, and a tumor mutational burden of 8.0 mutations per megabase—can you determine if this patient is likely to respond to Atezolizumab, and please provide your reasoning? Please utilize the COMPASS diagnostic tool to perform a comprehensive transcriptomic evaluation of the tumor. Begin by assessing immunosuppressive markers—specifically measuring natural killer cell activity, detecting markers indicative of T-cell exhaustion, and evaluating B-cell function. Subsequently, investigate immune activation by analyzing macrophage activity, the interferon-gamma signaling pathway, and assessing overall genomic stability. Finally, compile a detailed report that explains how these transcriptomic results might influence the tumor’s immune microenvironment and potentially modify the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"For a male White patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM data has been processed to characterize the tumor immune microenvironment and who has a tumor mutational burden of 13.0 mutations per megabase, what is the predicted responsiveness to Atezolizumab? Please include the rationale behind classifying this patient as a responder or non-responder.","For a male White patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM data has been processed to characterize the tumor immune microenvironment and who has a tumor mutational burden of 13.0 mutations per megabase, what is the predicted responsiveness to Atezolizumab? Please include the rationale behind classifying this patient as a responder or non-responder. Use the COMPASS diagnostic tool to conduct a comprehensive transcriptomic analysis of the tumor. Start by evaluating markers of immunosuppression, including natural killer cell activity, indicators of T-cell exhaustion, and B-cell function. Next, assess immune activation by examining macrophage activity, the interferon-gamma signaling pathway, and overall genomic stability. Finally, prepare a detailed report outlining how these transcriptomic findings could impact the tumor’s immune microenvironment and potentially influence the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"Based on processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) and considering the following clinical details—male, White, kidney tissue, FMOne mutation burden of 5.0 mutations per MB—could you please determine whether this patient is likely to respond to Atezolizumab, and explain the rationale behind your conclusion?","Based on processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA) and considering the following clinical details—male, White, kidney tissue, FMOne mutation burden of 5.0 mutations per MB—could you please determine whether this patient is likely to respond to Atezolizumab, and explain the rationale behind your conclusion? Please use the COMPASS diagnostic tool to perform a detailed transcriptomic analysis on the tumor sample. Begin by evaluating markers of immunosuppression, such as natural killer cell activity, signs of T-cell exhaustion, and B-cell function. Then, assess immune activation by examining macrophage function, the activity of the interferon-gamma signaling pathway, and overall genomic stability. Finally, compile a comprehensive report that explains how these findings may affect the tumor’s immune microenvironment and potentially impact the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"Based on the patient's mRNA TPM data reflecting the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you provide an assessment of her predicted responsiveness to Atezolizumab? The patient is a white female with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Please include your conclusion on whether she is likely to be a responder or non-responder, along with the supporting rationale.","Based on the patient's mRNA TPM data reflecting the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you provide an assessment of her predicted responsiveness to Atezolizumab? The patient is a white female with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Please include your conclusion on whether she is likely to be a responder or non-responder, along with the supporting rationale. Please use the COMPASS diagnostic tool to conduct a transcriptomic analysis on the provided tumor sample. Start by assessing markers of immunosuppression, including natural killer cell activity, indicators of T-cell exhaustion, and B-cell functionality. Next, evaluate immune activation by examining macrophage performance, interferon-gamma signaling activity, and the overall genomic stability of the sample. Conclude by compiling a detailed report that discusses how these results may influence the tumor's immune microenvironment and the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"I have analyzed mRNA TPM data representing the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA) with the following characteristics: female, White, specimen obtained from kidney tissue, and a tumor mutational burden of 5.0 mutations per megabase. Based on this information, could you provide an assessment of whether she is likely to respond to Atezolizumab, along with the supporting rationale for this evaluation?","I have analyzed mRNA TPM data representing the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA) with the following characteristics: female, White, specimen obtained from kidney tissue, and a tumor mutational burden of 5.0 mutations per megabase. Based on this information, could you provide an assessment of whether she is likely to respond to Atezolizumab, along with the supporting rationale for this evaluation? Using the COMPASS diagnostic tool, perform a transcriptomic analysis on the provided tumor sample. Begin by evaluating immunosuppressive markers—specifically, assess natural killer cell activity, T-cell exhaustion indicators, and B-cell functionality. Then, measure immune activation by analyzing macrophage function, interferon-gamma signaling, and the genomic stability of the sample. Finally, prepare a comprehensive report outlining how these findings could impact the tumor's immune microenvironment as well as the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"Based on the mRNA TPM data from the tumor immune microenvironment of a  male, White patient with bladder urothelial carcinoma (BLCA) – with a tissue sample labeled as ""other"" and unavailable tumor mutational burden (TMB) data – could you help determine whether this patient is likely to respond to atezolizumab? Please include the reasoning behind the conclusion.","Based on the mRNA TPM data from the tumor immune microenvironment of a  male, White patient with bladder urothelial carcinoma (BLCA) – with a tissue sample labeled as ""other"" and unavailable tumor mutational burden (TMB) data – could you help determine whether this patient is likely to respond to atezolizumab? Please include the reasoning behind the conclusion. Please use the COMPASS diagnostic tool to conduct a transcriptomic analysis on the tumor specimen. Begin by evaluating immunosuppressive markers, focusing on natural killer cell activity, indicators of T-cell exhaustion, and B-cell functionality. Next, assess immune activation by examining macrophage function, interferon-gamma signaling, and genomic stability within the sample. Finally, compile a detailed report that outlines how these findings may influence the tumor's immune microenvironment and affect the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"I have processed mRNA TPM data representing the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient's characteristics include female sex, white race, lymph node tissue involvement, and a tumor mutational burden of 12.0 mutations per megabase. Based on these details, could you please provide an assessment of the patient’s predicted responsiveness to Atezolizumab, including whether she would be classified as a responder or non-responder, along with the supporting rationale?","I have processed mRNA TPM data representing the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient's characteristics include female sex, white race, lymph node tissue involvement, and a tumor mutational burden of 12.0 mutations per megabase. Based on these details, could you please provide an assessment of the patient’s predicted responsiveness to Atezolizumab, including whether she would be classified as a responder or non-responder, along with the supporting rationale? Please use the COMPASS diagnostic tool to perform a transcriptomic analysis on the tumor specimen. Begin the evaluation by assessing immunosuppressive markers, specifically examining natural killer cell activity, signs of T-cell exhaustion, and B-cell functionality. Next, evaluate immune activation by analyzing macrophage function, interferon-gamma signaling, and the genomic stability of the sample. Finally, prepare a detailed report discussing how these findings may impact the tumor’s immune microenvironment and influence the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"Could you evaluate whether a male, Asian patient with bladder urothelial carcinoma (with a tumor mutational burden of 1.0 mutations per MB), based on his processed mRNA TPM data representing the tumor immune microenvironment, is predicted to respond to Atezolizumab? Please include your supporting rationale.","Could you evaluate whether a male, Asian patient with bladder urothelial carcinoma (with a tumor mutational burden of 1.0 mutations per MB), based on his processed mRNA TPM data representing the tumor immune microenvironment, is predicted to respond to Atezolizumab? Please include your supporting rationale. Please apply the COMPASS diagnostic tool to conduct a transcriptomic analysis of the tumor sample. Start by evaluating immunosuppressive indicators, with a focus on natural killer cell activity, evidence of T-cell exhaustion, and B-cell function. Following that, assess immune activation by analyzing macrophage performance, interferon-gamma signaling, and determining the genomic stability of the sample. Conclude by compiling a comprehensive report that elucidates how these findings might affect the tumor’s immune microenvironment and the patient's potential response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"Based on the available mRNA TPM data of the patient's tumor immune microenvironment and the following clinical details—male, white, bladder tissue, diagnosed with Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 6.0 mutations per megabase—can we predict whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Based on the available mRNA TPM data of the patient's tumor immune microenvironment and the following clinical details—male, white, bladder tissue, diagnosed with Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 6.0 mutations per megabase—can we predict whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Please use the COMPASS diagnostic tool to perform a transcriptomic analysis on the tumor sample. Begin by evaluating immunosuppressive markers, specifically examining the activity of natural killer cells, signs of T-cell exhaustion, and B-cell function. Next, assess immune activation by analyzing macrophage performance, interferon-gamma signaling, and the genomic stability of the sample. Finally, compile a detailed report that explains how these findings might influence the tumor’s immune microenvironment and indicate the patient’s potential response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"I have processed mRNA TPM data reflecting a patient’s tumor immune microenvironment for a case of Bladder Urothelial Carcinoma. The patient’s details are as follows: female, race unknown, bladder tissue sample, and a tumor mutational burden (FMOne mutation burden per MB) of 8.0. Based on these parameters, can you determine whether this patient is likely to respond to Atezolizumab, and please provide the supporting rationale for your assessment?","I have processed mRNA TPM data reflecting a patient’s tumor immune microenvironment for a case of Bladder Urothelial Carcinoma. The patient’s details are as follows: female, race unknown, bladder tissue sample, and a tumor mutational burden (FMOne mutation burden per MB) of 8.0. Based on these parameters, can you determine whether this patient is likely to respond to Atezolizumab, and please provide the supporting rationale for your assessment? Please utilize the COMPASS diagnostic tool to conduct a transcriptomic evaluation of the tumor sample. Begin by assessing immunosuppressive markers—specifically, review natural killer cell activity, evaluate for signs of T-cell exhaustion, and appraise B-cell function. Then, shift your focus to immune activation by examining macrophage functionality, analyzing interferon-gamma signaling, and checking the genomic stability of the sample. Finally, prepare a comprehensive report detailing how these results might affect the tumor’s immune microenvironment and predict the patient’s potential response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"I have processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a White male, with kidney tissue analyzed and a tumor mutational burden of 6 mutations per megabase. Could you provide an evaluation on whether this patient is likely to respond to Atezolizumab, along with the rationale for your conclusion?","I have processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a White male, with kidney tissue analyzed and a tumor mutational burden of 6 mutations per megabase. Could you provide an evaluation on whether this patient is likely to respond to Atezolizumab, along with the rationale for your conclusion? Please use the COMPASS tool to perform a transcriptomic analysis of the tumor sample. Begin by evaluating immunosuppressive markers: assess natural killer cell activity, look for signs of T-cell exhaustion, and evaluate B-cell function. Next, shift your assessment to immune activation by examining macrophage function, analyzing interferon-gamma signaling, and verifying the sample’s genomic stability. Finally, compile a detailed report outlining how these findings might influence the tumor’s immune microenvironment and the patient's potential response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"For a male, White patient with bladder urothelial carcinoma who has a tumor mutational burden of 22.0 mutations per MB and provided mRNA TPM data detailing the tumor immune microenvironment, can you determine whether this patient is likely to respond to Atezolizumab treatment? Please include your supportive reasoning.","For a male, White patient with bladder urothelial carcinoma who has a tumor mutational burden of 22.0 mutations per MB and provided mRNA TPM data detailing the tumor immune microenvironment, can you determine whether this patient is likely to respond to Atezolizumab treatment? Please include your supportive reasoning. Please utilize the COMPASS tool to conduct a transcriptomic evaluation of the tumor specimen. Begin by assessing markers indicative of immunosuppression: evaluate natural killer cell activity, identify indicators of T-cell exhaustion, and examine B-cell functionality. Then, shift your examination to immune activation by investigating macrophage performance, reviewing interferon-gamma signaling pathways, and confirming the genomic stability of the sample. Conclude by generating a comprehensive report that interprets these findings in the context of the tumor immune microenvironment and discusses their potential implications for the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"Based on the processed mRNA TPM data of the tumor immune microenvironment for a male patient diagnosed with Bladder Urothelial Carcinoma (BLCA), who is White and has a tumor mutational burden of 1.0 mutations per MB, could you determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the supporting rationale for your assessment.","Based on the processed mRNA TPM data of the tumor immune microenvironment for a male patient diagnosed with Bladder Urothelial Carcinoma (BLCA), who is White and has a tumor mutational burden of 1.0 mutations per MB, could you determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the supporting rationale for your assessment. Please use the COMPASS platform to perform a transcriptomic analysis of the tumor sample. Begin by evaluating markers related to immunosuppression by assessing natural killer cell activity, identifying signs of T-cell exhaustion, and examining B-cell function. Then, shift your focus to markers of immune activation by evaluating macrophage performance, analyzing interferon-gamma signaling pathways, and confirming the genomic stability of the sample. Finally, prepare a comprehensive report that interprets these findings within the context of the tumor immune microenvironment and discusses the potential impact on the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"For a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with mRNA TPM data reflecting the tumor immune microenvironment obtained from a ureter tissue sample, and given that the patient is a White female with an unspecified tumor mutational burden (reported as ""nan"" for FMOne mutation burden per MB), could you please evaluate the predicted responsiveness to Atezolizumab and provide the supporting rationale for your assessment?","For a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with mRNA TPM data reflecting the tumor immune microenvironment obtained from a ureter tissue sample, and given that the patient is a White female with an unspecified tumor mutational burden (reported as ""nan"" for FMOne mutation burden per MB), could you please evaluate the predicted responsiveness to Atezolizumab and provide the supporting rationale for your assessment? Please use the COMPASS platform to conduct a transcriptomic analysis on the tumor sample. Start by assessing immunosuppressive markers: evaluate natural killer cell activity, look for evidence of T-cell exhaustion, and review B-cell function. Next, evaluate markers indicative of immune activation by analyzing macrophage performance, examining interferon-gamma signaling pathways, and verifying the sample's genomic stability. Conclude by preparing a comprehensive report that interprets these findings with respect to the tumor’s immune microenvironment, while discussing potential implications for the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"Given the processed mRNA TPM data representing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), along with the following clinical attributes—male sex, white race, kidney tissue, and a tumor mutational burden of 2.0 mutations/MB—what is the predicted responsiveness to Atezolizumab, and what is the supporting rationale for classifying this patient as a responder or non-responder?","Given the processed mRNA TPM data representing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), along with the following clinical attributes—male sex, white race, kidney tissue, and a tumor mutational burden of 2.0 mutations/MB—what is the predicted responsiveness to Atezolizumab, and what is the supporting rationale for classifying this patient as a responder or non-responder? Please use the COMPASS platform to perform a transcriptomic analysis on the tumor sample. Begin by assessing immunosuppressive markers—specifically, evaluate the activity of natural killer cells, screen for signs of T-cell exhaustion, and examine B-cell functionality. Next, assess markers of immune activation by analyzing macrophage performance, investigating interferon-gamma signaling pathways, and confirming the genomic stability of the sample. Finally, prepare a detailed report that contextualizes these findings within the tumor’s immune microenvironment and discusses their potential implications for the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"Based on processed mRNA TPM data of the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), and considering the clinical details provided (male, white, bladder tissue, TMB of 11 mutations/MB), can you determine whether this patient is predicted to be a responder or non-responder to Atezolizumab? Please include the scientific rationale supporting your conclusion.","Based on processed mRNA TPM data of the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), and considering the clinical details provided (male, white, bladder tissue, TMB of 11 mutations/MB), can you determine whether this patient is predicted to be a responder or non-responder to Atezolizumab? Please include the scientific rationale supporting your conclusion. Please use the COMPASS platform to conduct a transcriptomic evaluation of the tumor sample. Start by examining immunosuppressive markers: assess natural killer cell activity, look for evidence of T-cell exhaustion, and evaluate B-cell function. Next, review indicators of immune activation by analyzing macrophage activity, investigating interferon-gamma signaling, and verifying the sample’s genomic stability. Finally, compile a comprehensive report that explains these findings within the context of the tumor’s immune microenvironment and discusses their potential impact on the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"Based on processed mRNA TPM data assessing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), along with the following clinical parameters—male sex, white race, bladder tissue involvement, and a tumor mutational burden of 9.0 mutations per megabase—could you please determine whether the patient is predicted to respond to Atezolizumab, and provide the supporting rationale for this classification?","Based on processed mRNA TPM data assessing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), along with the following clinical parameters—male sex, white race, bladder tissue involvement, and a tumor mutational burden of 9.0 mutations per megabase—could you please determine whether the patient is predicted to respond to Atezolizumab, and provide the supporting rationale for this classification? Please use the COMPASS platform to perform a transcriptomic assessment on the tumor sample. Begin by evaluating immunosuppressive markers: assess natural killer cell activity, identify signs of T-cell exhaustion, and evaluate B-cell function. Then, assess indicators of immune activation by examining macrophage activity, analyzing interferon-gamma signaling, and confirming the sample’s genomic stability. Finally, prepare a detailed report that integrates these findings within the context of the tumor’s immune microenvironment and discusses their potential implications for the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"Using mRNA TPM data that characterize the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), can we determine if this patient is likely to respond to Atezolizumab? The patient is a white male with a kidney tissue sample, and tumor mutational burden data are unavailable (nan). Please provide your assessment along with the key supporting factors for your conclusion.","Using mRNA TPM data that characterize the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), can we determine if this patient is likely to respond to Atezolizumab? The patient is a white male with a kidney tissue sample, and tumor mutational burden data are unavailable (nan). Please provide your assessment along with the key supporting factors for your conclusion. Please use the COMPASS platform to perform a transcriptomic analysis of the tumor sample. To start, assess immunosuppressive markers by evaluating natural killer (NK) cell function, identifying signs of T-cell exhaustion, and examining B-cell activity. Next, evaluate immune activation by analyzing macrophage function, examining interferon-gamma signaling, and confirming the genomic stability of the sample. Finally, compile a comprehensive report that integrates these findings within the context of the tumor’s immune microenvironment, highlighting potential implications for the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"A male, white patient with bladder urothelial carcinoma has been evaluated using mRNA TPM data from a kidney tissue sample, and his tumor mutational burden is 14 mutations per megabase. Based on this immunogenomic profile, can you assess the likelihood of a positive response to Atezolizumab? Please provide your conclusion on whether he is likely to be a responder or non-responder, along with the supporting rationale.","A male, white patient with bladder urothelial carcinoma has been evaluated using mRNA TPM data from a kidney tissue sample, and his tumor mutational burden is 14 mutations per megabase. Based on this immunogenomic profile, can you assess the likelihood of a positive response to Atezolizumab? Please provide your conclusion on whether he is likely to be a responder or non-responder, along with the supporting rationale. Use the COMPASS platform to conduct a transcriptomic analysis of the tumor sample. Begin by assessing immunosuppressive markers: evaluate natural killer (NK) cell function, identify evidence of T-cell exhaustion, and review B-cell activity. Next, examine immune activation by analyzing macrophage function, investigating interferon-gamma signaling, and confirming the sample’s genomic stability. Finally, compile a detailed report that integrates these findings within the context of the tumor’s immune microenvironment, emphasizing any potential implications for the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 18.0 mutations per megabase. Based on these clinical details, could you determine whether this patient is likely to respond to Atezolizumab, and please explain your reasoning?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 18.0 mutations per megabase. Based on these clinical details, could you determine whether this patient is likely to respond to Atezolizumab, and please explain your reasoning? Please use the COMPASS platform to perform a transcriptomic analysis on the tumor sample. Begin by evaluating immunosuppressive features: assess natural killer cell function, look for signs of T-cell exhaustion, and examine B-cell activity. Then, shift to assessing immune activation by analyzing macrophage function, investigating interferon-gamma signaling, and confirming the genomic stability of the sample. Finally, prepare a detailed report that integrates these findings within the context of the tumor’s immune microenvironment, with specific attention to how these factors might impact the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"Based on mRNA TPM data characterizing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) (male, white, tumor site: bladder, TMB: 13.0 mutations per megabase), could you assess the predicted responsiveness to Atezolizumab and provide the rationale for classifying this patient as either a responder or non-responder?","Based on mRNA TPM data characterizing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) (male, white, tumor site: bladder, TMB: 13.0 mutations per megabase), could you assess the predicted responsiveness to Atezolizumab and provide the rationale for classifying this patient as either a responder or non-responder? Please use the COMPASS platform to conduct a transcriptomic evaluation of the tumor sample. Start by examining immunosuppressive aspects, including natural killer cell functionality, indications of T-cell exhaustion, and B-cell activity. Next, evaluate immune activation by analyzing macrophage function, interferon-gamma signaling, and the genomic stability of the tumor. Finally, compile a comprehensive report that integrates these findings to illustrate how the tumor’s immune microenvironment may influence the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a female Black or African American patient with Bladder Urothelial Carcinoma (BLCA) originating from bladder tissue. With a tumor mutational burden of 8.0 mutations per MB, can you determine whether this patient is likely to respond to Atezolizumab therapy? Please include your supporting rationale in your conclusion.","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a female Black or African American patient with Bladder Urothelial Carcinoma (BLCA) originating from bladder tissue. With a tumor mutational burden of 8.0 mutations per MB, can you determine whether this patient is likely to respond to Atezolizumab therapy? Please include your supporting rationale in your conclusion. Use the COMPASS platform to perform a transcriptomic analysis of the tumor sample. Begin by assessing immunosuppressive features, focusing on natural killer cell activity, signs of T-cell exhaustion, and B-cell behavior. Next, evaluate immune activation by analyzing macrophage function, interferon-gamma signaling, and the tumor's genomic stability. Conclude by preparing a detailed report that integrates these findings to show how the tumor’s immune microenvironment might affect the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"A 67-year-old Caucasian female patient with bladder urothelial carcinoma has been assessed using mRNA TPM data of her tumor immune microenvironment, and her tumor mutational burden is 6.0 mutations per megabase. Based on these clinical and molecular parameters, could you determine whether she is likely to be a responder or a non-responder to Atezolizumab, and please provide the rationale behind your conclusion?","A 67-year-old Caucasian female patient with bladder urothelial carcinoma has been assessed using mRNA TPM data of her tumor immune microenvironment, and her tumor mutational burden is 6.0 mutations per megabase. Based on these clinical and molecular parameters, could you determine whether she is likely to be a responder or a non-responder to Atezolizumab, and please provide the rationale behind your conclusion? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor sample. Start by evaluating immunosuppressive characteristics, including natural killer cell activity, markers of T-cell exhaustion, and B-cell behavior. Then, assess immune activation by examining macrophage function, interferon-gamma signaling, and genomic stability within the tumor. Finally, compile a comprehensive report integrating these findings to clarify how the tumor’s immune microenvironment may influence the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"Given mRNA TPM data representing the immune microenvironment in a patient with bladder urothelial carcinoma (male, white, bladder tissue, and unavailable tumor mutational burden data), can you evaluate the predicted responsiveness to Atezolizumab and provide a detailed explanation supporting your conclusion?","Given mRNA TPM data representing the immune microenvironment in a patient with bladder urothelial carcinoma (male, white, bladder tissue, and unavailable tumor mutational burden data), can you evaluate the predicted responsiveness to Atezolizumab and provide a detailed explanation supporting your conclusion? Use the COMPASS platform to perform a transcriptomic analysis of the tumor sample. Begin by evaluating immunosuppressive factors, such as natural killer cell activity, markers indicative of T-cell exhaustion, and aspects of B-cell behavior. Next, assess immune activation by examining macrophage functionality, interferon-gamma signaling pathways, and the overall genomic stability of the tumor. Once these evaluations are complete, compile a detailed report that integrates all findings to shed light on how the tumor’s immune microenvironment may influence the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"I have mRNA TPM data assessing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a white male with a tumor mutational burden of 23 mutations per MB. Based on this information, can you determine if the patient is more likely to respond to Atezolizumab, and please provide the rationale supporting your conclusion?","I have mRNA TPM data assessing the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient is a white male with a tumor mutational burden of 23 mutations per MB. Based on this information, can you determine if the patient is more likely to respond to Atezolizumab, and please provide the rationale supporting your conclusion? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor sample. Start by assessing immunosuppressive factors—specifically, evaluate natural killer cell activity, markers of T-cell exhaustion, and B-cell behavior. Then, evaluate immune activation by analyzing macrophage function, interferon-gamma signaling pathways, and the tumor's overall genomic stability. Once these analyses are completed, compile a comprehensive report integrating all findings to illustrate how the tumor's immune microenvironment might impact the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"For a female patient with bladder urothelial carcinoma, who is Caucasian and whose tumor sample is from a lymph node, and whose mRNA TPM data reflecting the tumor immune microenvironment has been processed (with tumor mutational burden data unavailable), can you assess the predicted responsiveness to Atezolizumab and provide the supporting rationale for this prediction?","For a female patient with bladder urothelial carcinoma, who is Caucasian and whose tumor sample is from a lymph node, and whose mRNA TPM data reflecting the tumor immune microenvironment has been processed (with tumor mutational burden data unavailable), can you assess the predicted responsiveness to Atezolizumab and provide the supporting rationale for this prediction? Use the COMPASS platform to perform a transcriptomic analysis on the tumor sample. Begin by evaluating immunosuppressive factors, focusing on natural killer cell activity, indicators of T-cell exhaustion, and B-cell behavior. Next, assess immune activation by examining macrophage function, interferon-gamma signaling pathways, and overall tumor genomic stability. After completing these analyses, prepare a comprehensive report that integrates all findings to clarify the potential impact of the tumor's immune microenvironment on the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following clinical details—male, white, lymph node tissue, and a tumor mutational burden of 2.0 mutations per megabase—what is your assessment of his predicted responsiveness to Atezolizumab? Please indicate whether he would be classified as a responder or non-responder and provide a concise rationale for your conclusion.","Based on the patient's mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following clinical details—male, white, lymph node tissue, and a tumor mutational burden of 2.0 mutations per megabase—what is your assessment of his predicted responsiveness to Atezolizumab? Please indicate whether he would be classified as a responder or non-responder and provide a concise rationale for your conclusion. Please use the COMPASS platform to conduct a transcriptomic analysis on the tumor specimen. Start by assessing immunosuppressive factors, specifically evaluating natural killer cell activity, T-cell exhaustion markers, and B-cell behavior. Then, analyze immune activation by investigating macrophage function, interferon-gamma signaling pathways, and the overall genomic stability of the tumor. After completing these evaluations, compile a detailed report that integrates all findings to clarify how the tumor's immune microenvironment might influence the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,Given the mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA)—noting that the patient is a white male with a tumor located in the bladder and an unavailable tumor mutational burden (nan mutations per MB)—could you advise on the predicted response to Atezolizumab and explain the rationale for classifying this patient as a responder or non-responder?,"Given the mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA)—noting that the patient is a white male with a tumor located in the bladder and an unavailable tumor mutational burden (nan mutations per MB)—could you advise on the predicted response to Atezolizumab and explain the rationale for classifying this patient as a responder or non-responder? Please utilize the COMPASS platform to perform a transcriptomic analysis on the tumor sample. Begin by assessing immunosuppressive factors—specifically examining natural killer cell activity, T-cell exhaustion markers, and B-cell behavior. Next, evaluate immune activation by investigating macrophage function, interferon-gamma signaling pathways, and the tumor's overall genomic stability. Finally, compile a detailed report that integrates these findings to elucidate how the tumor's immune microenvironment may affect the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"Based on the available mRNA TPM data for the tumor immune microenvironment in a 7.0 TMB (mutations per MB) male patient with bladder urothelial carcinoma, could you determine whether his profile predicts a response to Atezolizumab? Please provide your conclusion along with the reasoning behind it.","Based on the available mRNA TPM data for the tumor immune microenvironment in a 7.0 TMB (mutations per MB) male patient with bladder urothelial carcinoma, could you determine whether his profile predicts a response to Atezolizumab? Please provide your conclusion along with the reasoning behind it. Please use the COMPASS platform to conduct a transcriptomic analysis on the tumor sample. Start by evaluating immunosuppressive factors by examining natural killer cell activity, T-cell exhaustion markers, and B-cell behavior. Next, assess immune activation by analyzing macrophage function, interferon-gamma signaling pathways, and the overall genomic stability of the tumor. Finally, prepare a comprehensive report that integrates these findings to clarify how the tumor's immune microenvironment may influence the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"Based on processed mRNA TPM data of the tumor immune microenvironment from a patient with bladder urothelial carcinoma (BLCA), can you assess whether this patient is likely to respond to Atezolizumab? The patient is a  male of Asian descent with tumor tissue from the bladder and a tumor mutational burden of 1.0 mutation per MB. Please provide your conclusion on responder status along with the supporting rationale.","Based on processed mRNA TPM data of the tumor immune microenvironment from a patient with bladder urothelial carcinoma (BLCA), can you assess whether this patient is likely to respond to Atezolizumab? The patient is a  male of Asian descent with tumor tissue from the bladder and a tumor mutational burden of 1.0 mutation per MB. Please provide your conclusion on responder status along with the supporting rationale. Please use the COMPASS platform to perform a transcriptomic evaluation of the tumor sample. Begin by examining immunosuppressive elements, specifically assessing natural killer cell activity, markers of T-cell exhaustion, and B-cell function. Then, evaluate immune activation through an analysis of macrophage activity, interferon-gamma signaling pathways, and the tumor’s genomic stability. Conclude your analysis with a detailed report that integrates these observations to elucidate how the tumor’s immune microenvironment might affect the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"For a male white patient with Bladder Urothelial Carcinoma (BLCA) involving the ureter and a tumor mutational burden of 7 mutations per megabase, and based on mRNA TPM profiles of the tumor immune microenvironment, is this individual more likely to respond or not respond to Atezolizumab? Please provide your conclusion along with the rationale for your assessment.","For a male white patient with Bladder Urothelial Carcinoma (BLCA) involving the ureter and a tumor mutational burden of 7 mutations per megabase, and based on mRNA TPM profiles of the tumor immune microenvironment, is this individual more likely to respond or not respond to Atezolizumab? Please provide your conclusion along with the rationale for your assessment. Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor sample. Start by examining immunosuppressive factors: evaluate natural killer cell activity, assess indicators of T-cell exhaustion, and analyze B-cell functionality. Next, assess immune activation by investigating macrophage activity, interferon-gamma signaling, and the tumor’s genomic stability. Finally, compile a detailed report that integrates these findings to provide insight into how the tumor’s immune microenvironment may influence the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"Based on the mRNA TPM data analyzed for the tumor immune microenvironment in a male, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations/Mb, can you determine whether this patient is likely to respond to Atezolizumab, and please provide the rationale for your interpretation?","Based on the mRNA TPM data analyzed for the tumor immune microenvironment in a male, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations/Mb, can you determine whether this patient is likely to respond to Atezolizumab, and please provide the rationale for your interpretation? Please use the COMPASS platform to perform a full transcriptomic analysis of the tumor sample. Begin by assessing immunosuppressive factors by evaluating natural killer cell activity, T-cell exhaustion markers, and B-cell function. Then, examine immune activation by looking at macrophage activity, interferon-gamma signaling, and the tumor's genomic stability. Finally, prepare a detailed report that integrates these results to help us understand how the tumor’s immune microenvironment could affect the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM analysis depicts the tumor immune microenvironment, and given the following details—Male, Caucasian, tumor located in the bladder, and a tumor mutational burden of 6 mutations per Mb—could you please evaluate the likelihood of a response to Atezolizumab, indicating whether the patient is predicted to be a responder or non-responder with supporting rationale?","For a patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM analysis depicts the tumor immune microenvironment, and given the following details—Male, Caucasian, tumor located in the bladder, and a tumor mutational burden of 6 mutations per Mb—could you please evaluate the likelihood of a response to Atezolizumab, indicating whether the patient is predicted to be a responder or non-responder with supporting rationale? Please utilize the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor sample. Begin by evaluating immunosuppressive elements, including natural killer cell activity, T-cell exhaustion markers, and B-cell function. Next, assess immune activation by analyzing macrophage activity, interferon-gamma signaling, and the stability of the tumor genome. Finally, compile a detailed report integrating these findings to elucidate how the tumor’s immune microenvironment may influence the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"For a male patient with Bladder Urothelial Carcinoma (BLCA), with mRNA TPM data characterizing the tumor immune microenvironment collected from lung tissue—and with a tumor mutational burden that is currently unavailable (nan)—could you please assess the predicted responsiveness to Atezolizumab and provide your rationale for classifying this patient as a responder or non‐responder?","For a male patient with Bladder Urothelial Carcinoma (BLCA), with mRNA TPM data characterizing the tumor immune microenvironment collected from lung tissue—and with a tumor mutational burden that is currently unavailable (nan)—could you please assess the predicted responsiveness to Atezolizumab and provide your rationale for classifying this patient as a responder or non‐responder? Use the COMPASS platform to perform a complete transcriptomic analysis on the tumor sample. First, evaluate key immunosuppressive factors, including natural killer cell activity, T-cell exhaustion markers, and B-cell function. Then, assess indicators of immune activation such as macrophage activity, interferon-gamma signaling, and tumor genome stability. Finally, prepare a detailed report that integrates these findings to clarify how the tumor's immune microenvironment might affect the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"For a white male patient with bladder urothelial carcinoma, a lymph node biopsy showing mRNA TPM data for the tumor immune microenvironment, and a tumor mutational burden of 2.0 mutations per MB, what is the predicted response to Atezolizumab treatment? Please provide a conclusion on whether the patient is likely a responder or non-responder, along with your supporting rationale.","For a white male patient with bladder urothelial carcinoma, a lymph node biopsy showing mRNA TPM data for the tumor immune microenvironment, and a tumor mutational burden of 2.0 mutations per MB, what is the predicted response to Atezolizumab treatment? Please provide a conclusion on whether the patient is likely a responder or non-responder, along with your supporting rationale. Utilize the COMPASS platform to conduct an in-depth transcriptomic analysis of the tumor specimen. Begin by assessing key immunosuppressive markers, including natural killer cell activity, indicators of T-cell exhaustion, and B-cell functionality. Next, evaluate immune activation parameters such as macrophage activity, interferon-gamma signaling, and the stability of the tumor genome. Finally, compile a comprehensive report that integrates these findings to elucidate how the tumor's immune microenvironment may influence the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"I have processed mRNA TPM data characterizing the tumor immune microenvironment of a male patient with Bladder Urothelial Carcinoma (BLCA) whose tumor mutational burden is 44 mutations per MB. Given these clinical parameters, could you assess the likelihood of this patient responding to Atezolizumab and provide detailed supporting reasoning for your evaluation?","I have processed mRNA TPM data characterizing the tumor immune microenvironment of a male patient with Bladder Urothelial Carcinoma (BLCA) whose tumor mutational burden is 44 mutations per MB. Given these clinical parameters, could you assess the likelihood of this patient responding to Atezolizumab and provide detailed supporting reasoning for your evaluation? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample. Begin by evaluating key immunosuppressive markers, such as natural killer cell activity, signs of T-cell exhaustion, and B-cell functionality. Then, assess immune activation markers, including macrophage activity, interferon-gamma signaling, and tumor genome stability. Finally, integrate these results into a detailed report that explains how the tumor's immune microenvironment might affect the patient’s response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"Based on this patient's processed mRNA TPM data for tumor immune microenvironment profiling in the context of Bladder Urothelial Carcinoma (BLCA), could you evaluate the likelihood of response to Atezolizumab? The patient's details are as follows: male, white, tissue sample obtained from the kidney, with a tumor mutational burden of 15.0 FMOne mutations per megabase. Please provide your conclusion regarding responder status and the supporting rationale.","Based on this patient's processed mRNA TPM data for tumor immune microenvironment profiling in the context of Bladder Urothelial Carcinoma (BLCA), could you evaluate the likelihood of response to Atezolizumab? The patient's details are as follows: male, white, tissue sample obtained from the kidney, with a tumor mutational burden of 15.0 FMOne mutations per megabase. Please provide your conclusion regarding responder status and the supporting rationale. Use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor sample. Start by analyzing key immunosuppressive indicators, such as natural killer cell activity, evidence of T-cell exhaustion, and B-cell functionality. Next, evaluate markers of immune activation, including macrophage activity, interferon-gamma signaling, and assessments of tumor genome stability. Finally, compile these findings into a comprehensive report that discusses the potential impact of the tumor’s immune microenvironment on the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"I have analyzed mRNA TPM data representing the tumor immune microenvironment from a lymph node biopsy in a  patient with bladder urothelial carcinoma (BLCA). The patient is a  white male with a tumor mutational burden of 17 mutations/Mb. Based on this information, can you provide an assessment regarding whether this patient is predicted to be responsive or non-responsive to atezolizumab, along with the underlying rationale?","I have analyzed mRNA TPM data representing the tumor immune microenvironment from a lymph node biopsy in a  patient with bladder urothelial carcinoma (BLCA). The patient is a  white male with a tumor mutational burden of 17 mutations/Mb. Based on this information, can you provide an assessment regarding whether this patient is predicted to be responsive or non-responsive to atezolizumab, along with the underlying rationale? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor sample. Begin by evaluating key immunosuppressive markers, such as natural killer cell activity, indicators of T-cell exhaustion, and B-cell functionality. Next, assess markers of immune activation, including macrophage activity, interferon-gamma signaling, and measures of tumor genome stability. Finally, compile your results into a comprehensive report that discusses how the tumor’s immune microenvironment might influence treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"Based on the processed mRNA TPM data of the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA), along with the following clinical attributes—male sex, White race, tissue origin from the kidney, and a tumor mutational burden of 11 mutations per megabase—can you assess whether this patient is likely to respond to Atezolizumab therapy? Please provide your conclusion along with the supporting rationale.","Based on the processed mRNA TPM data of the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA), along with the following clinical attributes—male sex, White race, tissue origin from the kidney, and a tumor mutational burden of 11 mutations per megabase—can you assess whether this patient is likely to respond to Atezolizumab therapy? Please provide your conclusion along with the supporting rationale. Please use the COMPASS platform to conduct a transcriptomic profiling of the tumor sample. Begin by analyzing immunosuppressive biomarkers, including assessments of natural killer cell activity, markers of T-cell exhaustion, and measures of B-cell functionality. Then, evaluate indicators of immune activation such as macrophage activity, interferon-gamma signaling, and indicators of tumor genomic stability. Once completed, compile a detailed report interpreting how the tumor’s immune microenvironment may affect treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) and would like your assessment regarding their predicted response to Atezolizumab. The patient's details are as follows: Male, White, bladder tissue origin, with a BLCA diagnosis, and tumor mutational burden data unavailable. Based on this information, can you provide a conclusion on whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your evaluation?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA) and would like your assessment regarding their predicted response to Atezolizumab. The patient's details are as follows: Male, White, bladder tissue origin, with a BLCA diagnosis, and tumor mutational burden data unavailable. Based on this information, can you provide a conclusion on whether the patient is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your evaluation? Please perform a transcriptomic analysis of the tumor sample using the COMPASS platform. Start by evaluating immunosuppressive biomarkers, such as natural killer cell activity, T-cell exhaustion markers, and B-cell functional indicators. Next, assess immune activation by measuring macrophage activity, interferon-gamma signaling, and markers of tumor genomic stability. Finally, prepare a comprehensive report that interprets how the tumor’s immune microenvironment might impact treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"Based on a patient's mRNA TPM data of the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you determine whether this male patient (White, with bladder tissue involvement) is predicted to respond to Atezolizumab? The analysis includes mRNA expression, but note that Tumor Mutational Burden data is unavailable (nan). Please provide a conclusion regarding predicted response status with supporting rationale.","Based on a patient's mRNA TPM data of the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you determine whether this male patient (White, with bladder tissue involvement) is predicted to respond to Atezolizumab? The analysis includes mRNA expression, but note that Tumor Mutational Burden data is unavailable (nan). Please provide a conclusion regarding predicted response status with supporting rationale. Please conduct a transcriptomic analysis of the tumor specimen using the COMPASS platform. Begin by assessing immunosuppressive biomarkers, including natural killer cell activity, markers indicative of T-cell exhaustion, and indicators of B-cell function. Then, evaluate immune activation by measuring macrophage activity, interferon-gamma signaling, and markers related to tumor genomic stability. Finally, compile a detailed report interpreting how these immune microenvironment features might affect the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"Based on the patient's processed mRNA TPM data and the following clinical attributes—male, white, bladder tissue, a diagnosis of Bladder Urothelial Carcinoma, and a tumor mutational burden of 12 mutations/Mb—can you determine whether this patient is likely to respond to Atezolizumab and provide the rationale behind this prediction?","Based on the patient's processed mRNA TPM data and the following clinical attributes—male, white, bladder tissue, a diagnosis of Bladder Urothelial Carcinoma, and a tumor mutational burden of 12 mutations/Mb—can you determine whether this patient is likely to respond to Atezolizumab and provide the rationale behind this prediction? Please perform a transcriptomic analysis of the tumor tissue using the COMPASS platform. Start by evaluating immunosuppressive biomarkers—specifically, assess natural killer cell activity, markers of T-cell exhaustion, and B-cell functional indicators. Next, determine the level of immune activation by measuring macrophage activity, interferon-gamma signaling, and markers associated with tumor genomic stability. Finally, prepare a comprehensive report that explains how these immune microenvironment characteristics might influence the patient's response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"I have mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a bladder tumor and a tumor mutational burden of 6.0 mutations per megabase. Based on these clinical and molecular characteristics, could you evaluate whether the patient is likely to respond to Atezolizumab, and provide the rationale for your assessment?","I have mRNA TPM data assessing the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a bladder tumor and a tumor mutational burden of 6.0 mutations per megabase. Based on these clinical and molecular characteristics, could you evaluate whether the patient is likely to respond to Atezolizumab, and provide the rationale for your assessment? Please conduct a transcriptomic analysis of the patient's tumor tissue using the COMPASS platform. Begin by examining the immunosuppressive milieu by assessing natural killer cell activity, markers indicative of T-cell exhaustion, and functional indicators of B cells. Then, evaluate the level of immune activation by measuring macrophage activity, interferon-gamma signaling, and markers linked to tumor genomic stability. Conclude by compiling a detailed report that explains how these immune microenvironment characteristics might influence the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"For a 5.0 TMB, white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized using mRNA TPM data from bladder tissue, does the molecular profile suggest that he is likely to respond to Atezolizumab? Please provide your assessment along with the underlying rationale.","For a 5.0 TMB, white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized using mRNA TPM data from bladder tissue, does the molecular profile suggest that he is likely to respond to Atezolizumab? Please provide your assessment along with the underlying rationale. Please perform a transcriptomic analysis of the patient's tumor tissue using the COMPASS platform. First, assess the immunosuppressive environment by evaluating natural killer cell activity, markers of T-cell exhaustion, and indicators of B cell function. Next, examine immune activation by measuring macrophage activity, interferon-gamma signaling, and markers associated with tumor genomic stability. Finally, prepare a comprehensive report detailing how these immune microenvironment characteristics may affect the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma. The patient is a white male with a tumor mutational burden of 8.0 mutations per megabyte. Based on this molecular and clinical profile, could you assess whether the patient is predicted to respond to Atezolizumab, and provide your reasoning supporting this conclusion?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma. The patient is a white male with a tumor mutational burden of 8.0 mutations per megabyte. Based on this molecular and clinical profile, could you assess whether the patient is predicted to respond to Atezolizumab, and provide your reasoning supporting this conclusion? Please perform a transcriptomic analysis of the patient's tumor sample using the COMPASS platform. Begin by evaluating the immunosuppressive environment, specifically by assessing the activity of natural killer cells, markers indicative of T-cell exhaustion, and indicators of B cell function. Next, assess immune activation by measuring macrophage activity, interferon-gamma signaling, and markers associated with tumor genomic stability. Finally, compile a comprehensive report that explains how these immune microenvironment characteristics might influence the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"For a patient with bladder urothelial carcinoma (BLCA) presenting with a tumor mutational burden of 8.0 mutations/MB, male sex, white race, and primary bladder tumor tissue, based on processed mRNA TPM data of the tumor immune microenvironment, do we predict a favorable response to Atezolizumab? Please provide your conclusion on whether this patient is more likely to be a responder or a non-responder, along with the rationale for your determination.","For a patient with bladder urothelial carcinoma (BLCA) presenting with a tumor mutational burden of 8.0 mutations/MB, male sex, white race, and primary bladder tumor tissue, based on processed mRNA TPM data of the tumor immune microenvironment, do we predict a favorable response to Atezolizumab? Please provide your conclusion on whether this patient is more likely to be a responder or a non-responder, along with the rationale for your determination. Please conduct a transcriptomic analysis of the patient's tumor sample using the COMPASS platform. Begin by assessing the immunosuppressive microenvironment by evaluating natural killer cell function, T-cell exhaustion markers, and B cell activity indicators. Then, evaluate the immune activation profile by measuring macrophage activity, interferon-gamma signaling, and indicators of tumor genomic stability. Finally, prepare a comprehensive report detailing how these immune microenvironment characteristics may impact the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment of a male patient with bladder urothelial carcinoma (BLCA). The patient’s tumor tissue was obtained from the bladder, with a tumor mutational burden of 0.0 mutations per megabase. Based on these data, can you determine whether the patient is likely to respond to Atezolizumab therapy, and please provide the clinical reasoning behind your conclusion?","I have mRNA TPM data reflecting the tumor immune microenvironment of a male patient with bladder urothelial carcinoma (BLCA). The patient’s tumor tissue was obtained from the bladder, with a tumor mutational burden of 0.0 mutations per megabase. Based on these data, can you determine whether the patient is likely to respond to Atezolizumab therapy, and please provide the clinical reasoning behind your conclusion? Please perform a transcriptomic analysis of the patient's tumor sample using the COMPASS platform. Start by evaluating the immunosuppressive tumor microenvironment, focusing on natural killer cell activity, T-cell exhaustion markers, and B cell functional indicators. Next, assess the immune activation profile by measuring macrophage activity, interferon-gamma signaling, and markers of tumor genomic stability. Conclude by preparing a detailed report that explains how these immune microenvironment characteristics could affect the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA) who has a Tumor Mutational Burden of 5.0 mutations/MB. The patient is a white male, and the tissue sample was taken from the kidney. Based on this information, could you please determine whether the patient is likely to respond to Atezolizumab, and provide the supporting evidence for your conclusion?","I have analyzed mRNA TPM data from the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA) who has a Tumor Mutational Burden of 5.0 mutations/MB. The patient is a white male, and the tissue sample was taken from the kidney. Based on this information, could you please determine whether the patient is likely to respond to Atezolizumab, and provide the supporting evidence for your conclusion? Please conduct a transcriptomic analysis of the patient’s tumor sample using the COMPASS platform. Begin by examining the immunosuppressive aspects of the tumor microenvironment, with a focus on natural killer cell function, markers indicative of T-cell exhaustion, and assays evaluating B-cell activity. Next, assess the immune activation components by quantifying macrophage function, interferon-gamma signaling, and relevant markers that indicate tumor genomic stability. Finally, compile a detailed report that outlines how these immune microenvironment parameters may influence the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"Based on mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following clinical details—male, white, kidney tissue, and a tumor mutational burden of 6.0 mutations per MB—can you evaluate the predicted responsiveness to Atezolizumab? Please provide a conclusion regarding whether this patient is likely to be a responder or a non-responder, along with your supporting rationale.","Based on mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA), and considering the following clinical details—male, white, kidney tissue, and a tumor mutational burden of 6.0 mutations per MB—can you evaluate the predicted responsiveness to Atezolizumab? Please provide a conclusion regarding whether this patient is likely to be a responder or a non-responder, along with your supporting rationale. Please perform a transcriptomic analysis on the patient’s tumor sample using the COMPASS platform. Begin by evaluating the tumor microenvironment's immunosuppressive characteristics, specifically by assessing natural killer cell activity, markers of T-cell exhaustion, and assays for B-cell function. Next, analyze immune activation by measuring macrophage function, interferon-gamma signaling, and markers that reflect tumor genomic stability. Finally, compile a comprehensive report detailing how these immune microenvironment parameters might impact the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"I have processed mRNA TPM data assessing the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a  female of White race, with kidney tissue analysis, and the tumor mutational burden value is not available. Based on these data, how would you classify her predicted responsiveness to atezolizumab—as a responder or non-responder—and what is the rationale for your assessment?","I have processed mRNA TPM data assessing the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a  female of White race, with kidney tissue analysis, and the tumor mutational burden value is not available. Based on these data, how would you classify her predicted responsiveness to atezolizumab—as a responder or non-responder—and what is the rationale for your assessment? Please conduct a transcriptomic analysis of the patient's tumor sample using the COMPASS platform. First, assess the immunosuppressive aspects of the tumor microenvironment by measuring natural killer cell activity, evaluating markers of T-cell exhaustion, and performing assays to gauge B-cell functionality. Then, evaluate immune activation by studying macrophage activity, interferon-gamma signaling, and indicators of tumor genomic stability. Finally, compile a detailed report explaining how these findings may affect the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"Given that we have mRNA TPM data representing the tumor immune microenvironment and the following patient parameters—a male of white ethnicity, with bladder urothelial carcinoma (BLCA) originating from the ureter and a tumor mutational burden of 59.0 mutations/MB—what is the predicted responsiveness of this patient to Atezolizumab? Please provide your classification (responder or non-responder) along with the supporting rationale.","Given that we have mRNA TPM data representing the tumor immune microenvironment and the following patient parameters—a male of white ethnicity, with bladder urothelial carcinoma (BLCA) originating from the ureter and a tumor mutational burden of 59.0 mutations/MB—what is the predicted responsiveness of this patient to Atezolizumab? Please provide your classification (responder or non-responder) along with the supporting rationale. Please perform a transcriptomic analysis of the patient’s tumor sample using the COMPASS platform. Begin by evaluating the immunosuppressive features of the tumor microenvironment: measure natural killer cell activity, assess markers indicating T-cell exhaustion, and run assays to determine B-cell functionality. Next, assess immune activation by examining macrophage activity, interferon-gamma signaling levels, and markers of tumor genomic stability. Conclude by preparing a detailed report that discusses how these findings could influence the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"I have processed mRNA TPM data that characterize the immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a tumor tissue sample from the kidney and a tumor mutational burden of 13.0 mutations per megabase. Based on this information, could you please provide an assessment of whether this patient is likely to respond to Atezolizumab, including the rationale behind your conclusion?","I have processed mRNA TPM data that characterize the immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a tumor tissue sample from the kidney and a tumor mutational burden of 13.0 mutations per megabase. Based on this information, could you please provide an assessment of whether this patient is likely to respond to Atezolizumab, including the rationale behind your conclusion? Please conduct a transcriptomic analysis of the patient's tumor sample using the COMPASS platform. Start by examining the tumor microenvironment's immunosuppressive characteristics by measuring natural killer cell activity, identifying markers of T-cell exhaustion, and assessing B-cell functionality. Then, evaluate immune activation by analyzing macrophage activity, interferon-gamma signaling levels, and markers that reflect tumor genomic stability. Finally, compile a detailed report that explains how these findings might impact the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"Based on mRNA TPM data from a patient’s tumor immune microenvironment for bladder urothelial carcinoma, could you evaluate the likelihood of a positive response to Atezolizumab? The patient is a female of “other” race, with tumor tissue from the ureter, a diagnosis of bladder urothelial carcinoma, and a tumor mutational burden of 12.0 mutations per megabase. Please provide your conclusion on whether this patient is more likely to be a responder or non-responder, including the rationale for your assessment.","Based on mRNA TPM data from a patient’s tumor immune microenvironment for bladder urothelial carcinoma, could you evaluate the likelihood of a positive response to Atezolizumab? The patient is a female of “other” race, with tumor tissue from the ureter, a diagnosis of bladder urothelial carcinoma, and a tumor mutational burden of 12.0 mutations per megabase. Please provide your conclusion on whether this patient is more likely to be a responder or non-responder, including the rationale for your assessment. Perform a transcriptomic analysis of the patient's tumor sample using the COMPASS platform. First, assess the immunosuppressive traits within the tumor microenvironment by quantifying natural killer cell activity, identifying T-cell exhaustion markers, and evaluating B-cell function. Next, evaluate immune activation by examining macrophage activity, measuring interferon-gamma signaling levels, and assessing markers of tumor genomic stability. Finally, compile a detailed report that discusses how these findings might influence the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"I have analyzed mRNA TPM data from a lymph node biopsy of a  male Caucasian patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and with a tumor mutational burden of 4.0 (FMOne mutation burden per MB). Based on this information, how would you predict the patient's response to Atezolizumab treatment, and could you provide the rationale behind categorizing the patient as either a responder or non-responder?","I have analyzed mRNA TPM data from a lymph node biopsy of a  male Caucasian patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and with a tumor mutational burden of 4.0 (FMOne mutation burden per MB). Based on this information, how would you predict the patient's response to Atezolizumab treatment, and could you provide the rationale behind categorizing the patient as either a responder or non-responder? Please perform a transcriptomic analysis on the patient's tumor sample using the COMPASS platform. Begin by characterizing the tumor microenvironment's immunosuppressive features: quantify natural killer cell activity, identify markers of T-cell exhaustion, and assess B-cell function. Then, evaluate immune activation by measuring macrophage activity, interferon-gamma signaling levels, and markers related to tumor genomic stability. Finally, compile a comprehensive report that explains how these findings might affect the patient’s likely response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"For a patient with bladder urothelial carcinoma characterized by mRNA TPM data of the tumor immune microenvironment (male, White, bladder tissue, TMB of 11.0 mutations per MB), how would you assess the likelihood of response to Atezolizumab, and what is your rationale for classifying them as a responder or non-responder?","For a patient with bladder urothelial carcinoma characterized by mRNA TPM data of the tumor immune microenvironment (male, White, bladder tissue, TMB of 11.0 mutations per MB), how would you assess the likelihood of response to Atezolizumab, and what is your rationale for classifying them as a responder or non-responder? Please conduct transcriptomic profiling of the patient’s tumor sample using the COMPASS platform. Start by assessing the tumor microenvironment for immunosuppressive characteristics: measure natural killer cell activity, identify markers indicative of T-cell exhaustion, and evaluate B-cell function. Next, examine indicators of immune activation by quantifying macrophage activity, monitoring interferon-gamma signaling, and assessing markers associated with tumor genomic stability. Finally, compile a detailed report that discusses how these findings may influence the patient’s likely response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"Based on mRNA TPM data for the tumor immune microenvironment in a male white patient with bladder tissue involvement diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations per MB, can you provide an assessment of his predicted responsiveness to Atezolizumab? Please include a detailed explanation supporting whether he is likely to be classified as a responder or non-responder.","Based on mRNA TPM data for the tumor immune microenvironment in a male white patient with bladder tissue involvement diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations per MB, can you provide an assessment of his predicted responsiveness to Atezolizumab? Please include a detailed explanation supporting whether he is likely to be classified as a responder or non-responder. Please perform transcriptomic profiling of the patient’s tumor sample using the COMPASS platform. Begin by evaluating the tumor microenvironment for signs of immunosuppression by assessing natural killer cell activity, identifying markers of T-cell exhaustion, and examining B-cell function. Next, assess indicators of immune activation by quantifying macrophage activity, monitoring interferon-gamma signaling, and evaluating markers related to tumor genomic stability. Finally, prepare a comprehensive report outlining how these results might affect the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM data reflect their tumor immune microenvironment—with the following details: White female, tissue origin from the kidney, and an indeterminate tumor mutational burden—could you evaluate the likelihood of a favorable response to Atezolizumab and explain the rationale for your conclusion?","For a patient with Bladder Urothelial Carcinoma (BLCA) whose mRNA TPM data reflect their tumor immune microenvironment—with the following details: White female, tissue origin from the kidney, and an indeterminate tumor mutational burden—could you evaluate the likelihood of a favorable response to Atezolizumab and explain the rationale for your conclusion? Please use the COMPASS platform to perform transcriptomic profiling on the patient’s tumor sample. Begin by assessing the tumor microenvironment for signs of immunosuppression—evaluate natural killer cell activity, look for markers indicating T-cell exhaustion, and examine B-cell functionality. Then, measure immune activation by quantifying macrophage activity, monitoring interferon-gamma signaling, and evaluating markers associated with tumor genomic stability. Finally, compile a detailed report that explains how these findings could impact the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"Based on the processed mRNA TPM data for a patient with bladder urothelial carcinoma, could you assess the likelihood of response to Atezolizumab? The patient is a white male with tumor tissue from the ureter and a tumor mutational burden of 5.0 mutations per megabase. Please provide your evaluation and the reasoning behind your conclusion.","Based on the processed mRNA TPM data for a patient with bladder urothelial carcinoma, could you assess the likelihood of response to Atezolizumab? The patient is a white male with tumor tissue from the ureter and a tumor mutational burden of 5.0 mutations per megabase. Please provide your evaluation and the reasoning behind your conclusion. Please use the COMPASS platform to conduct transcriptomic profiling of the patient's tumor sample. Start by evaluating the tumor microenvironment for immunosuppressive features. Specifically, assess natural killer cell activity, check for markers of T-cell exhaustion, and evaluate B-cell functionality. Next, quantify immune activation by measuring macrophage activity, examining interferon-gamma signaling, and assessing markers related to tumor genomic stability. Finally, prepare a comprehensive report outlining how these findings might affect the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"Based on our mRNA TPM analysis of the tumor immune microenvironment, along with the following patient details—a male patient of Native Hawaiian or other Pacific Islander descent with Bladder Urothelial Carcinoma (BLCA), a non-urothelial tissue sample, and a tumor mutational burden of 19.0 mutations per MB—can we determine if this patient is likely to respond to Atezolizumab treatment? Please include the reasoning supporting your conclusion.","Based on our mRNA TPM analysis of the tumor immune microenvironment, along with the following patient details—a male patient of Native Hawaiian or other Pacific Islander descent with Bladder Urothelial Carcinoma (BLCA), a non-urothelial tissue sample, and a tumor mutational burden of 19.0 mutations per MB—can we determine if this patient is likely to respond to Atezolizumab treatment? Please include the reasoning supporting your conclusion. Please use the COMPASS platform for transcriptomic profiling of the patient’s tumor sample. Begin by analyzing the tumor microenvironment for signs of immunosuppression. Focus on assessing natural killer cell activity, markers indicative of T-cell exhaustion, and B-cell functionality. Next, evaluate immune activation by quantifying macrophage activity, examining interferon-gamma signaling, and analyzing markers related to tumor genomic stability. Conclude by preparing a comprehensive report that details how these findings might influence the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"We have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma. The patient’s characteristics are as follows: Male, White, with a bladder tissue sample, and a tumor mutational burden (FMO mutation burden per MB) reported as nan. Based on these molecular findings, what is the predicted likelihood of response to atezolizumab, and what evidence supports this conclusion?","We have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma. The patient’s characteristics are as follows: Male, White, with a bladder tissue sample, and a tumor mutational burden (FMO mutation burden per MB) reported as nan. Based on these molecular findings, what is the predicted likelihood of response to atezolizumab, and what evidence supports this conclusion? Please perform transcriptomic profiling on the patient's tumor sample using the COMPASS platform. Start by assessing the tumor microenvironment for any indications of immunosuppression, with particular attention to natural killer cell activity, markers of T-cell exhaustion, and B-cell functionality. Then, evaluate immune activation by measuring macrophage activity, examining interferon-gamma signaling pathways, and analyzing markers of tumor genomic stability. Conclude by compiling a detailed report that explains how these findings may impact the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/563d62-ar-563d623.pkl. "
BLCA,,,,NR,"For a patient with bladder urothelial carcinoma (BLCA) showing mRNA TPM data of the tumor immune microenvironment, how should we interpret their predicted response to Atezolizumab given the following clinical details: female, White, bladder tissue origin, and an unspecified tumor mutational burden?","For a patient with bladder urothelial carcinoma (BLCA) showing mRNA TPM data of the tumor immune microenvironment, how should we interpret their predicted response to Atezolizumab given the following clinical details: female, White, bladder tissue origin, and an unspecified tumor mutational burden? Please use the COMPASS platform to perform transcriptomic profiling on the patient's tumor sample. Begin by examining the tumor microenvironment for signs of immunosuppression, with a focus on natural killer cell function, markers suggestive of T-cell exhaustion, and B-cell performance. Next, assess immune activation by evaluating macrophage activity, analyzing interferon-gamma signaling, and reviewing indicators of tumor genomic stability. Finally, compile a detailed report explaining how these findings might affect the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"Based on the patient's mRNA TPM expression data reflecting the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you evaluate the predicted response to Atezolizumab treatment? The patient is a male of White ethnicity with kidney tissue involvement, diagnosed with BLCA, and has a tumor mutational burden of 33.0 per MB. Please provide a conclusion on whether this patient is likely to be classified as a responder or a non-responder, including your supporting rationale.","Based on the patient's mRNA TPM expression data reflecting the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you evaluate the predicted response to Atezolizumab treatment? The patient is a male of White ethnicity with kidney tissue involvement, diagnosed with BLCA, and has a tumor mutational burden of 33.0 per MB. Please provide a conclusion on whether this patient is likely to be classified as a responder or a non-responder, including your supporting rationale. Please use the COMPASS platform to perform transcriptomic profiling on the patient's tumor sample. Begin by investigating the tumor microenvironment for evidence of immunosuppression, specifically evaluating natural killer cell function, markers of T-cell exhaustion, and B-cell activity. Next, assess immune activation by analyzing macrophage activity, interferon-gamma signaling, and indicators of tumor genomic stability. Finally, prepare a detailed report discussing how these findings could influence the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"I have mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a white male, whose tissue sample type is categorized as ""other"", and his tumor mutational burden is 32.0 mutations per MB. Based on these clinical and molecular details, could you classify the patient as a responder or non-responder to Atezolizumab, and provide your reasoning for this prediction?","I have mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a white male, whose tissue sample type is categorized as ""other"", and his tumor mutational burden is 32.0 mutations per MB. Based on these clinical and molecular details, could you classify the patient as a responder or non-responder to Atezolizumab, and provide your reasoning for this prediction? Utilize the COMPASS platform to conduct a transcriptomic analysis of the patient’s tumor sample. Start by examining the tumor microenvironment for signs of immunosuppression—specifically, evaluate the function of natural killer cells, look for markers indicative of T-cell exhaustion, and assess B-cell activity. Then, assess immune activation by analyzing macrophage function, interferon-gamma signaling pathways, and metrics related to tumor genomic stability. Finally, compile a comprehensive report that discusses how these molecular findings may impact the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"Given the following patient data for Bladder Urothelial Carcinoma (BLCA)—Sex: M, Race: White, Tissue: bladder, Tumor Mutational Burden: 2.0 mutations per MB—could you provide an assessment of the predicted responsiveness to Atezolizumab? Please include whether the patient is likely to be a responder or non-responder along with the rationale for your conclusion.","Given the following patient data for Bladder Urothelial Carcinoma (BLCA)—Sex: M, Race: White, Tissue: bladder, Tumor Mutational Burden: 2.0 mutations per MB—could you provide an assessment of the predicted responsiveness to Atezolizumab? Please include whether the patient is likely to be a responder or non-responder along with the rationale for your conclusion. Please use the COMPASS platform for a transcriptomic evaluation of the patient’s tumor specimen. Begin by analyzing the tumor microenvironment for signs of immunosuppression, including the activity of natural killer cells, markers of T-cell exhaustion, and B-cell function. Next, evaluate indicators of immune activation by assessing macrophage function, interferon-gamma signaling pathways, and measures of tumor genomic stability. Finally, prepare a detailed report that interprets these molecular findings and discusses their potential impact on the patient's therapy response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"Given the mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA), can you determine if this patient, a male of ""OTHER"" race with a bladder tumor and a tumor mutational burden of 14.0 mutations per megabase, is likely to respond to Atezolizumab treatment? Please provide your conclusion along with the rationale behind the classification as a responder or non-responder.","Given the mRNA TPM data from a patient with bladder urothelial carcinoma (BLCA), can you determine if this patient, a male of ""OTHER"" race with a bladder tumor and a tumor mutational burden of 14.0 mutations per megabase, is likely to respond to Atezolizumab treatment? Please provide your conclusion along with the rationale behind the classification as a responder or non-responder. Please conduct a transcriptomic evaluation of the patient’s tumor specimen using the COMPASS platform. Start by examining the tumor microenvironment for evidence of immunosuppression, specifically assessing natural killer cell activity, T-cell exhaustion markers, and B-cell functionality. Then, evaluate markers of immune activation by analyzing macrophage function, interferon-gamma signaling pathways, and the tumor’s genomic stability. Conclude by preparing a comprehensive report that interprets these molecular findings and discusses their potential implications for the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"Based on this patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), could you evaluate the likelihood of a response to Atezolizumab? The patient is a 79-year-old white male with BLCA, although tissue source and tumor mutational burden (FMOne mutation burden per MB) data are unavailable. Please provide your conclusion on whether this patient should be classified as a responder or non-responder, along with the rationale for your assessment.","Based on this patient's mRNA TPM data for the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), could you evaluate the likelihood of a response to Atezolizumab? The patient is a 79-year-old white male with BLCA, although tissue source and tumor mutational burden (FMOne mutation burden per MB) data are unavailable. Please provide your conclusion on whether this patient should be classified as a responder or non-responder, along with the rationale for your assessment. Perform a transcriptomic analysis of the patient's tumor specimen using the COMPASS platform. Begin by assessing the tumor microenvironment for signs of immunosuppression by evaluating natural killer cell activity, T-cell exhaustion markers, and B-cell functionality. Next, investigate markers of immune activation by analyzing macrophage function, interferon-gamma signaling pathways, and genomic stability of the tumor. Finally, compile a detailed report that interprets these molecular findings and explores their potential implications for the patient’s treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"Based on the mRNA TPM data from the patient's tumor immune microenvironment, could you evaluate whether the patient with bladder urothelial carcinoma (BLCA) is likely to respond to Atezolizumab? The patient’s profile includes: male sex, identified as White, tumor located in the bladder, and a tumor mutational burden of 9.0 mutations per megabase. Please provide your assessment along with the supporting rationale.","Based on the mRNA TPM data from the patient's tumor immune microenvironment, could you evaluate whether the patient with bladder urothelial carcinoma (BLCA) is likely to respond to Atezolizumab? The patient’s profile includes: male sex, identified as White, tumor located in the bladder, and a tumor mutational burden of 9.0 mutations per megabase. Please provide your assessment along with the supporting rationale. Conduct a comprehensive transcriptomic analysis on the patient's tumor sample using the COMPASS platform. Start by evaluating the tumor microenvironment for immunosuppressive characteristics, focusing on natural killer cell activity, T-cell exhaustion, and B-cell function. Then, assess immune activation by examining macrophage performance, interferon-gamma signaling pathways, and the tumor’s genomic stability. Finally, prepare a detailed report that interprets these molecular findings and discusses their potential implications for the patient's treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"Based on the provided mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA), including patient characteristics (Female, Asian, tissue source: ureter) and a tumor mutational burden of 12 mutations per megabase, can we determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the rationale for your conclusion.","Based on the provided mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA), including patient characteristics (Female, Asian, tissue source: ureter) and a tumor mutational burden of 12 mutations per megabase, can we determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include the rationale for your conclusion. Please perform a comprehensive transcriptomic analysis of the patient’s tumor sample using the COMPASS platform. Begin by assessing the tumor microenvironment for potential immunosuppressive features, specifically examining natural killer cell activity, signs of T-cell exhaustion, and B-cell function. Next, evaluate markers of immune activation by analyzing macrophage performance, interferon-gamma signaling pathways, and the tumor’s genomic stability. Finally, compile a detailed report that interprets these molecular findings and discusses their potential implications for the patient’s treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and need to determine the likelihood of a favorable response to atezolizumab. The patient is a white male with bladder tissue involvement and a diagnosis of BLCA, but the tumor mutational burden data (FMOne mutations per MB) is unavailable. Based on these findings, could you classify this patient as a responder or non-responder to atezolizumab, and please explain the reasoning behind your conclusion?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA) and need to determine the likelihood of a favorable response to atezolizumab. The patient is a white male with bladder tissue involvement and a diagnosis of BLCA, but the tumor mutational burden data (FMOne mutations per MB) is unavailable. Based on these findings, could you classify this patient as a responder or non-responder to atezolizumab, and please explain the reasoning behind your conclusion? Please conduct a detailed transcriptomic profiling of this patient’s tumor sample using the COMPASS platform. Begin by examining the tumor microenvironment for any immunosuppressive features—specifically, evaluate natural killer cell activity, look for indicators of T-cell exhaustion, and assess B-cell function. Then, analyze markers of immune activation by reviewing macrophage activity, interferon-gamma signaling pathways, and the tumor's genomic stability. Conclude with a comprehensive report that interprets these molecular findings and discusses their possible impact on the patient’s treatment prognosis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a male, white patient diagnosed with Bladder Urothelial Carcinoma, who has a tumor mutational burden of 11 mutations/MB. Could you please determine whether this patient is likely to respond to Atezolizumab, providing detailed clinical reasoning for the assessment?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a male, white patient diagnosed with Bladder Urothelial Carcinoma, who has a tumor mutational burden of 11 mutations/MB. Could you please determine whether this patient is likely to respond to Atezolizumab, providing detailed clinical reasoning for the assessment? Please perform a comprehensive transcriptomic analysis of the patient’s tumor sample using the COMPASS platform. Start by evaluating the tumor microenvironment for immunosuppressive characteristics by assessing natural killer cell activity, examining evidence of T-cell exhaustion, and evaluating B-cell function. Next, review markers of immune activation, including macrophage activity, interferon-gamma signaling pathways, and the tumor’s genomic stability. Finally, prepare a detailed report that interprets these molecular findings and outlines their potential implications for the patient’s treatment prognosis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"A  M, White patient with Bladder Urothelial Carcinoma, whose tumor mRNA TPM profiling and a TMB of 10.0 mutations per MB have been analyzed, presents with liver tissue involvement. Based on these findings, can we determine whether the patient is likely to respond to Atezolizumab treatment? Please explain your rationale.","A  M, White patient with Bladder Urothelial Carcinoma, whose tumor mRNA TPM profiling and a TMB of 10.0 mutations per MB have been analyzed, presents with liver tissue involvement. Based on these findings, can we determine whether the patient is likely to respond to Atezolizumab treatment? Please explain your rationale. Please conduct a detailed transcriptomic analysis of the patient’s tumor using the COMPASS platform. Begin by examining the tumor microenvironment for signs of immunosuppression, specifically by assessing natural killer cell function, identifying indicators of T‐cell exhaustion, and evaluating B‐cell activity. Then, analyze immune activation markers, including macrophage activity, interferon-gamma signaling pathways, and overall genomic stability of the tumor. Finally, compile a comprehensive report that interprets these molecular findings and discusses their potential impact on the patient’s treatment prognosis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"Based on mRNA TPM data for the tumor immune microenvironment in a bladder urothelial carcinoma patient (M, White, bladder tissue) with a tumor mutational burden of 12.0 mutations per MB, could you please determine whether the patient is likely to respond to Atezolizumab and explain the rationale behind your assessment?","Based on mRNA TPM data for the tumor immune microenvironment in a bladder urothelial carcinoma patient (M, White, bladder tissue) with a tumor mutational burden of 12.0 mutations per MB, could you please determine whether the patient is likely to respond to Atezolizumab and explain the rationale behind your assessment? Please perform an in-depth transcriptomic evaluation of the patient’s tumor using the COMPASS platform. First, evaluate the tumor microenvironment by assessing natural killer cell functionality, detecting markers of T-cell exhaustion, and measuring B-cell activity to identify any immunosuppressive features. Next, examine key immune activation markers such as macrophage activity, interferon-gamma signaling pathways, as well as the overall genomic stability of the tumor. Finally, prepare a detailed report that interprets these molecular findings and assesses their potential implications for the patient’s treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA), based on processed mRNA TPM data assessing the tumor immune microenvironment, can you determine whether the patient is likely to respond to Atezolizumab? The patient is female, race is unspecified, tissue sample is from the bladder, and the tumor mutational burden is 13.0 mutations/MB. Please include your rationale for classifying the patient as a responder or non-responder.","For a patient with Bladder Urothelial Carcinoma (BLCA), based on processed mRNA TPM data assessing the tumor immune microenvironment, can you determine whether the patient is likely to respond to Atezolizumab? The patient is female, race is unspecified, tissue sample is from the bladder, and the tumor mutational burden is 13.0 mutations/MB. Please include your rationale for classifying the patient as a responder or non-responder. Conduct a comprehensive transcriptomic analysis of the patient's tumor using the COMPASS platform. Begin by characterizing the tumor microenvironment: evaluate natural killer cell function, identify markers indicative of T-cell exhaustion, and measure B-cell activity to search for signs of immunosuppression. Next, assess key immune activation parameters, including macrophage response and interferon-gamma signaling, along with overall genomic stability of the tumor. Finally, compile a detailed report that interprets these molecular findings and discusses their potential impact on the patient's treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"I have collected TPM mRNA data reflecting the tumor immune microenvironment from a patient with Bladder Urothelial Carcinoma (BLCA) and would like to assess their predicted responsiveness to Atezolizumab. The patient's details are as follows: Male; White; tissue sample obtained from the kidney; and a tumor mutational burden of 6.0 FMOne mutations per megabase. Could you please evaluate whether this patient is more likely to be a responder or a non-responder to Atezolizumab, and explain the factors that support this assessment?","I have collected TPM mRNA data reflecting the tumor immune microenvironment from a patient with Bladder Urothelial Carcinoma (BLCA) and would like to assess their predicted responsiveness to Atezolizumab. The patient's details are as follows: Male; White; tissue sample obtained from the kidney; and a tumor mutational burden of 6.0 FMOne mutations per megabase. Could you please evaluate whether this patient is more likely to be a responder or a non-responder to Atezolizumab, and explain the factors that support this assessment? Please use the COMPASS platform to perform an in-depth transcriptomic evaluation of the patient’s tumor. Start by analyzing the tumor microenvironment: examine natural killer cell functionality, assess markers of T-cell exhaustion, and evaluate B-cell activity for evidence of immunosuppression. Next, evaluate key indicators of immune activation—specifically the macrophage response and interferon-gamma signaling—as well as assess genomic stability. Finally, prepare a comprehensive report that interprets these molecular findings and discusses their implications for the patient’s treatment options.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"I have processed mRNA TPM data from a patient's tumor immune microenvironment sample for Bladder Urothelial Carcinoma (BLCA), with the following characteristics: male, white, tissue from the ureter, and a tumor mutational burden of 21.0 mutations per MB. Could you provide your assessment on whether this patient is likely to respond to Atezolizumab, and explain the reasoning behind your conclusion?","I have processed mRNA TPM data from a patient's tumor immune microenvironment sample for Bladder Urothelial Carcinoma (BLCA), with the following characteristics: male, white, tissue from the ureter, and a tumor mutational burden of 21.0 mutations per MB. Could you provide your assessment on whether this patient is likely to respond to Atezolizumab, and explain the reasoning behind your conclusion? Please utilize the COMPASS platform to conduct a comprehensive transcriptomic analysis of the patient’s tumor. Begin by investigating the tumor microenvironment: assess the functioning of natural killer cells, identify markers that indicate T-cell exhaustion, and evaluate B-cell activity that may suggest immunosuppression. Then, focus on determining the level of immune activation by examining the macrophage response and interferon-gamma signaling, while also monitoring for any signs of genomic instability. Conclude by compiling a detailed report that interprets these findings and explores their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"Given the mRNA TPM data for a patient's tumor immune microenvironment and the following clinical details—sex: male, race: White, tumor site: bladder, diagnosis: Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 14.0 mutations per MB—would you consider this patient a likely responder or non-responder to Atezolizumab? Please include your rationale in your response.","Given the mRNA TPM data for a patient's tumor immune microenvironment and the following clinical details—sex: male, race: White, tumor site: bladder, diagnosis: Bladder Urothelial Carcinoma (BLCA), and a tumor mutational burden of 14.0 mutations per MB—would you consider this patient a likely responder or non-responder to Atezolizumab? Please include your rationale in your response. Use the COMPASS platform to perform an in-depth transcriptomic analysis of the patient’s tumor. Start by examining the tumor microenvironment: evaluate natural killer cell activity, look for markers of T-cell exhaustion, and assess B-cell activity that might indicate immunosuppression. Next, determine the level of immune activation by analyzing the macrophage response and interferon-gamma signaling, and check for signs of genomic instability. Finally, prepare a detailed report interpreting these findings and discussing their implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"I have processed mRNA TPM data that characterize the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 9 mutations per MB. Based on these data, could you assess whether this patient is likely to respond to Atezolizumab, and explain the reasoning behind your conclusion?","I have processed mRNA TPM data that characterize the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement and a tumor mutational burden of 9 mutations per MB. Based on these data, could you assess whether this patient is likely to respond to Atezolizumab, and explain the reasoning behind your conclusion? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient’s tumor. Begin with an examination of the tumor microenvironment: assess natural killer cell functionality, identify markers indicative of T-cell exhaustion, and evaluate B-cell activity that could suggest an immunosuppressive state. Next, measure the level of immune activation by analyzing the macrophage response and interferon-gamma signaling; also, evaluate the sample for any signs of genomic instability. Finally, compile a comprehensive report that interprets these findings and outlines their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"Based on mRNA TPM data for the tumor immune microenvironment and a tumor mutational burden of 27.0 mutations per megabase in a male, white patient with bladder urothelial carcinoma (BLCA), how do you predict this patient will respond to Atezolizumab? Please provide your conclusion along with the supporting reasoning.","Based on mRNA TPM data for the tumor immune microenvironment and a tumor mutational burden of 27.0 mutations per megabase in a male, white patient with bladder urothelial carcinoma (BLCA), how do you predict this patient will respond to Atezolizumab? Please provide your conclusion along with the supporting reasoning. Please use the COMPASS platform to perform an in-depth transcriptomic analysis of the patient's tumor. Start by examining the tumor microenvironment: evaluate the functionality of natural killer cells, identify markers that may indicate T-cell exhaustion, and assess B-cell activity for signs of an immunosuppressive state. Next, assess immune activation by analyzing the macrophage responses and interferon-gamma signaling, and check for any indicators of genomic instability. Finally, prepare a comprehensive report that summarizes these findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient's profile includes: Sex: Female; Race: White; Tissue: lymph node; and a tumor mutational burden recorded as ""nan"" (not available). Based on this information, could you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and please provide your supporting rationale?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient's profile includes: Sex: Female; Race: White; Tissue: lymph node; and a tumor mutational burden recorded as ""nan"" (not available). Based on this information, could you determine whether the patient is likely to be a responder or non-responder to Atezolizumab, and please provide your supporting rationale? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient's tumor. Begin by characterizing the tumor microenvironment: assess natural killer cell functionality, identify any markers indicating T-cell exhaustion, and examine B-cell activity for evidence of an immunosuppressive state. Then, evaluate immune activation by analyzing macrophage responses, interferon-gamma signaling, and any signs of genomic instability. Finally, compile a comprehensive report summarizing these findings and discussing their implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"I have evaluated mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient's details are as follows: Sex: Female; Race: White; Tissue sampled: kidney; Tumor Mutational Burden: 5.0 mutations/MB. Based on these parameters, could you provide an assessment on whether this patient is likely to respond to Atezolizumab, along with your supporting rationale?","I have evaluated mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient's details are as follows: Sex: Female; Race: White; Tissue sampled: kidney; Tumor Mutational Burden: 5.0 mutations/MB. Based on these parameters, could you provide an assessment on whether this patient is likely to respond to Atezolizumab, along with your supporting rationale? Use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient's tumor. Start by examining the tumor microenvironment: evaluate natural killer cell function, detect markers of T-cell exhaustion, and review B-cell activity for signs of an immunosuppressive state. Next, assess immune activation by analyzing macrophage responses, interferon-gamma signaling, and indicators of genomic instability. Conclude by compiling a detailed report that summarizes these findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"Based on mRNA TPM data from this patient's bladder tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA), can you assess the likelihood of a positive response to Atezolizumab? The patient is a  Male of White race, with tumor tissue originating from the bladder, and the tumor mutational burden data is currently unavailable. Please provide a conclusion on whether the patient is likely to be a responder, along with your supporting reasoning.","Based on mRNA TPM data from this patient's bladder tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA), can you assess the likelihood of a positive response to Atezolizumab? The patient is a  Male of White race, with tumor tissue originating from the bladder, and the tumor mutational burden data is currently unavailable. Please provide a conclusion on whether the patient is likely to be a responder, along with your supporting reasoning. Please use the COMPASS platform to conduct an integrated transcriptomic analysis of the patient’s tumor. Begin by evaluating the tumor microenvironment: assess the function of natural killer cells, identify markers of T-cell exhaustion, and review B-cell activity for evidence of an immunosuppressive state. Next, examine immune activation by analyzing macrophage responses, interferon-gamma signaling, and markers of genomic instability. Finally, compile a detailed report summarizing these findings and discussing their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"Based on the mRNA TPM profile of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), along with the following clinical characteristics—male, White, bladder tissue origin, and a tumor mutational burden of 14 mutations/MB—could you assess the likelihood of response to Atezolizumab? Please provide your conclusion regarding responder status and include the supporting rationale.","Based on the mRNA TPM profile of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), along with the following clinical characteristics—male, White, bladder tissue origin, and a tumor mutational burden of 14 mutations/MB—could you assess the likelihood of response to Atezolizumab? Please provide your conclusion regarding responder status and include the supporting rationale. Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient's tumor. Initially, assess the tumor microenvironment by evaluating natural killer cell function, identifying markers indicative of T-cell exhaustion, and reviewing B-cell activity to detect possible immunosuppressive conditions. Next, evaluate immune activation by analyzing macrophage responses, interferon-gamma signaling pathways, and any markers that indicate genomic instability. Finally, compile a detailed report summarizing your findings and discussing how these insights might influence the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"Given the mRNA TPM data from a bladder urothelial carcinoma patient’s tumor immune microenvironment, and considering the following details: male, white, bladder tissue origin, and a tumor mutational burden of 4.0 mutations per megabase, could you please assess the patient’s predicted response to Atezolizumab? Please include a conclusion regarding responder status along with the supporting rationale.","Given the mRNA TPM data from a bladder urothelial carcinoma patient’s tumor immune microenvironment, and considering the following details: male, white, bladder tissue origin, and a tumor mutational burden of 4.0 mutations per megabase, could you please assess the patient’s predicted response to Atezolizumab? Please include a conclusion regarding responder status along with the supporting rationale. Use the COMPASS platform to conduct a comprehensive transcriptomic profiling of the patient's tumor. Begin by assessing the tumor microenvironment: evaluate natural killer cell functionality, identify markers of T-cell exhaustion, and review B-cell activity for signs of immunosuppression. Next, analyze immune activation by examining macrophage responses, interferon-gamma signaling pathways, and any indicators of genomic instability. Conclude by preparing a detailed report that summarizes your findings and discusses their potential impact on the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"I have analyzed mRNA TPM data of a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA). The patient is a white male, with a bladder tumor displaying a mutational burden of 5.0 mutations per megabase. Based on this information, can you determine if the patient is likely to respond to Atezolizumab, and explain the clinical reasoning behind your assessment?","I have analyzed mRNA TPM data of a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA). The patient is a white male, with a bladder tumor displaying a mutational burden of 5.0 mutations per megabase. Based on this information, can you determine if the patient is likely to respond to Atezolizumab, and explain the clinical reasoning behind your assessment? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the patient's tumor. Begin by characterizing the tumor microenvironment—assess natural killer cell functionality, identify markers of T-cell exhaustion, and examine B-cell activity for evidence of immunosuppression. Next, evaluate immune activation by analyzing macrophage responses, interferon-gamma signaling pathways, and any signs of genomic instability. Finally, compile your observations into a comprehensive report that summarizes your findings and discusses their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"Based on the mRNA TPM data of the tumor immune microenvironment and additional clinical details for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA)—including female sex, White race, tumor located in the bladder, and a tumor mutational burden of 15.0 mutations per MB—could you please assess whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Based on the mRNA TPM data of the tumor immune microenvironment and additional clinical details for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA)—including female sex, White race, tumor located in the bladder, and a tumor mutational burden of 15.0 mutations per MB—could you please assess whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient’s tumor. Begin by thoroughly characterizing the tumor microenvironment: evaluate natural killer cell activity, assess markers indicative of T-cell exhaustion, and investigate B-cell function for signs of immunosuppression. Next, assess immune activation by examining macrophage responses, analyzing interferon-gamma signaling pathways, and looking for indicators of genomic instability. Finally, compile a detailed report summarizing your findings and discussing their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"For a patient with bladder urothelial carcinoma (BLCA) whose tumor profiling indicates an mRNA TPM-based immune microenvironment, male sex, white race, and a tumor mutational burden of 13.0 mutations/MB, can you evaluate the likelihood of responsiveness to Atezolizumab and provide the rationale for your assessment?","For a patient with bladder urothelial carcinoma (BLCA) whose tumor profiling indicates an mRNA TPM-based immune microenvironment, male sex, white race, and a tumor mutational burden of 13.0 mutations/MB, can you evaluate the likelihood of responsiveness to Atezolizumab and provide the rationale for your assessment? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient's tumor. Start by examining the tumor microenvironment: assess natural killer cell activity, evaluate markers associated with T-cell exhaustion, and investigate B-cell function for signs of immunosuppression. Then, evaluate immune activation by analyzing macrophage responses, examining interferon-gamma signaling pathways, and identifying any indicators of genomic instability. Finally, prepare a comprehensive report that summarizes your findings and discusses how these observations might influence the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"Based on an analysis of mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma, and considering the following clinical characteristics—Female, White, bladder tissue, and a tumor mutational burden of 14.0 mutations per MB—could you provide your assessment on whether this patient is expected to respond to Atezolizumab? Please include the conclusion along with the reasoning supporting your prediction.","Based on an analysis of mRNA TPM data reflecting the tumor immune microenvironment in a patient with bladder urothelial carcinoma, and considering the following clinical characteristics—Female, White, bladder tissue, and a tumor mutational burden of 14.0 mutations per MB—could you provide your assessment on whether this patient is expected to respond to Atezolizumab? Please include the conclusion along with the reasoning supporting your prediction. Utilize the COMPASS platform for a comprehensive transcriptomic evaluation of the patient's tumor. Begin by examining the tumor microenvironment: specifically, assess natural killer cell activity, identify markers indicative of T-cell exhaustion, and evaluate B-cell function for evidence of immunosuppression. Next, analyze immune activation by studying macrophage responses, interrogating interferon-gamma signaling pathways, and detecting markers of genomic instability. Finally, compile a detailed report summarizing your findings and discussing potential impacts on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"Based on mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA), can you provide an assessment of the patient’s predicted response to Atezolizumab? The patient is a 17.0 TMB (mutations per MB) male of Black or African American descent, with bladder tissue involvement. Please clarify whether this patient would be classified as a responder or non-responder, and summarize the supporting evidence for your conclusion.","Based on mRNA TPM data from a patient with Bladder Urothelial Carcinoma (BLCA), can you provide an assessment of the patient’s predicted response to Atezolizumab? The patient is a 17.0 TMB (mutations per MB) male of Black or African American descent, with bladder tissue involvement. Please clarify whether this patient would be classified as a responder or non-responder, and summarize the supporting evidence for your conclusion. Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient’s tumor. Start by evaluating the tumor microenvironment: assess natural killer cell activity, identify markers of T-cell exhaustion, and investigate B-cell function for signs of immunosuppression. Then, examine immune activation by analyzing macrophage responses, exploring interferon-gamma signaling pathways, and detecting markers of genomic instability. Finally, prepare a detailed report summarizing these findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"I have processed mRNA TPM data outlining the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient’s profile is as follows: male, white, bladder tissue, and a tumor mutational burden of 7.0 mutations per megabase. Based on these parameters, can you determine whether the patient is likely to respond to Atezolizumab and explain the reasoning behind your conclusion?","I have processed mRNA TPM data outlining the tumor immune microenvironment for a patient with bladder urothelial carcinoma (BLCA). The patient’s profile is as follows: male, white, bladder tissue, and a tumor mutational burden of 7.0 mutations per megabase. Based on these parameters, can you determine whether the patient is likely to respond to Atezolizumab and explain the reasoning behind your conclusion? Use the COMPASS platform to conduct a full transcriptomic evaluation of the patient’s tumor. Begin by characterizing the tumor microenvironment: measure natural killer cell activity, determine the presence of T-cell exhaustion markers, and assess B-cell function for any immunosuppressive signals. Next, evaluate immune activation by examining macrophage responses, analyzing interferon-gamma signaling pathways, and identifying markers of genomic instability. Finally, compile a comprehensive report detailing your findings and discussing how they may influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a white male, with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Based on these data, can you provide an assessment of whether the patient is likely to respond to Atezolizumab, along with the supporting clinical rationale?","I have mRNA TPM data reflecting the tumor immune microenvironment for a patient with bladder urothelial carcinoma. The patient is a white male, with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Based on these data, can you provide an assessment of whether the patient is likely to respond to Atezolizumab, along with the supporting clinical rationale? Please use the COMPASS platform to perform a complete transcriptomic analysis of the patient’s tumor. Start by assessing the tumor microenvironment: quantify natural killer cell activity, evaluate for T-cell exhaustion markers, and analyze B-cell functionality for any signs of immune suppression. Then, assess immune activation by examining macrophage responses, evaluating interferon-gamma signaling, and identifying markers of genomic instability. Finally, compile a detailed report outlining your findings and explaining their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA) and am considering the likelihood of a positive response to Atezolizumab. The patient is a male of White race, with a lung tissue sample, and has a tumor mutational burden of 20.0 mutations per megabase. Based on these clinical details, could you provide an assessment of whether this patient is likely to be a responder or non-responder to Atezolizumab, along with an explanation of the supporting rationale?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma (BLCA) and am considering the likelihood of a positive response to Atezolizumab. The patient is a male of White race, with a lung tissue sample, and has a tumor mutational burden of 20.0 mutations per megabase. Based on these clinical details, could you provide an assessment of whether this patient is likely to be a responder or non-responder to Atezolizumab, along with an explanation of the supporting rationale? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the patient's tumor. Begin by characterizing the tumor microenvironment: quantify the activity of natural killer cells, assess the expression of T-cell exhaustion markers, and evaluate B-cell functionality for potential immunosuppressive features. Next, analyze the degree of immune activation by examining macrophage responses, interferon-gamma signaling pathways, and indicators of genomic instability. Conclude by assembling a detailed report that summarizes your findings and discusses their possible implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"Based on the patient's mRNA TPM data from the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following clinical details: male, White, bladder tissue origin, BLCA diagnosis, and a tumor mutational burden of 3.0 mutations per megabase; does this profile predict responsiveness to Atezolizumab? Please classify the patient as a responder or non-responder and provide your supporting rationale.","Based on the patient's mRNA TPM data from the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA) and the following clinical details: male, White, bladder tissue origin, BLCA diagnosis, and a tumor mutational burden of 3.0 mutations per megabase; does this profile predict responsiveness to Atezolizumab? Please classify the patient as a responder or non-responder and provide your supporting rationale. Please use the COMPASS platform to perform an in-depth transcriptomic evaluation of the patient's tumor. Begin by examining the tumor microenvironment: quantify natural killer cell activity, evaluate the expression of T-cell exhaustion markers, and assess B-cell functionality to identify any immunosuppressive characteristics. Then, assess the overall level of immune activation by analyzing macrophage responses, interferon-gamma signaling pathways, and signs of genomic instability. Finally, compile a comprehensive report detailing your findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"I have obtained mRNA TPM data reflecting the immune microenvironment in a patient with Bladder Urothelial Carcinoma. The patient's characteristics are as follows: male, African American, tissue sample obtained from a lymph node, and tumor mutational burden data is unavailable. Based on these details, could you provide an assessment of the patient's likely responsiveness to atezolizumab and elaborate on the rationale behind this classification?","I have obtained mRNA TPM data reflecting the immune microenvironment in a patient with Bladder Urothelial Carcinoma. The patient's characteristics are as follows: male, African American, tissue sample obtained from a lymph node, and tumor mutational burden data is unavailable. Based on these details, could you provide an assessment of the patient's likely responsiveness to atezolizumab and elaborate on the rationale behind this classification? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient's tumor. Start by examining the tumor microenvironment, including quantifying natural killer cell activity, evaluating markers of T-cell exhaustion, and assessing B-cell functionality to detect any immunosuppressive features. Next, evaluate the overall immune activation by analyzing macrophage responses, interferon-gamma signaling pathways, and indicators of genomic instability. Finally, prepare a comprehensive report summarizing your findings and discussing their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement, and the tumor mutational burden (TMB) data is currently unavailable. Based on these details, could you help determine whether the patient is more likely to be a responder or non-responder to Atezolizumab, including the rationale behind your assessment?","I have mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with bladder tissue involvement, and the tumor mutational burden (TMB) data is currently unavailable. Based on these details, could you help determine whether the patient is more likely to be a responder or non-responder to Atezolizumab, including the rationale behind your assessment? Utilize the COMPASS platform to perform a comprehensive transcriptomic evaluation of the patient’s tumor. Begin by analyzing the tumor microenvironment: quantify natural killer cell activity, assess markers of T-cell exhaustion, and evaluate B-cell functionality to identify any immunosuppressive characteristics. Then, assess overall immune activation by examining macrophage responses, interferon-gamma signaling pathways, and indicators of genomic instability. Finally, compile a detailed report summarizing your findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate her tumor immune microenvironment and predict responsiveness to Atezolizumab. The patient is a white female with a tumor mutational burden of 8.0 mutations per MB. Based on these clinical details, could you determine if she is likely to be a responder or non-responder to Atezolizumab, and please elaborate on the rationale behind your conclusion?","I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) to evaluate her tumor immune microenvironment and predict responsiveness to Atezolizumab. The patient is a white female with a tumor mutational burden of 8.0 mutations per MB. Based on these clinical details, could you determine if she is likely to be a responder or non-responder to Atezolizumab, and please elaborate on the rationale behind your conclusion? Use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient’s tumor. Start by examining the tumor microenvironment, specifically quantifying natural killer cell activity, evaluating markers of T-cell exhaustion, and assessing B-cell function to identify any immunosuppressive features. Next, review overall immune activation by analyzing macrophage responses, interferon-gamma signaling pathways, and indicators of genomic instability. Finally, prepare a comprehensive report that summarizes these findings and discusses their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"Using mRNA TPM data from a tumor immune microenvironment analysis in a patient with bladder urothelial carcinoma (BLCA) and the following characteristics—male, white, kidney tissue sample, and a tumor mutational burden of 6.0 mutations/MB—do you consider the patient likely to respond to Atezolizumab treatment? Please include your supporting rationale.","Using mRNA TPM data from a tumor immune microenvironment analysis in a patient with bladder urothelial carcinoma (BLCA) and the following characteristics—male, white, kidney tissue sample, and a tumor mutational burden of 6.0 mutations/MB—do you consider the patient likely to respond to Atezolizumab treatment? Please include your supporting rationale. Please use the COMPASS platform to perform a comprehensive transcriptomic evaluation of the patient's tumor. Begin by analyzing the tumor microenvironment: quantify natural killer cell activity, assess markers associated with T-cell exhaustion, and examine B-cell function to detect any signs of immunosuppression. Then, evaluate overall immune activation by studying macrophage responses, interferon-gamma signaling pathways, and indicators of genomic instability. Finally, compile a detailed report that summarizes these findings and discusses their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"A 65-year-old white male with bladder urothelial carcinoma has been evaluated using mRNA TPM data to characterize his tumor immune microenvironment. With a tumor mutational burden of 17.0 mutations per megabase, how would you assess his predicted responsiveness to Atezolizumab, and could you provide the supporting rationale for your conclusion?","A 65-year-old white male with bladder urothelial carcinoma has been evaluated using mRNA TPM data to characterize his tumor immune microenvironment. With a tumor mutational burden of 17.0 mutations per megabase, how would you assess his predicted responsiveness to Atezolizumab, and could you provide the supporting rationale for your conclusion? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient’s tumor. Start with an evaluation of the tumor microenvironment by quantifying natural killer cell activity, assessing markers indicative of T-cell exhaustion, and analyzing B-cell function to determine any immunosuppressive effects. Next, assess overall immune activation by examining macrophage responses, characterizing interferon-gamma signaling pathways, and identifying signs of genomic instability. Finally, prepare a comprehensive report that summarizes these observations and explores their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"I have mRNA TPM data reflecting a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a kidney tissue sample and a tumor mutational burden of 6.0 mutations per megabase. Based on this information, could you determine whether the patient is likely to respond to Atezolizumab, and provide the supporting reasoning for your conclusion?","I have mRNA TPM data reflecting a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA). The patient is a white male with a kidney tissue sample and a tumor mutational burden of 6.0 mutations per megabase. Based on this information, could you determine whether the patient is likely to respond to Atezolizumab, and provide the supporting reasoning for your conclusion? Please utilize the COMPASS platform to perform an in-depth transcriptomic evaluation of the patient's tumor. Begin by assessing the tumor microenvironment: quantify natural killer cell activity, evaluate markers associated with T-cell exhaustion, and investigate B-cell function to detect any immunosuppressive influences. Then, examine overall immune activation by analyzing macrophage responses, delineating interferon-gamma signaling pathways, and searching for indicators of genomic instability. Finally, compile a detailed report summarizing these findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"Based on the processed mRNA TPM data and clinical details for a patient with Bladder Urothelial Carcinoma (BLCA) (male, white, lymph node tissue, FMOne mutation burden of 1.0 per MB), can you determine whether this patient is predicted to be a responder or non-responder to Atezolizumab? Please include your reasoning for this classification.","Based on the processed mRNA TPM data and clinical details for a patient with Bladder Urothelial Carcinoma (BLCA) (male, white, lymph node tissue, FMOne mutation burden of 1.0 per MB), can you determine whether this patient is predicted to be a responder or non-responder to Atezolizumab? Please include your reasoning for this classification. Please use the COMPASS platform to carry out a comprehensive transcriptomic analysis of the patient’s tumor. Start by evaluating the tumor microenvironment: measure natural killer cell activity, assess markers of T-cell exhaustion, and investigate B-cell function for signs of immunosuppression. Next, evaluate overall immune activation by examining macrophage responses, characterizing interferon-gamma signaling pathways, and identifying any indicators of genomic instability. Finally, prepare a detailed report summarizing your findings and discussing how these results might influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"Considering a male patient of White descent diagnosed with Bladder Urothelial Carcinoma, for whom we have processed mRNA TPM data from a kidney-derived tumor sample (with unavailable tumor mutational burden data), could you assess whether he is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Considering a male patient of White descent diagnosed with Bladder Urothelial Carcinoma, for whom we have processed mRNA TPM data from a kidney-derived tumor sample (with unavailable tumor mutational burden data), could you assess whether he is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient’s tumor. Begin by examining the tumor microenvironment—quantify natural killer cell activity, evaluate markers indicative of T-cell exhaustion, and assess B-cell function for evidence of immunosuppression. Next, assess overall immune activation by analyzing macrophage responses, characterizing interferon-gamma signaling pathways, and detecting any signs of genomic instability. Finally, compile a detailed report summarizing your observations and discuss how these findings might inform the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"A patient with Bladder Urothelial Carcinoma has been evaluated using mRNA TPM data to profile the tumor immune microenvironment, with the following clinical details: female, White, kidney tissue, and a tumor mutational burden of 7.0 mutations per MB. Based on these findings, could you please determine whether the patient is predicted to respond to Atezolizumab and provide the clinical rationale for this conclusion?","A patient with Bladder Urothelial Carcinoma has been evaluated using mRNA TPM data to profile the tumor immune microenvironment, with the following clinical details: female, White, kidney tissue, and a tumor mutational burden of 7.0 mutations per MB. Based on these findings, could you please determine whether the patient is predicted to respond to Atezolizumab and provide the clinical rationale for this conclusion? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient’s tumor. Begin by assessing the tumor microenvironment; specifically, quantify natural killer cell activity, evaluate markers that indicate T-cell exhaustion, and examine B-cell function for any signs of immunosuppression. Next, evaluate overall immune activation by analyzing macrophage responses, characterizing interferon-gamma signaling pathways, and identifying any indicators of genomic instability. Finally, prepare a comprehensive report summarizing your findings and discussing their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"Given mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA), could you determine whether this female, white patient—with a bladder tumor and a tumor mutational burden of 21 mutations per MB—is predicted to respond to Atezolizumab? Please provide a conclusion supported by your analysis.","Given mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA), could you determine whether this female, white patient—with a bladder tumor and a tumor mutational burden of 21 mutations per MB—is predicted to respond to Atezolizumab? Please provide a conclusion supported by your analysis. Please use the COMPASS platform to perform an in-depth transcriptomic analysis on the patient’s tumor sample. Begin by evaluating the tumor microenvironment: quantify natural killer cell activity, assess markers of T-cell exhaustion, and examine B-cell functions for any evidence of immunosuppression. Then, evaluate the overall immune response by analyzing macrophage activity, characterizing interferon-gamma signaling pathways, and identifying any signs of genomic instability. Finally, prepare a detailed report that summarizes your findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"Based on the mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma (male, white, tumor tissue from the ureter, and an FMOne mutation burden of 7.0 per MB), could you determine whether this patient is likely to respond to atezolizumab? Please provide your conclusion along with the reasoning behind it.","Based on the mRNA TPM data for the tumor immune microenvironment in a patient with bladder urothelial carcinoma (male, white, tumor tissue from the ureter, and an FMOne mutation burden of 7.0 per MB), could you determine whether this patient is likely to respond to atezolizumab? Please provide your conclusion along with the reasoning behind it. Please use the COMPASS platform to conduct a comprehensive transcriptomic evaluation of the patient’s tumor sample. First, assess the tumor microenvironment by measuring natural killer cell activity, evaluating markers of T-cell exhaustion, and analyzing B-cell function for any indications of immunosuppression. Next, examine the overall immune response by investigating macrophage activity, characterizing interferon-gamma signaling pathways, and detecting any evidence of genomic instability. Finally, compile a detailed report summarizing your findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"Given the patient's mRNA TPM data profiling the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with the following clinical details: male, White, lung tissue sampling, and a tumor mutational burden of 6.0 mutations per MB, can you evaluate whether this patient is likely to respond to Atezolizumab therapy? Please include your reasoning for the classification.","Given the patient's mRNA TPM data profiling the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with the following clinical details: male, White, lung tissue sampling, and a tumor mutational burden of 6.0 mutations per MB, can you evaluate whether this patient is likely to respond to Atezolizumab therapy? Please include your reasoning for the classification. Please use the COMPASS platform to perform a detailed transcriptomic analysis of the patient’s tumor sample. Begin by evaluating the tumor microenvironment: quantify natural killer cell activity, assess markers of T-cell exhaustion, and examine B-cell function for potential immunosuppressive effects. Then, investigate the overall immune response by measuring macrophage activity, analyzing interferon-gamma signaling pathways, and checking for signs of genomic instability. Finally, compile a comprehensive report that summarizes these findings and discusses their possible impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"Considering the mRNA TPM data of the tumor immune microenvironment for a male patient with Bladder Urothelial Carcinoma (BLCA) who has a tumor mutational burden of 6.0 mutations per MB and a kidney tissue sample, how likely is this patient to respond to Atezolizumab therapy, and what evidence supports classifying him as a responder or non-responder?","Considering the mRNA TPM data of the tumor immune microenvironment for a male patient with Bladder Urothelial Carcinoma (BLCA) who has a tumor mutational burden of 6.0 mutations per MB and a kidney tissue sample, how likely is this patient to respond to Atezolizumab therapy, and what evidence supports classifying him as a responder or non-responder? Use the COMPASS platform to conduct an in-depth transcriptomic evaluation of the patient's tumor sample. Start by characterizing the tumor microenvironment: measure the activity of natural killer cells, identify markers indicating T-cell exhaustion, and assess B-cell functionality for any immunosuppressive effects. Next, evaluate the broader immune response by quantifying macrophage activity, examining interferon-gamma signaling pathways, and looking for evidence of genomic instability. Conclude by preparing a detailed report that encapsulates these results and considers their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"Based on mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma, can you evaluate the likely responsiveness to atezolizumab? The patient is a  White male with bladder tissue involvement, and the tumor mutational burden data is not available. Please provide a conclusion on whether the patient is predicted to be a responder or non-responder, along with the supporting rationale.","Based on mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma, can you evaluate the likely responsiveness to atezolizumab? The patient is a  White male with bladder tissue involvement, and the tumor mutational burden data is not available. Please provide a conclusion on whether the patient is predicted to be a responder or non-responder, along with the supporting rationale. Please use the COMPASS platform to thoroughly analyze the transcriptomic profile of the patient's tumor. Begin by assessing the tumor microenvironment: evaluate natural killer cell activity, identify specific markers associated with T-cell exhaustion, and examine B-cell functionality for any immunosuppressive indicators. Subsequently, investigate the broader immune response by measuring macrophage activity, analyzing interferon-gamma signaling pathways, and detecting any signs of genomic instability. Finally, compile a comprehensive report summarizing these findings and discussing their potential impact on the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma, focusing on the tumor immune microenvironment. The patient's details are: male, White, bladder tissue origin, with a Tumor Mutational Burden of 3.0 mutations per MB. Based on these findings, could you assess whether the patient is likely to respond to Atezolizumab, and please provide the clinical reasoning behind your conclusion?","I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma, focusing on the tumor immune microenvironment. The patient's details are: male, White, bladder tissue origin, with a Tumor Mutational Burden of 3.0 mutations per MB. Based on these findings, could you assess whether the patient is likely to respond to Atezolizumab, and please provide the clinical reasoning behind your conclusion? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the patient’s tumor. Start by evaluating the tumor microenvironment: assess natural killer cell activity, look for markers indicative of T-cell exhaustion, and review B-cell function for signs of immunosuppressive behavior. Next, analyze the overall immune response by measuring macrophage activity, examining interferon-gamma signaling pathways, and identifying any evidence of genomic instability. Finally, prepare a comprehensive report that summarizes these findings and discusses how they may influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"Given the patient's mRNA TPM data outlining the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), along with their clinical factors (male, Asian, bladder tissue involvement, and a tumor mutational burden of 5.0 mutations per MB), can you provide an assessment of whether this patient is likely to respond to Atezolizumab, including the supporting rationale for your conclusion?","Given the patient's mRNA TPM data outlining the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), along with their clinical factors (male, Asian, bladder tissue involvement, and a tumor mutational burden of 5.0 mutations per MB), can you provide an assessment of whether this patient is likely to respond to Atezolizumab, including the supporting rationale for your conclusion? Utilize the COMPASS platform to carry out an in-depth transcriptomic analysis of the patient's tumor. Begin by assessing the tumor microenvironment—evaluate natural killer cell activity, identify markers indicative of T-cell exhaustion, and review B-cell functionality for signs of immunosuppressive behavior. Next, analyze the overall immune response by measuring macrophage activity, examining interferon-gamma signaling pathways, and determining any evidence of genomic instability. Finally, compile a comprehensive report that summarizes these observations and discusses how they might impact the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) who is under consideration for Atezolizumab therapy. The patient is a white male with a bladder tumor and unavailable tumor mutational burden information. Based on this data, can we determine whether the patient is likely to respond or not respond to Atezolizumab, and could you explain the rationale behind your conclusion?","I have mRNA TPM data reflecting the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA) who is under consideration for Atezolizumab therapy. The patient is a white male with a bladder tumor and unavailable tumor mutational burden information. Based on this data, can we determine whether the patient is likely to respond or not respond to Atezolizumab, and could you explain the rationale behind your conclusion? Use the COMPASS platform for a detailed transcriptomic analysis of the patient's tumor. Begin by examining the tumor microenvironment: assess natural killer cell function, identify markers of T-cell exhaustion, and evaluate B-cell activity for signs of immunosuppressive behavior. Next, analyze the overall immune response by quantifying macrophage activity, scrutinizing interferon-gamma signaling pathways, and investigating indicators of genomic instability. Finally, compile a comprehensive report summarizing these findings and outlining their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and would like to evaluate her predicted response to Atezolizumab immunotherapy. The patient is a white female with a ureter tissue specimen and a tumor mutational burden of 12.0 mutations per megabase. Based on these molecular and clinical characteristics, could you provide your assessment on whether she is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your conclusion?","I have processed mRNA TPM data for a patient with Bladder Urothelial Carcinoma (BLCA) and would like to evaluate her predicted response to Atezolizumab immunotherapy. The patient is a white female with a ureter tissue specimen and a tumor mutational burden of 12.0 mutations per megabase. Based on these molecular and clinical characteristics, could you provide your assessment on whether she is likely to be a responder or non-responder to Atezolizumab, and explain the rationale behind your conclusion? Utilize the COMPASS platform to perform an in-depth transcriptomic analysis of the patient’s tumor. Start by assessing the tumor microenvironment: evaluate natural killer cell function, detect markers indicating T-cell exhaustion, and determine whether B-cell activity exhibits immunosuppressive characteristics. Then, assess the overall immune response by measuring macrophage activity, examining interferon-gamma signaling pathways, and looking for signs of genomic instability. Finally, prepare a detailed report summarizing these results and discussing their implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma. The patient is a white male with a tumor located in the ureter, and the tumor mutational burden is not available. Based on this information, can you evaluate whether this patient is likely to respond to Atezolizumab and provide supporting reasoning for your conclusion?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma. The patient is a white male with a tumor located in the ureter, and the tumor mutational burden is not available. Based on this information, can you evaluate whether this patient is likely to respond to Atezolizumab and provide supporting reasoning for your conclusion? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the patient’s tumor. Begin by assessing the tumor microenvironment: evaluate the function of natural killer cells, identify markers that indicate T‐cell exhaustion, and determine if B-cell activity is contributing to an immunosuppressive milieu. Next, evaluate the overall immune response by measuring macrophage activity, analyzing interferon‐gamma signaling pathways, and detecting any signs of genomic instability. Finally, compile your findings into a detailed report that discusses the implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"For a female, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations per megabase, whose tumor immune microenvironment has been profiled via mRNA TPM data, how would you predict her responsiveness to Atezolizumab? Please provide a conclusion on whether she is likely to be a responder or non-responder, along with the supporting rationale.","For a female, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations per megabase, whose tumor immune microenvironment has been profiled via mRNA TPM data, how would you predict her responsiveness to Atezolizumab? Please provide a conclusion on whether she is likely to be a responder or non-responder, along with the supporting rationale. Please use the COMPASS platform to perform an in-depth transcriptomic analysis of the patient’s tumor. Start by examining the tumor microenvironment: assess the functionality of natural killer cells, look for markers indicative of T-cell exhaustion, and evaluate whether B-cell activity may be creating an immunosuppressive environment. Following this, analyze the overall immune response by measuring macrophage activity, studying the interferon-gamma signaling pathways, and identifying any evidence of genomic instability. Once the analysis is complete, prepare a detailed report summarizing your findings and discussing their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"For a patient with bladder urothelial carcinoma who is a white male, with a lymph node sample and a tumor mutational burden of 4.0 mutations per MB, how would you predict his likely response to Atezolizumab? Please include your reasoning regarding whether you would classify him as a responder or non-responder based on the processed mRNA TPM data from his tumor immune microenvironment.","For a patient with bladder urothelial carcinoma who is a white male, with a lymph node sample and a tumor mutational burden of 4.0 mutations per MB, how would you predict his likely response to Atezolizumab? Please include your reasoning regarding whether you would classify him as a responder or non-responder based on the processed mRNA TPM data from his tumor immune microenvironment. Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the patient’s tumor. Begin by assessing the tumor microenvironment: evaluate natural killer cell functionality, detect markers of T-cell exhaustion, and determine if B-cell activity might contribute to an immunosuppressive milieu. Next, examine the overall immune response by quantifying macrophage activity, analyzing interferon-gamma signaling pathways, and identifying any signs of genomic instability. Finally, compile your findings into a detailed report that discusses the potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient's details are: male, white, bladder tissue involved, and a tumor mutational burden of 8 mutations per MB. Could you help determine whether this patient is likely to respond to Atezolizumab, and provide the rationale behind your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient's details are: male, white, bladder tissue involved, and a tumor mutational burden of 8 mutations per MB. Could you help determine whether this patient is likely to respond to Atezolizumab, and provide the rationale behind your conclusion? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the patient’s tumor. Start by examining the tumor microenvironment: assess the functionality of natural killer cells, check for markers indicating T-cell exhaustion, and evaluate whether B-cell activity is contributing to an immunosuppressive environment. Then, analyze the overall immune response by quantifying macrophage activity, reviewing interferon-gamma signaling pathways, and detecting any evidence of genomic instability. Finally, prepare a comprehensive report that explains how these findings may impact the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with data indicating an unavailable tumor mutational burden (TMB). Based on these findings, can you determine whether this patient is likely to respond to Atezolizumab, and provide the rationale behind your conclusion?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment in a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with data indicating an unavailable tumor mutational burden (TMB). Based on these findings, can you determine whether this patient is likely to respond to Atezolizumab, and provide the rationale behind your conclusion? Please utilize the COMPASS platform to carry out a comprehensive transcriptomic analysis of the patient’s tumor sample. Begin by evaluating the tumor microenvironment—specifically:

1. Assess the functional status of natural killer cells.
2. Check for markers that indicate T-cell exhaustion.
3. Determine if there is evidence that B-cell activity is fostering an immunosuppressive milieu.

Next, extend the analysis to the overall immune response by:

1. Quantifying macrophage activity.
2. Reviewing interferon-gamma signaling pathways.
3. Investigating any signs of genomic instability.

Finally, prepare a detailed report that interprets these findings and discusses how they might influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"I have processed mRNA TPM data from a bladder urothelial carcinoma (BLCA) patient, and I need to evaluate his predicted response to atezolizumab. The patient is a Black or African American male with a bladder tumor and a tumor mutational burden of 1.0 mutation per megabase. Based on this genomic and clinical data, could you determine whether he is likely to be a responder or non-responder to atezolizumab, and explain the reasoning behind your conclusion?","I have processed mRNA TPM data from a bladder urothelial carcinoma (BLCA) patient, and I need to evaluate his predicted response to atezolizumab. The patient is a Black or African American male with a bladder tumor and a tumor mutational burden of 1.0 mutation per megabase. Based on this genomic and clinical data, could you determine whether he is likely to be a responder or non-responder to atezolizumab, and explain the reasoning behind your conclusion? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis on the patient's tumor sample. Start by examining the tumor microenvironment: evaluate the functional status of natural killer cells, identify any markers of T-cell exhaustion, and assess whether B-cell activity is contributing to an immunosuppressive environment. Then, broaden your analysis to the overall immune response by quantifying macrophage activity, reviewing interferon-gamma signaling pathways, and assessing for signs of genomic instability. Finally, compile a detailed report that interprets these findings and discusses the potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"I have mRNA TPM data for the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a male of Asian descent, with a kidney tissue sample and a tumor mutational burden of 11.0 mutations/MB. Based on these parameters, can you assess whether the patient is more likely to be a responder or a non-responder to Atezolizumab, and explain the reasoning behind your assessment?","I have mRNA TPM data for the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a male of Asian descent, with a kidney tissue sample and a tumor mutational burden of 11.0 mutations/MB. Based on these parameters, can you assess whether the patient is more likely to be a responder or a non-responder to Atezolizumab, and explain the reasoning behind your assessment? Please use the COMPASS platform to conduct an in-depth transcriptomic profiling of the tumor sample. Begin by examining the tumor microenvironment: assess the functional status of natural killer cells, look for indicators of T-cell exhaustion, and determine if B-cell activity is fostering an immunosuppressive environment. Then, expand your evaluation to the overall immune response by measuring macrophage activity, analyzing interferon-gamma signaling pathways, and identifying any evidence of genomic instability. Finally, compile a detailed report that interprets these findings and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"I have processed mRNA TPM data for the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma. The patient is a  white male, and the analysis was based on a kidney tissue sample with a tumor mutational burden of 8.0 mutations per MB. Based on this information, can you determine whether the patient is predicted to be a responder or non-responder to atezolizumab, and please provide your supporting reasoning?","I have processed mRNA TPM data for the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma. The patient is a  white male, and the analysis was based on a kidney tissue sample with a tumor mutational burden of 8.0 mutations per MB. Based on this information, can you determine whether the patient is predicted to be a responder or non-responder to atezolizumab, and please provide your supporting reasoning? Please utilize the COMPASS platform to perform a comprehensive transcriptomic analysis on the tumor sample. Start by assessing the tumor microenvironment: evaluate natural killer cell functionality, identify signs of T-cell exhaustion, and determine whether B-cell activity is contributing to an immunosuppressive milieu. Next, assess the overall immune response by measuring macrophage activity, analyzing interferon-gamma signaling pathways, and detecting any indications of genomic instability. Finally, prepare a detailed report that interprets these findings and explores their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"For a patient with Bladder Urothelial Carcinoma characterized by the following attributes—female, White, bladder tissue origin, and a tumor mutational burden of 7.0 mutations per MB—can you interpret the mRNA TPM data from the tumor immune microenvironment to determine whether she is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","For a patient with Bladder Urothelial Carcinoma characterized by the following attributes—female, White, bladder tissue origin, and a tumor mutational burden of 7.0 mutations per MB—can you interpret the mRNA TPM data from the tumor immune microenvironment to determine whether she is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Please use the COMPASS platform to perform a thorough transcriptomic analysis of the tumor sample. Begin by examining the tumor microenvironment: assess natural killer cell function, look for signs of T-cell exhaustion, and evaluate whether B-cell activity might be contributing to immunosuppression. Then, evaluate the overall immune response by measuring macrophage activity, analyzing interferon-gamma signaling pathways, and screening for genomic instability. Finally, compile a detailed report that interprets your findings and discusses the potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"We have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a  male of White ethnicity, with a tissue sample labeled ""other,"" and the tumor mutational burden data are not available. Based on these clinical and molecular findings, how would you assess the likelihood of response to Atezolizumab, and could you provide the reasoning behind your conclusion?","We have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma. The patient is a  male of White ethnicity, with a tissue sample labeled ""other,"" and the tumor mutational burden data are not available. Based on these clinical and molecular findings, how would you assess the likelihood of response to Atezolizumab, and could you provide the reasoning behind your conclusion? Use the COMPASS platform to conduct a detailed transcriptomic evaluation of the tumor sample. Begin by assessing the tumor microenvironment: evaluate natural killer cell function, look for evidence of T-cell exhaustion, and determine if B-cell activity is contributing to immunosuppression. Next, investigate the overall immune response by analyzing macrophage activity, examining interferon-gamma signaling pathways, and screening for genomic instability. Finally, compile a comprehensive report that interprets your findings and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"A male, white patient with bladder urothelial carcinoma (BLCA) has been profiled using mRNA TPM data of the tumor immune microenvironment, and his tumor mutational burden is 5.0 mutations per megabase. Based on this molecular and clinical information, can you assess whether he is likely to respond to atezolizumab, and please provide the supporting rationale for your conclusion?","A male, white patient with bladder urothelial carcinoma (BLCA) has been profiled using mRNA TPM data of the tumor immune microenvironment, and his tumor mutational burden is 5.0 mutations per megabase. Based on this molecular and clinical information, can you assess whether he is likely to respond to atezolizumab, and please provide the supporting rationale for your conclusion? Utilize the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample. Start by evaluating the tumor microenvironment: assess natural killer cell function, identify any signs of T-cell exhaustion, and determine the role of B-cells in immunosuppression. Next, analyze the broader immune response by examining macrophage activity, reviewing interferon-gamma signaling pathways, and screening for genomic instability. Finally, compile a detailed report that interprets your findings and discusses their potential impact on the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"I have processed mRNA TPM data for a patient with bladder urothelial carcinoma whose tumor immune microenvironment has been characterized. The patient's clinical details include: male, white, with a lung tissue sample and a tumor mutational burden of 8 mutations per megabase. Based on these findings, could you assess the likelihood of this patient responding to Atezolizumab, and detail the rationale behind your determination?","I have processed mRNA TPM data for a patient with bladder urothelial carcinoma whose tumor immune microenvironment has been characterized. The patient's clinical details include: male, white, with a lung tissue sample and a tumor mutational burden of 8 mutations per megabase. Based on these findings, could you assess the likelihood of this patient responding to Atezolizumab, and detail the rationale behind your determination? Please use the COMPASS platform to conduct a full transcriptomic analysis of the tumor sample. Begin by examining the tumor microenvironment—evaluate natural killer cell activity, look for evidence of T-cell exhaustion, and assess if B-cells are contributing to immunosuppression. Next, broaden your analysis to include the overall immune response; specifically, review macrophage activity, analyze interferon-gamma signaling pathways, and check for signs of genomic instability. Finally, compile a comprehensive report summarizing your findings and outlining how these may affect the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"For a 14.0 mutations/MB bladder urothelial carcinoma patient (white female) with available mRNA TPM data reflecting the tumor immune microenvironment, could you determine whether this patient is likely to respond to atezolizumab and provide the clinical rationale behind your assessment?","For a 14.0 mutations/MB bladder urothelial carcinoma patient (white female) with available mRNA TPM data reflecting the tumor immune microenvironment, could you determine whether this patient is likely to respond to atezolizumab and provide the clinical rationale behind your assessment? Please perform a comprehensive transcriptomic analysis of the tumor sample using the COMPASS platform. Begin by investigating the tumor microenvironment: assess natural killer cell activity, look for indications of T-cell exhaustion, and determine whether B-cells are playing a role in immunosuppression. Then, extend your evaluation to the overall immune response by examining macrophage activity, analyzing interferon-gamma signaling pathways, and identifying any markers of genomic instability. Finally, prepare a detailed report that summarizes your findings and discusses how they may inform the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"Based on processed mRNA TPM data from the tumor immune microenvironment in a case of bladder urothelial carcinoma (BLCA), could you evaluate the predicted response to Atezolizumab for this patient? The patient is a male, White individual with a bladder tumor, and the tumor mutational burden is 13 mutations/Mb. Please provide your assessment of whether the patient is likely to respond to treatment, along with the rationale for your conclusion.","Based on processed mRNA TPM data from the tumor immune microenvironment in a case of bladder urothelial carcinoma (BLCA), could you evaluate the predicted response to Atezolizumab for this patient? The patient is a male, White individual with a bladder tumor, and the tumor mutational burden is 13 mutations/Mb. Please provide your assessment of whether the patient is likely to respond to treatment, along with the rationale for your conclusion. Conduct a thorough transcriptomic analysis of the tumor sample using the COMPASS platform. Start by evaluating the tumor microenvironment: quantify natural killer cell activity, assess for signs of T-cell exhaustion, and determine if B-cells contribute to immunosuppression. Next, broaden the evaluation to include the overall immune response by assessing macrophage activity, analyzing interferon-gamma signaling pathways, and identifying any markers indicative of genomic instability. Finally, compile a detailed report that summarizes these findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"I have analyzed mRNA TPM data of a patient's tumor immune microenvironment for bladder urothelial carcinoma. The patient is a 14-mutations/Mb tumor-bearing, Asian male with bladder tissue involvement. Based on these parameters, could you evaluate and determine if this patient is likely to respond to Atezolizumab, and explain your reasoning?","I have analyzed mRNA TPM data of a patient's tumor immune microenvironment for bladder urothelial carcinoma. The patient is a 14-mutations/Mb tumor-bearing, Asian male with bladder tissue involvement. Based on these parameters, could you evaluate and determine if this patient is likely to respond to Atezolizumab, and explain your reasoning? Perform a comprehensive transcriptomic assessment of the tumor sample using the COMPASS platform. Begin by characterizing the tumor microenvironment: quantify natural killer cell activity, evaluate markers of T-cell exhaustion, and determine whether B-cells are contributing to immunosuppressive processes. Subsequently, expand your analysis to include the overall immune response by assessing macrophage function, examining interferon-gamma signaling pathways, and identifying markers of genomic instability. Finally, prepare a detailed report that synthesizes these findings and outlines their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"In a patient with Bladder Urothelial Carcinoma (BLCA) presenting with the following attributes—male, white, kidney tissue, and a tumor mutational burden of 7.0 mutations per MB—and having processed mRNA TPM data profiling the tumor immune microenvironment, could you assess the predicted responsiveness to Atezolizumab? Please include the rationale for classifying this patient as a responder or non-responder.","In a patient with Bladder Urothelial Carcinoma (BLCA) presenting with the following attributes—male, white, kidney tissue, and a tumor mutational burden of 7.0 mutations per MB—and having processed mRNA TPM data profiling the tumor immune microenvironment, could you assess the predicted responsiveness to Atezolizumab? Please include the rationale for classifying this patient as a responder or non-responder. Conduct a thorough transcriptomic analysis of the tumor using the COMPASS platform. Begin by evaluating the tumor microenvironment: measure natural killer cell activity, assess markers indicative of T-cell exhaustion, and determine whether B cells are involved in promoting immunosuppression. Then, broaden your investigation to encompass the overall immune response by assessing macrophage function, analyzing interferon-gamma signaling pathways, and identifying indicators of genomic instability. Conclude by preparing a comprehensive report that integrates these data and discusses their relevance to the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"A patient diagnosed with Bladder Urothelial Carcinoma (BLCA) has undergone mRNA TPM profiling of the tumor immune microenvironment. The patient is a white male with a tumor mutational burden of 6 mutations per megabase. Based on these data, could you provide your assessment on the likelihood of a positive response to Atezolizumab, along with the clinical reasoning behind your conclusion?","A patient diagnosed with Bladder Urothelial Carcinoma (BLCA) has undergone mRNA TPM profiling of the tumor immune microenvironment. The patient is a white male with a tumor mutational burden of 6 mutations per megabase. Based on these data, could you provide your assessment on the likelihood of a positive response to Atezolizumab, along with the clinical reasoning behind your conclusion? Please perform a comprehensive transcriptomic analysis of the tumor using the COMPASS platform. Start by evaluating the tumor microenvironment: measure natural killer cell activity, assess markers of T-cell exhaustion, and determine whether B cells play a role in immunosuppression. Next, expand your analysis to include the overall immune response by examining macrophage function, analyzing interferon-gamma signaling pathways, and identifying signs of genomic instability. Finally, compile a detailed report that integrates these findings and discusses their implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"For a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled using mRNA TPM data, can you determine whether they are likely to respond to Atezolizumab? The patient is a white male with kidney tissue involvement and a tumor mutational burden of 6.0 mutations per megabase (FMOne mutation burden). Please provide your conclusion along with the supporting rationale.","For a patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled using mRNA TPM data, can you determine whether they are likely to respond to Atezolizumab? The patient is a white male with kidney tissue involvement and a tumor mutational burden of 6.0 mutations per megabase (FMOne mutation burden). Please provide your conclusion along with the supporting rationale. Please conduct a detailed transcriptomic analysis of the tumor using the COMPASS platform. Begin by examining the tumor microenvironment: assess natural killer cell activity, evaluate markers of T-cell exhaustion, and determine the potential role of B cells in immunosuppression. Then, broaden your assessment to include the overall immune response by analyzing macrophage function, investigating interferon-gamma signaling pathways, and identifying any indicators of genomic instability. Once these evaluations are complete, compile a comprehensive report that integrates all findings and discusses their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"I have analyzed mRNA TPM data of the tumor immune microenvironment for a white male patient with Bladder Urothelial Carcinoma (BLCA), whose tumor mutational burden is 5.0 mutations/MB. Based on this information, could you provide your assessment of whether this patient is likely to respond to Atezolizumab, along with your supporting rationale?","I have analyzed mRNA TPM data of the tumor immune microenvironment for a white male patient with Bladder Urothelial Carcinoma (BLCA), whose tumor mutational burden is 5.0 mutations/MB. Based on this information, could you provide your assessment of whether this patient is likely to respond to Atezolizumab, along with your supporting rationale? Please perform a comprehensive transcriptomic analysis of the tumor using the COMPASS platform. Start by evaluating the tumor microenvironment: measure natural killer cell activity, assess markers associated with T-cell exhaustion, and investigate the role of B cells in mediating immunosuppression. Next, expand your evaluation to capture the overall immune response by analyzing macrophage functionality, exploring interferon-gamma signaling pathways, and detecting any signs of genomic instability. After completing these assessments, prepare a detailed report that integrates all findings and discusses how they may influence the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"Based on the processed mRNA TPM data detailing the tumor immune microenvironment, along with the patient’s characteristics (male, white, bladder tissue diagnosis of bladder urothelial carcinoma with a tumor mutational burden of 49.0 mutations per megabase), can you determine whether this patient is likely to be a responder to Atezolizumab? Please include your rationale for this prediction.","Based on the processed mRNA TPM data detailing the tumor immune microenvironment, along with the patient’s characteristics (male, white, bladder tissue diagnosis of bladder urothelial carcinoma with a tumor mutational burden of 49.0 mutations per megabase), can you determine whether this patient is likely to be a responder to Atezolizumab? Please include your rationale for this prediction. Please conduct an in-depth transcriptomic analysis of the tumor sample using the COMPASS platform. Begin by examining the tumor microenvironment: quantify natural killer cell activity, evaluate markers indicative of T-cell exhaustion, and assess the role of B cells in promoting immunosuppression. Then extend your analysis to encompass the overall immune response by investigating macrophage functionality, detailing interferon-gamma signaling pathways, and identifying any evidence of genomic instability. Finally, compile a comprehensive report that integrates these findings, with a discussion on how they may guide the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a White male with bladder tissue involvement and a tumor mutational burden of 12 mutations per MB. Based on these clinical characteristics, could you evaluate whether he is likely to respond to atezolizumab, providing detailed reasoning for your conclusion?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a White male with bladder tissue involvement and a tumor mutational burden of 12 mutations per MB. Based on these clinical characteristics, could you evaluate whether he is likely to respond to atezolizumab, providing detailed reasoning for your conclusion? Please perform a comprehensive transcriptomic evaluation of the patient's tumor sample using the COMPASS platform. Start by analyzing the tumor microenvironment: measure the activity of natural killer cells, assess markers of T-cell exhaustion, and evaluate the contribution of B cells toward immunosuppression. Next, broaden the investigation to include the overall immune response by assessing macrophage function, characterizing interferon-gamma signaling pathways, and examining the sample for signs of genomic instability. Finally, prepare a detailed report that integrates all these findings and discusses their implications for guiding the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data reflecting this patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA) and am currently evaluating their predicted response to Atezolizumab. The patient is a male, White, with a bladder tumor and a reported tumor mutational burden (FMOne mutation burden per MB) value of ""nan."" Could you please provide your assessment of whether this patient is likely a responder or non-responder to Atezolizumab, including the rationale for your conclusion?","I have processed mRNA TPM data reflecting this patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA) and am currently evaluating their predicted response to Atezolizumab. The patient is a male, White, with a bladder tumor and a reported tumor mutational burden (FMOne mutation burden per MB) value of ""nan."" Could you please provide your assessment of whether this patient is likely a responder or non-responder to Atezolizumab, including the rationale for your conclusion? Perform a comprehensive transcriptomic analysis of the patient's tumor sample using the COMPASS platform. Begin by characterizing the tumor microenvironment: quantify natural killer cell activity, evaluate markers of T-cell exhaustion, and assess the influence of B cells on immunosuppression. Then, extend your evaluation to the broader immune response by examining macrophage function, analyzing interferon-gamma signaling pathways, and detecting signs of genomic instability. Conclude by preparing an integrated, detailed report that outlines the findings and discusses their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,Please review the patient's mRNA TPM data reflecting the tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA) and determine the predicted response to Atezolizumab. The patient is a white male with bladder tissue tumors and a tumor mutational burden of 5.0 mutations per megabase. Could you classify this patient as a responder or non-responder to Atezolizumab and provide your clinical reasoning?,"Please review the patient's mRNA TPM data reflecting the tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA) and determine the predicted response to Atezolizumab. The patient is a white male with bladder tissue tumors and a tumor mutational burden of 5.0 mutations per megabase. Could you classify this patient as a responder or non-responder to Atezolizumab and provide your clinical reasoning? Please perform an in-depth transcriptomic analysis of the patient's tumor sample using the COMPASS platform. Your analysis should begin with an evaluation of the tumor microenvironment, focusing on quantifying natural killer cell activity, assessing markers indicative of T-cell exhaustion, and examining the role of B cells in mediating immunosuppression. Next, address the broader immune response by analyzing macrophage function, characterizing interferon-gamma signaling pathways, and identifying any evidence of genomic instability. Finally, compile a comprehensive and detailed report summarizing your findings and discussing how these results may influence the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"Based on the following patient data—male, Black or African American, with Bladder Urothelial Carcinoma (BLCA) (tumor tissue sample from the kidney) and a tumor mutational burden of 11.0 mutations per megabase—can you determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the rationale behind your assessment.","Based on the following patient data—male, Black or African American, with Bladder Urothelial Carcinoma (BLCA) (tumor tissue sample from the kidney) and a tumor mutational burden of 11.0 mutations per megabase—can you determine whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the rationale behind your assessment. Please conduct a comprehensive transcriptomic analysis of the patient's tumor sample using the COMPASS platform. Begin by evaluating the tumor microenvironment—specifically, quantify natural killer cell activity, assess markers of T-cell exhaustion, and explore the contribution of B cells to immunosuppression. Next, examine the overall immune response by analyzing macrophage function, detailing interferon-gamma signaling pathways, and investigating signs of genomic instability. Finally, compile a detailed report that summarizes your findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment of a 67-year-old white male with bladder urothelial carcinoma (BLCA) and noting that the tumor mutational burden is unavailable, could you provide a clinical interpretation of this patient’s predicted responsiveness to Atezolizumab? Please include a detailed rationale supporting your conclusion on whether he is likely to be classified as a responder or non-responder.","Based on processed mRNA TPM data reflecting the tumor immune microenvironment of a 67-year-old white male with bladder urothelial carcinoma (BLCA) and noting that the tumor mutational burden is unavailable, could you provide a clinical interpretation of this patient’s predicted responsiveness to Atezolizumab? Please include a detailed rationale supporting your conclusion on whether he is likely to be classified as a responder or non-responder. Please perform a detailed transcriptomic analysis of the patient's tumor sample using the COMPASS platform. Start by assessing the tumor microenvironment: measure natural killer cell activity, evaluate T-cell exhaustion markers, and determine the role of B cells in promoting immunosuppression. Then, analyze the overall immune response by examining macrophage activity, detailing interferon-gamma signaling pathways, and identifying any indications of genomic instability. Conclude by generating a comprehensive report that summarizes your findings and discusses their implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and would like to assess the predicted responsiveness to Atezolizumab. The patient’s characteristics are as follows: male, White, tumor tissue derived from the ureter, and a reported tumor mutational burden of ""nan."" Could you please provide an analysis on whether this patient is more likely to be a responder or a non-responder to Atezolizumab, including the rationale for your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and would like to assess the predicted responsiveness to Atezolizumab. The patient’s characteristics are as follows: male, White, tumor tissue derived from the ureter, and a reported tumor mutational burden of ""nan."" Could you please provide an analysis on whether this patient is more likely to be a responder or a non-responder to Atezolizumab, including the rationale for your conclusion? Please analyze the patient's tumor sample using the COMPASS platform by conducting a comprehensive transcriptomic evaluation. Begin by characterizing the tumor microenvironment: assess natural killer cell activity, examine T-cell exhaustion markers, and investigate the influence of B cells on immunosuppression. Next, evaluate the broader immune response by analyzing macrophage function and detailing interferon-gamma signaling pathways, while also checking for signs of genomic instability. Finally, compile a complete report that summarizes these findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The clinical details include male sex, white race, bladder tissue involvement, and a tumor mutational burden of 17.0 mutations per megabase. Based on these findings, could you assess the likelihood of a favorable response to Atezolizumab and provide your reasoning for classifying the patient as a responder or non-responder?","I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The clinical details include male sex, white race, bladder tissue involvement, and a tumor mutational burden of 17.0 mutations per megabase. Based on these findings, could you assess the likelihood of a favorable response to Atezolizumab and provide your reasoning for classifying the patient as a responder or non-responder? Please examine the patient's tumor sample using the COMPASS platform with a full transcriptomic analysis. Start by characterizing the tumor microenvironment, including an assessment of natural killer cell activity, evaluation of T-cell exhaustion markers, and analysis of how B cells may be contributing to immunosuppression. Then, investigate the overall immune response by determining macrophage function, outlining the interferon-gamma signaling pathways, and identifying any signs of genomic instability. Finally, prepare a detailed report summarizing your findings and discussing their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"Based on the patient's mRNA TPM data representing the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with a tumor mutational burden of 22.0 mutations per MB, can you assess whether this individual—a white male with bladder tissue involvement—is likely to respond to Atezolizumab therapy? Please provide your conclusion with supporting evidence.","Based on the patient's mRNA TPM data representing the tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with a tumor mutational burden of 22.0 mutations per MB, can you assess whether this individual—a white male with bladder tissue involvement—is likely to respond to Atezolizumab therapy? Please provide your conclusion with supporting evidence. Please analyze the patient’s tumor specimen utilizing the COMPASS platform with comprehensive transcriptomic profiling. Begin by assessing the tumor microenvironment: evaluate natural killer cell activity, measure markers of T-cell exhaustion, and determine the role of B cells in immunosuppression. Next, assess the overall immune response by investigating macrophage function, mapping interferon-gamma signaling pathways, and detecting any indicators of genomic instability. Finally, compile a detailed report of your findings, including a discussion of their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"Based on the mRNA TPM data from the tumor immune microenvironment analysis of a male, White patient with bladder urothelial carcinoma, could you determine whether this patient is likely to respond to Atezolizumab? The assessment should consider that the tumor mutational burden (FMOne mutation burden per MB) is reported as nan, and provide a rationale for classifying the patient as a responder or non-responder.","Based on the mRNA TPM data from the tumor immune microenvironment analysis of a male, White patient with bladder urothelial carcinoma, could you determine whether this patient is likely to respond to Atezolizumab? The assessment should consider that the tumor mutational burden (FMOne mutation burden per MB) is reported as nan, and provide a rationale for classifying the patient as a responder or non-responder. Please examine the tumor specimen using the COMPASS platform with a thorough transcriptomic analysis. Start by evaluating the tumor microenvironment: assess natural killer cell activity, quantify markers of T-cell exhaustion, and investigate the contribution of B cells to immunosuppression. Next, review the overall immune response by analyzing macrophage function, outlining the interferon-gamma signaling pathways, and identifying any signs of genomic instability. Finally, prepare a comprehensive report detailing your findings and discussing their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"Given a patient's tumor immune microenvironment mRNA TPM data from Bladder Urothelial Carcinoma, along with the following clinical details: Sex: Male; Race: Other; Tissue: Kidney; Tumor Mutational Burden: 18.0 mutations per MB, would you classify the patient as a responder or non-responder to Atezolizumab? Please provide your conclusion with supporting reasoning.","Given a patient's tumor immune microenvironment mRNA TPM data from Bladder Urothelial Carcinoma, along with the following clinical details: Sex: Male; Race: Other; Tissue: Kidney; Tumor Mutational Burden: 18.0 mutations per MB, would you classify the patient as a responder or non-responder to Atezolizumab? Please provide your conclusion with supporting reasoning. Using the COMPASS platform, perform a comprehensive transcriptomic analysis of the tumor specimen. Begin by evaluating the tumor microenvironment: assess natural killer cell activity, measure markers of T-cell exhaustion, and determine the role of B cells in immunosuppression. Next, analyze the immune response by examining macrophage function, detailing the interferon‐gamma signaling pathway, and checking for any evidence of genomic instability. Finally, compile a detailed report outlining your findings and discussing how these results might influence the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"Based on the mRNA TPM analysis of this patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with the following details—male, White, tissue sampled from kidney, and a tumor mutational burden of 5.0 mutations per MB—could you please determine whether this patient is likely to respond to Atezolizumab, and explain the rationale behind your conclusion?","Based on the mRNA TPM analysis of this patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA), along with the following details—male, White, tissue sampled from kidney, and a tumor mutational burden of 5.0 mutations per MB—could you please determine whether this patient is likely to respond to Atezolizumab, and explain the rationale behind your conclusion? Using the COMPASS platform, perform a comprehensive transcriptomic analysis of the tumor tissue. First, evaluate the tumor microenvironment by assessing natural killer cell functionality, quantifying markers indicative of T-cell exhaustion, and examining the contribution of B cells to immunosuppressive processes. Then, analyze the immune response by characterizing macrophage activity, detailing the interferon‐gamma signaling pathway, and investigating any signs of genomic instability. Finally, prepare a detailed report summarizing your findings and explaining their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"Can you interpret the mRNA TPM data from a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma to estimate their likelihood of responding to Atezolizumab? The patient is a white male with bladder tissue involvement, a confirmed BLCA diagnosis, and a tumor mutational burden of 4.0 mutations per MB. Please provide your assessment on whether this patient would likely be classified as a responder or non-responder, along with your supporting rationale.","Can you interpret the mRNA TPM data from a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma to estimate their likelihood of responding to Atezolizumab? The patient is a white male with bladder tissue involvement, a confirmed BLCA diagnosis, and a tumor mutational burden of 4.0 mutations per MB. Please provide your assessment on whether this patient would likely be classified as a responder or non-responder, along with your supporting rationale. Using the COMPASS platform, please conduct an in-depth transcriptomic evaluation of the tumor tissue. Begin by assessing the tumor microenvironment: evaluate the functionality of natural killer cells, quantify markers related to T-cell exhaustion, and determine the role of B cells in immunosuppressive processes. Next, analyze the immune response by evaluating macrophage activity, detailing the interferon-gamma signaling pathway, and looking for any evidence of genomic instability. Conclude by preparing a comprehensive report that summarizes your observations and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"In a patient with bladder urothelial carcinoma (BLCA) and mRNA TPM data describing the tumor immune microenvironment, the following details are noted: male, White, tissue obtained from the kidney, and a tumor mutational burden of 5.0 mutations per megabase. Based on this information, could you assess whether the patient is more likely to respond to Atezolizumab, and please provide the rationale behind your conclusion?","In a patient with bladder urothelial carcinoma (BLCA) and mRNA TPM data describing the tumor immune microenvironment, the following details are noted: male, White, tissue obtained from the kidney, and a tumor mutational burden of 5.0 mutations per megabase. Based on this information, could you assess whether the patient is more likely to respond to Atezolizumab, and please provide the rationale behind your conclusion? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor tissue. Begin by evaluating the tumor microenvironment: assess the functionality of natural killer cells, measure indicators of T-cell exhaustion, and examine the contribution of B cells to immunosuppressive processes. Then, evaluate the immune response by analyzing macrophage activity, characterizing the interferon-gamma signaling pathway, and checking for signs of genomic instability. Finally, compile a comprehensive report summarizing your findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"Based on the processed mRNA TPM data for the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), along with the following clinical details—male, White, kidney tissue, and a tumor mutational burden of 12 mutations per megabase—could you clarify whether the patient is likely to respond to Atezolizumab and elaborate on the reasoning behind this prediction?","Based on the processed mRNA TPM data for the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA), along with the following clinical details—male, White, kidney tissue, and a tumor mutational burden of 12 mutations per megabase—could you clarify whether the patient is likely to respond to Atezolizumab and elaborate on the reasoning behind this prediction? Utilize the COMPASS platform to conduct an in-depth transcriptomic evaluation of the tumor tissue. Begin by assessing the tumor microenvironment: evaluate natural killer cell functionality, quantify markers of T-cell exhaustion, and determine the role of B cells in fostering immunosuppressive conditions. Next, examine the immune response by monitoring macrophage activity, analyzing the interferon-gamma signaling pathway, and identifying any evidence of genomic instability. Finally, prepare a comprehensive report that summarizes your findings and discusses their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a male, white patient with Bladder Urothelial Carcinoma (BLCA) whose tissue sample is from the liver. The patient's tumor mutational burden (FMOne mutations per MB) is not available. Based on these data, can you assess whether this patient is likely to respond to Atezolizumab, and provide your supporting rationale?","I have processed mRNA TPM data representing the tumor immune microenvironment for a male, white patient with Bladder Urothelial Carcinoma (BLCA) whose tissue sample is from the liver. The patient's tumor mutational burden (FMOne mutations per MB) is not available. Based on these data, can you assess whether this patient is likely to respond to Atezolizumab, and provide your supporting rationale? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor tissue. Start by examining the tumor microenvironment: assess the activity of natural killer cells, measure markers indicative of T-cell exhaustion, and evaluate the contribution of B cells to immunosuppressive processes. Then, focus on the immune response by monitoring macrophage activity, analyzing the interferon-gamma signaling pathway, and looking for signs of genomic instability. Conclude by compiling a comprehensive report that summarizes your observations and discusses their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"I have processed mRNA TPM data describing the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma. The patient is a white female, with the tumor tissue sourced from the kidney, and the tumor mutational burden (FMO per MB) is not available (nan). Could you please evaluate whether, based on these data, the patient is likely to be a responder or non-responder to Atezolizumab, and explain the reasoning behind your assessment?","I have processed mRNA TPM data describing the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma. The patient is a white female, with the tumor tissue sourced from the kidney, and the tumor mutational burden (FMO per MB) is not available (nan). Could you please evaluate whether, based on these data, the patient is likely to be a responder or non-responder to Atezolizumab, and explain the reasoning behind your assessment? Using the COMPASS platform, perform a comprehensive transcriptomic analysis on the tumor sample. Begin by evaluating the tumor microenvironment: assess the activity of natural killer cells, quantify markers of T-cell exhaustion, and determine the role of B cells in promoting immunosuppression. Next, shift your focus to the immune response by monitoring macrophage activity, analyzing the interferon-gamma signaling pathway, and checking for evidence of genomic instability. Finally, prepare a detailed report that summarizes your findings and discusses their potential implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"A male patient with bladder tissue, diagnosed with Bladder Urothelial Carcinoma (BLCA) and exhibiting a tumor mutational burden of 10 mutations per MB, has been profiled using mRNA TPM data from his tumor immune microenvironment. Based on this molecular and clinical profile, could you assess his predicted responsiveness to Atezolizumab, and provide the rationale for classifying him as a responder or non-responder?","A male patient with bladder tissue, diagnosed with Bladder Urothelial Carcinoma (BLCA) and exhibiting a tumor mutational burden of 10 mutations per MB, has been profiled using mRNA TPM data from his tumor immune microenvironment. Based on this molecular and clinical profile, could you assess his predicted responsiveness to Atezolizumab, and provide the rationale for classifying him as a responder or non-responder? Using the COMPASS platform, conduct a transcriptomic analysis of the tumor sample. Start by examining the tumor microenvironment: evaluate natural killer cell activity, quantify markers of T-cell exhaustion, and assess the immunosuppressive role of B cells. Then, investigate aspects of the immune response by monitoring macrophage activity, analyzing the interferon-gamma signaling pathway, and looking for signs of genomic instability. Conclude by preparing a detailed report that summarizes your findings and discusses their potential impact on the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"Based on processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and given the following patient details—
• Sex: Female  
• Race: White  
• Tissue: Bladder  
• Tumor Mutational Burden: 6 mutations per MB  
—could you assess the likelihood that this patient will respond to Atezolizumab, and explain the rationale behind your assessment?","Based on processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), and given the following patient details—
• Sex: Female  
• Race: White  
• Tissue: Bladder  
• Tumor Mutational Burden: 6 mutations per MB  
—could you assess the likelihood that this patient will respond to Atezolizumab, and explain the rationale behind your assessment? Use the COMPASS platform to perform a transcriptomic analysis of the tumor sample. Begin by examining the tumor microenvironment: assess natural killer cell activity, quantify markers indicative of T-cell exhaustion, and evaluate the immunosuppressive function of B cells. Next, analyze the immune response by monitoring macrophage activity, investigating the interferon-gamma signaling pathway, and identifying any evidence of genomic instability. Finally, compile your findings into a detailed report that outlines their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"Based on the processed mRNA TPM data from the patient’s bladder tumor immune microenvironment and the following details: female, White, confirmed diagnosis of bladder urothelial carcinoma (BLCA), and an FMOne tumor mutational burden per MB reported as not available, could you please determine whether this patient is more likely to respond to Atezolizumab? Please include the reasoning behind your conclusion.","Based on the processed mRNA TPM data from the patient’s bladder tumor immune microenvironment and the following details: female, White, confirmed diagnosis of bladder urothelial carcinoma (BLCA), and an FMOne tumor mutational burden per MB reported as not available, could you please determine whether this patient is more likely to respond to Atezolizumab? Please include the reasoning behind your conclusion. Please use the COMPASS platform for a transcriptomic evaluation of the tumor sample. Start by analyzing the tumor microenvironment: evaluate natural killer cell activity, measure markers associated with T-cell exhaustion, and assess the suppressive activity of B cells. Then focus on the immune response by monitoring macrophage activity, examining the interferon-gamma signaling pathway, and checking for signs of genomic instability. Lastly, prepare a comprehensive report detailing these findings and discussing their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a White female with bladder tissue involvement and a tumor mutational burden (FMOne mutation burden per MB) of 15.0. Based on these molecular and clinical characteristics, could you evaluate the likelihood of this patient responding to Atezolizumab and provide the rationale for your assessment?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a White female with bladder tissue involvement and a tumor mutational burden (FMOne mutation burden per MB) of 15.0. Based on these molecular and clinical characteristics, could you evaluate the likelihood of this patient responding to Atezolizumab and provide the rationale for your assessment? Using the COMPASS platform, please perform a transcriptomic evaluation of the tumor sample with the following steps:

1. Begin by analyzing the tumor microenvironment. Specifically, assess natural killer cell activity, measure markers indicative of T-cell exhaustion, and evaluate the suppressive function of B cells.

2. Next, concentrate on the broader immune response. This involves monitoring macrophage activity, examining the interferon-gamma signaling pathway, and identifying any indicators of genomic instability.

3. Finally, compile a detailed report that outlines your findings and explains their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"A patient with bladder urothelial carcinoma has been profiled using mRNA TPM data of the tumor immune microenvironment. The patient’s characteristics are as follows: male, white, lymph node tissue origin, and a tumor mutational burden of 8.0 mutations per MB. Based on these details, can you provide an assessment of whether this patient is predicted to respond to Atezolizumab, along with the rationale behind your conclusion?","A patient with bladder urothelial carcinoma has been profiled using mRNA TPM data of the tumor immune microenvironment. The patient’s characteristics are as follows: male, white, lymph node tissue origin, and a tumor mutational burden of 8.0 mutations per MB. Based on these details, can you provide an assessment of whether this patient is predicted to respond to Atezolizumab, along with the rationale behind your conclusion? Please use the COMPASS platform to conduct a transcriptomic analysis of the provided tumor sample, following these steps:

1. Assess the tumor microenvironment by examining natural killer cell activity, quantifying markers of T-cell exhaustion, and evaluating the suppressive role of B cells.
2. Evaluate the overall immune response by monitoring macrophage activation, analyzing the interferon-gamma signaling pathway, and checking for signs of genomic instability.
3. Prepare a comprehensive report that details your observations and discusses their potential impact on the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"Based on the evaluated mRNA TPM data reflecting the tumor immune microenvironment in a BLCA patient (male, white, bladder cancer) with a tumor mutational burden of 6.0 mutations per megabase, could you determine whether this patient is more likely to respond or not respond to Atezolizumab treatment, and please explain the reasoning behind your conclusion?","Based on the evaluated mRNA TPM data reflecting the tumor immune microenvironment in a BLCA patient (male, white, bladder cancer) with a tumor mutational burden of 6.0 mutations per megabase, could you determine whether this patient is more likely to respond or not respond to Atezolizumab treatment, and please explain the reasoning behind your conclusion? Please use the COMPASS platform to perform a transcriptomic analysis on the provided tumor sample. Your analysis should include the following steps:

1. Characterize the tumor microenvironment by examining natural killer cell activity, assessing markers indicative of T-cell exhaustion, and evaluating the immunosuppressive role of B cells.
2. Investigate the overall immune response by monitoring macrophage activation, analyzing the interferon-gamma signaling pathway, and assessing for genomic instability.
3. Prepare a comprehensive report detailing your findings and discuss how these observations may influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a Tumor Mutational Burden of 19.0 mutations/MB. Based on this information, how would you assess the likelihood of a positive response to Atezolizumab, and what factors support your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a male, White patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a Tumor Mutational Burden of 19.0 mutations/MB. Based on this information, how would you assess the likelihood of a positive response to Atezolizumab, and what factors support your conclusion? Using the COMPASS platform, please conduct a transcriptomic analysis of the provided tumor specimen. Your evaluation should include:

1. An assessment of the tumor microenvironment, focusing on natural killer cell function, identifying markers of T-cell exhaustion, and determining the immunosuppressive contributions of B cells.
2. An investigation into the overall immune response, which involves assessing macrophage activation, analyzing the interferon-gamma signaling pathway, and determining the presence of genomic instability.
3. The preparation of a detailed report summarizing your findings and discussing the potential impact of these results on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"Based on the processed mRNA TPM data that characterizes the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma and considering the patient's attributes (male, white, non-standard tissue type, and a tumor mutational burden of 12.0 mutations per MB), could you please evaluate whether this patient is more likely to respond or not respond to Atezolizumab, and explain the reasoning behind that assessment?","Based on the processed mRNA TPM data that characterizes the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma and considering the patient's attributes (male, white, non-standard tissue type, and a tumor mutational burden of 12.0 mutations per MB), could you please evaluate whether this patient is more likely to respond or not respond to Atezolizumab, and explain the reasoning behind that assessment? Please use the COMPASS platform to perform a transcriptomic analysis on the provided tumor specimen. In your assessment, ensure you:

• Evaluate the tumor microenvironment by:
 – Examining natural killer cell activity,
 – Identifying markers indicative of T-cell exhaustion, and
 – Assessing the immunosuppressive contributions from B cells.

• Investigate the overall immune response by:
 – Analyzing macrophage activation,
 – Evaluating the interferon-gamma signaling pathway, and
 – Detecting any signs of genomic instability.

After completing the analysis, compile a comprehensive report that clearly outlines your findings and discusses how these results might influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"Based on the mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), could you evaluate his predicted response to Atezolizumab? The patient is a white male with tumor tissue originating from the kidney and an indeterminate tumor mutational burden. Please provide your conclusion on whether he is likely to be a responder or non-responder, along with the supporting clinical reasoning.","Based on the mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), could you evaluate his predicted response to Atezolizumab? The patient is a white male with tumor tissue originating from the kidney and an indeterminate tumor mutational burden. Please provide your conclusion on whether he is likely to be a responder or non-responder, along with the supporting clinical reasoning. Please use the COMPASS platform to conduct a transcriptomic analysis on the provided tumor specimen. In your evaluation, perform the following:

1. Examine the tumor microenvironment by:
 • Assessing natural killer (NK) cell activity.
 • Identifying markers that indicate T-cell exhaustion.
 • Evaluating the contribution of B cells to immunosuppression.

2. Investigate the overall immune response by:
 • Analyzing macrophage activation.
 • Evaluating the interferon-gamma signaling pathway.
 • Detecting any evidence of genomic instability.

Once the analysis is complete, prepare a comprehensive report that details your findings and discusses the potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"For a patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM data reflects their tumor immune microenvironment, and who is described as a white male with bladder tissue involvement and a tumor mutational burden of 3.0 mutations per megabase, could you please evaluate the likelihood of response to atezolizumab and provide the supporting clinical rationale?","For a patient with bladder urothelial carcinoma (BLCA) whose mRNA TPM data reflects their tumor immune microenvironment, and who is described as a white male with bladder tissue involvement and a tumor mutational burden of 3.0 mutations per megabase, could you please evaluate the likelihood of response to atezolizumab and provide the supporting clinical rationale? Please use the COMPASS platform to perform a transcriptomic analysis of the provided tumor specimen. In your evaluation, please:

1. Analyze the tumor microenvironment by:
 • Assessing natural killer (NK) cell activity.
 • Identifying markers that indicate T-cell exhaustion.
 • Evaluating the role of B cells in mediating immunosuppression.

2. Assess the overall immune response by:
 • Analyzing macrophage activation.
 • Evaluating the interferon-gamma signaling pathway.
 • Investigating evidence of genomic instability.

After completing the analysis, compile a detailed report summarizing your findings and discussing their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"I have analyzed mRNA TPM data detailing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male representing a lymph node tissue sample, and his tumor mutational burden is 18 mutations per megabase. Could you please provide an assessment of whether this patient is likely to respond to Atezolizumab, along with the supporting rationale for that conclusion?","I have analyzed mRNA TPM data detailing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male representing a lymph node tissue sample, and his tumor mutational burden is 18 mutations per megabase. Could you please provide an assessment of whether this patient is likely to respond to Atezolizumab, along with the supporting rationale for that conclusion? Please use the COMPASS platform to conduct a transcriptomic analysis on the tumor specimen provided. Your evaluation should include the following steps:

1. Examine the tumor microenvironment by:
 a. Evaluating the activity of natural killer (NK) cells.
 b. Detecting markers that suggest T-cell exhaustion.
 c. Investigating the contribution of B cells to immunosuppression.

2. Evaluate the overall immune response by:
 a. Assessing macrophage activation.
 b. Analyzing the interferon-gamma signaling pathway.
 c. Searching for signs of genomic instability.

Once your analysis is complete, please prepare a detailed report summarizing your findings and discussing the potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"Given the following patient details—a male, White patient with Bladder Urothelial Carcinoma (BLCA), whose tumor mRNA TPM data for the immune microenvironment was processed from a kidney tissue sample and who has a tumor mutational burden of 15 mutations per megabase—could you provide an assessment of this patient's predicted responsiveness to Atezolizumab, including the supporting rationale?","Given the following patient details—a male, White patient with Bladder Urothelial Carcinoma (BLCA), whose tumor mRNA TPM data for the immune microenvironment was processed from a kidney tissue sample and who has a tumor mutational burden of 15 mutations per megabase—could you provide an assessment of this patient's predicted responsiveness to Atezolizumab, including the supporting rationale? Please use the COMPASS platform to perform a transcriptomic analysis on the provided tumor specimen. For this analysis, carry out the following steps:

1. Analyze the tumor microenvironment by:
 a. Assessing natural killer (NK) cell activity.
 b. Identifying markers indicative of T-cell exhaustion.
 c. Evaluating the role of B cells in mediating immunosuppression.

2. Assess the overall immune response by:
 a. Evaluating macrophage activation.
 b. Analyzing the interferon-gamma signaling pathway.
 c. Investigating the presence of genomic instability.

After completing the analysis, compile a detailed report that summarizes your findings and discusses their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"Based on the following patient data—a male patient with Bladder Urothelial Carcinoma (BLCA), a tumor sample obtained from a lymph node, and processed mRNA TPM data characterizing the tumor immune microenvironment (with tumor mutational burden data unavailable)—how would you assess his likelihood of responding to Atezolizumab? Please provide your classification as responder or non-responder and include your supporting rationale.","Based on the following patient data—a male patient with Bladder Urothelial Carcinoma (BLCA), a tumor sample obtained from a lymph node, and processed mRNA TPM data characterizing the tumor immune microenvironment (with tumor mutational burden data unavailable)—how would you assess his likelihood of responding to Atezolizumab? Please provide your classification as responder or non-responder and include your supporting rationale. Please perform a transcriptomic analysis of the tumor specimen using the COMPASS platform. Your analysis should include the following steps:

1. Examine the tumor microenvironment by:
 a. Evaluating natural killer (NK) cell activity.
 b. Detecting markers that indicate T-cell exhaustion.
 c. Assessing the involvement of B cells in immunosuppression.

2. Evaluate the overall immune response by:
 a. Assessing macrophage activation.
 b. Analyzing the interferon-gamma signaling pathway.
 c. Investigating signs of genomic instability.

Once you have completed these analyses, please prepare a comprehensive report detailing your findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"Based on processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), how would you assess her likelihood of responding to Atezolizumab? The patient is a white female with bladder tissue involvement, and her tumor mutational burden is reported as “nan.” Please indicate whether she is predicted to be a responder or non-responder, along with the clinical rationale for your conclusion.","Based on processed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA), how would you assess her likelihood of responding to Atezolizumab? The patient is a white female with bladder tissue involvement, and her tumor mutational burden is reported as “nan.” Please indicate whether she is predicted to be a responder or non-responder, along with the clinical rationale for your conclusion. Please conduct a transcriptomic evaluation of the tumor sample using the COMPASS platform with the following steps:

1. Analyze the tumor microenvironment by:
 a. Assessing natural killer (NK) cell activity.
 b. Identifying markers associated with T-cell exhaustion.
 c. Evaluating the role of B cells in mediating immunosuppression.

2. Evaluate the overall immune response by:
 a. Measuring macrophage activation.
 b. Investigating the interferon-gamma signaling pathway.
 c. Detecting signs of genomic instability.

After completing these analyses, please prepare a detailed report that summarizes your findings and explores their potential implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"Based on mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), and given the following clinical details—male, white, kidney tissue sample, with an FMOne mutation burden of 6.0 mutations per megabase—what is the predicted likelihood of a positive response to Atezolizumab? Please explain your reasoning for classifying the patient as a responder or non-responder.","Based on mRNA TPM data characterizing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), and given the following clinical details—male, white, kidney tissue sample, with an FMOne mutation burden of 6.0 mutations per megabase—what is the predicted likelihood of a positive response to Atezolizumab? Please explain your reasoning for classifying the patient as a responder or non-responder. Please perform a comprehensive transcriptomic analysis of the tumor sample utilizing the COMPASS platform. Your evaluation should include the following steps:

1. Characterize the tumor microenvironment by:
 a. Assessing natural killer (NK) cell activity.
 b. Identifying markers indicative of T-cell exhaustion.
 c. Evaluating the involvement of B cells in promoting immunosuppression.

2. Assess the overall immune response by:
 a. Measuring macrophage activation.
 b. Investigating the interferon-gamma signaling pathway.
 c. Identifying any indicators of genomic instability.

Once these analyses are complete, prepare a detailed report summarizing your findings and discussing their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"Based on mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma, could you determine whether this patient is likely to respond to Atezolizumab? The patient is a white female, with kidney tissue involved, and her tumor mutational burden is not available (reported as ""nan""). Please provide evidence-based reasoning to support your assessment of her responder status.","Based on mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma, could you determine whether this patient is likely to respond to Atezolizumab? The patient is a white female, with kidney tissue involved, and her tumor mutational burden is not available (reported as ""nan""). Please provide evidence-based reasoning to support your assessment of her responder status. Please conduct a detailed transcriptomic evaluation of the tumor sample using the COMPASS platform. In your analysis, address the following:

1. Tumor microenvironment:
 a. Evaluate natural killer (NK) cell functionality.
 b. Identify markers that suggest T-cell exhaustion.
 c. Determine the role of B cells in potential immunosuppression.

2. Overall immune response:
 a. Assess macrophage activation levels.
 b. Examine the activity of the interferon-gamma signaling pathway.
 c. Look for signs of genomic instability.

After completing these analyses, compile a comprehensive report that summarizes your findings and discusses how they might influence the patient's treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data from a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA). The patient is a Black or African American male, with tumor tissue from the ureter, and the reported tumor mutational burden (FMOne mutations per MB) is not available (NaN). Based on this data, can you determine whether the patient is likely to respond to Atezolizumab, and please provide the supporting reasoning?","I have processed mRNA TPM data from a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA). The patient is a Black or African American male, with tumor tissue from the ureter, and the reported tumor mutational burden (FMOne mutations per MB) is not available (NaN). Based on this data, can you determine whether the patient is likely to respond to Atezolizumab, and please provide the supporting reasoning? Please perform a comprehensive transcriptomic analysis of the tumor sample using the COMPASS platform with a focus on two main areas:

1. Tumor Microenvironment:
 a. Assess the functional status of natural killer (NK) cells.
 b. Identify and quantify markers associated with T-cell exhaustion.
 c. Evaluate the contribution of B cells to any immunosuppressive activity.

2. Overall Immune Response:
 a. Measure macrophage activation levels.
 b. Investigate the activity of the interferon-gamma signaling pathway.
 c. Detect and report any signs of genomic instability.

Once the analyses are complete, prepare a detailed report summarizing your findings and discussing their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data of the tumor immune microenvironment from a patient with Bladder Urothelial Carcinoma (BLCA) and seek to determine the patient's likelihood of responding to Atezolizumab treatment. The patient is a White female with a primary tumor in the bladder, and the tumor mutational burden is not available. Could you please provide an assessment of whether this patient should be classified as a responder or non-responder, along with the rationale for your conclusion?","I have analyzed mRNA TPM data of the tumor immune microenvironment from a patient with Bladder Urothelial Carcinoma (BLCA) and seek to determine the patient's likelihood of responding to Atezolizumab treatment. The patient is a White female with a primary tumor in the bladder, and the tumor mutational burden is not available. Could you please provide an assessment of whether this patient should be classified as a responder or non-responder, along with the rationale for your conclusion? Please conduct a detailed transcriptomic analysis of the tumor sample using the COMPASS platform, concentrating on the following two areas:

1. Tumor Microenvironment:
 a. Evaluate the functional status of natural killer (NK) cells.
 b. Identify and quantify markers indicative of T-cell exhaustion.
 c. Assess the role of B cells in any observed immunosuppressive activity.

2. Overall Immune Response:
 a. Determine the activation levels of macrophages.
 b. Analyze the activity of the interferon-gamma signaling pathway.
 c. Identify and document any evidence of genomic instability.

After completing these analyses, compile a comprehensive report that summarizes your findings and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"For a male white patient with bladder urothelial carcinoma (BLCA) using ureter tissue, whose processed mRNA TPM data from the tumor immune microenvironment indicates a tumor mutational burden of 4.0 FMOne mutations per MB, does the evidence suggest that he is likely to respond to Atezolizumab treatment? Please provide a conclusion regarding his responder status and include the underlying rationale for your assessment.","For a male white patient with bladder urothelial carcinoma (BLCA) using ureter tissue, whose processed mRNA TPM data from the tumor immune microenvironment indicates a tumor mutational burden of 4.0 FMOne mutations per MB, does the evidence suggest that he is likely to respond to Atezolizumab treatment? Please provide a conclusion regarding his responder status and include the underlying rationale for your assessment. Please perform a comprehensive transcriptomic analysis of the tumor sample using the COMPASS platform, with a focus on the following aspects:

1. Tumor Microenvironment:
 a. Assess the functional activity of natural killer (NK) cells.
 b. Identify and quantify markers associated with T-cell exhaustion.
 c. Evaluate the contribution of B cells to any immunosuppressive mechanisms observed.

2. Overall Immune Response:
 a. Determine the activation status of macrophages.
 b. Analyze the activity of the interferon-gamma signaling pathway.
 c. Identify and record any indicators of genomic instability.

Once these analyses are complete, please prepare a detailed report summarizing the findings and discussing their potential implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and need to assess their predicted response to Atezolizumab. The patient’s details are as follows: Male, White, bladder tissue, BLCA diagnosis, and a tumor mutational burden of 14 mutations per megabase. Based on these parameters, could you please provide your evaluation of whether the patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting reasoning?","I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and need to assess their predicted response to Atezolizumab. The patient’s details are as follows: Male, White, bladder tissue, BLCA diagnosis, and a tumor mutational burden of 14 mutations per megabase. Based on these parameters, could you please provide your evaluation of whether the patient is likely to be a responder or non-responder to Atezolizumab, along with the supporting reasoning? Please conduct a detailed transcriptomic analysis of the tumor sample using the COMPASS platform. Focus first on the tumor microenvironment by evaluating natural killer cell function, quantifying markers of T-cell exhaustion, and assessing the role of B cells in any immunosuppressive processes. Then, assess the overall immune response by determining macrophage activation, analyzing the activity of the interferon-gamma signaling pathway, and identifying indicators of genomic instability. Once all analyses are complete, compile a comprehensive report outlining the findings and their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"Based on the mRNA TPM data reflecting the tumor immune microenvironment, can you determine whether this patient with Bladder Urothelial Carcinoma—a white male with lung tissue involvement and a tumor mutational burden of 7.0 mutations per MB—is likely to respond to atezolizumab? Please include your clinical reasoning behind the assessment.","Based on the mRNA TPM data reflecting the tumor immune microenvironment, can you determine whether this patient with Bladder Urothelial Carcinoma—a white male with lung tissue involvement and a tumor mutational burden of 7.0 mutations per MB—is likely to respond to atezolizumab? Please include your clinical reasoning behind the assessment. Perform a comprehensive transcriptomic analysis of the tumor sample using the COMPASS platform. Begin by characterizing the tumor microenvironment: evaluate the function of natural killer cells, quantify markers of T-cell exhaustion, and assess the involvement of B cells in immunosuppressive processes. Next, analyze the overall immune response by determining macrophage activation, examining interferon-gamma signaling activity, and identifying signs of genomic instability. Once all analyses are complete, prepare a detailed report summarizing the findings and discussing their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"I have processed an mRNA TPM dataset that characterizes the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient’s key attributes are as follows: Female, White, tissue sample from the lung, and a tumor mutational burden of 3.0 mutations per MB. Based on these data, could you evaluate whether this patient is likely to respond to Atezolizumab, and please provide the rationale for your assessment?","I have processed an mRNA TPM dataset that characterizes the tumor immune microenvironment in a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient’s key attributes are as follows: Female, White, tissue sample from the lung, and a tumor mutational burden of 3.0 mutations per MB. Based on these data, could you evaluate whether this patient is likely to respond to Atezolizumab, and please provide the rationale for your assessment? Please conduct an in-depth transcriptomic analysis of the patient’s tumor sample using the COMPASS platform. Start by evaluating the tumor’s microenvironment with a focus on: (1) assessing the functional activity of natural killer cells; (2) quantifying markers indicative of T-cell exhaustion; and (3) examining the role of B cells in mediating immunosuppressive processes. Next, perform an overall immune response analysis by: (1) determining the activation status of macrophages; (2) analyzing the activity of interferon-gamma signaling pathways; and (3) detecting any indicators of genomic instability. Finally, compile your findings into a detailed report that discusses the results and their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"Based on mRNA TPM expression data that characterizes the tumor immune microenvironment for a  male white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 11.0 per MB, how should we assess his likelihood of responding to Atezolizumab therapy? Please provide a conclusion on whether he would be classified as a responder or non-responder, along with the supporting rationale.","Based on mRNA TPM expression data that characterizes the tumor immune microenvironment for a  male white patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 11.0 per MB, how should we assess his likelihood of responding to Atezolizumab therapy? Please provide a conclusion on whether he would be classified as a responder or non-responder, along with the supporting rationale. Please perform a comprehensive transcriptomic analysis of the patient’s tumor using the COMPASS platform with the following steps in mind:

1. Begin by examining the tumor microenvironment. This should include:
   • Evaluating the functional activity of natural killer cells.
   • Measuring markers that indicate T-cell exhaustion.
   • Investigating how B cells contribute to immunosuppressive processes.

2. Proceed with an overall analysis of the immune response by:
   • Assessing the activation state of macrophages.
   • Analyzing the activity of interferon-gamma signaling pathways.
   • Identifying any signs of genomic instability.

3. Summarize all findings in a detailed report, ensuring that you discuss the implications of the results for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"Given a female, White patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 4.0 mutations per megabase, with processed mRNA TPM data representing the tumor immune microenvironment available, can you assess the likelihood of response to Atezolizumab and provide your supporting reasoning?","Given a female, White patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 4.0 mutations per megabase, with processed mRNA TPM data representing the tumor immune microenvironment available, can you assess the likelihood of response to Atezolizumab and provide your supporting reasoning? Please perform a comprehensive transcriptomic analysis of the patient’s tumor using the COMPASS platform, as follows:

1. Analyze the tumor microenvironment by:
   • Assessing the functional activity of natural killer cells.
   • Quantifying markers associated with T-cell exhaustion.
   • Evaluating the role of B cells in mediating immunosuppressive processes.

2. Conduct an overall immune response evaluation by:
   • Determining the activation state of macrophages.
   • Examining the activity of interferon-gamma signaling pathways.
   • Identifying any evidence of genomic instability.

3. Compile all findings into a detailed report that discusses the potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA). The patient is a white female with bladder tissue origin, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Based on this information, could you determine whether the patient is likely to respond to Atezolizumab and explain the rationale for this assessment?","I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in the context of Bladder Urothelial Carcinoma (BLCA). The patient is a white female with bladder tissue origin, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Based on this information, could you determine whether the patient is likely to respond to Atezolizumab and explain the rationale for this assessment? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient’s tumor. Specifically:

1. For the tumor microenvironment:
 a. Assess the functional activity of natural killer cells.
 b. Quantify markers indicative of T-cell exhaustion.
 c. Evaluate the contribution of B cells to immunosuppressive processes.

2. For the overall immune response:
 a. Determine the activation state of macrophages.
 b. Examine the activity of interferon-gamma signaling pathways.
 c. Look for signs of genomic instability.

Once these analyses are complete, compile your findings into a detailed report that includes an interpretation of how these results might influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement, and his tumor mutational burden data is unavailable (nan per MB). Based on these details, could you assess whether he is likely to be classified as a responder or non-responder to atezolizumab, and explain the rationale behind this prediction?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a patient with bladder urothelial carcinoma. The patient is a white male with bladder tissue involvement, and his tumor mutational burden data is unavailable (nan per MB). Based on these details, could you assess whether he is likely to be classified as a responder or non-responder to atezolizumab, and explain the rationale behind this prediction? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient’s tumor. Start by examining the tumor microenvironment: evaluate the functional activity of natural killer cells, measure markers associated with T-cell exhaustion, and assess the role of B cells in immunosuppressive processes. Next, analyze the overall immune response by determining the activation state of macrophages, investigating the activity of interferon-gamma signaling pathways, and identifying any indications of genomic instability. Once these analyses are complete, prepare a comprehensive report that interprets the results and discusses their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"Given processed mRNA TPM data that characterize the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), how would you assess the predicted response to Atezolizumab? The patient is a white male with BLCA, has a tumor mutational burden of 18.0 mutations per megabase, and the tissue sample is classified as ""other."" Based on these details, should this patient be considered a responder or non-responder to Atezolizumab, and what is the rationale behind this classification?","Given processed mRNA TPM data that characterize the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), how would you assess the predicted response to Atezolizumab? The patient is a white male with BLCA, has a tumor mutational burden of 18.0 mutations per megabase, and the tissue sample is classified as ""other."" Based on these details, should this patient be considered a responder or non-responder to Atezolizumab, and what is the rationale behind this classification? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient's tumor. Begin by characterizing the tumor microenvironment: assess the functional activity of natural killer cells, quantify markers indicative of T-cell exhaustion, and evaluate the involvement of B cells in immunosuppression. Next, broaden your analysis to the overall immune response by determining macrophage activation, examining interferon-gamma signaling pathways, and identifying any evidence of genomic instability. Finally, compile a detailed report that interprets these findings and discusses their potential impact on the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"I have processed mRNA TPM data representing the tumor immune microenvironment of a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 19.0 mutations/MB. Based on these details, can you determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include your supporting reasoning.","I have processed mRNA TPM data representing the tumor immune microenvironment of a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 19.0 mutations/MB. Based on these details, can you determine whether this patient is likely to be a responder or non-responder to Atezolizumab? Please include your supporting reasoning. Please utilize the COMPASS platform to conduct a transcriptomic profiling of the patient's tumor. Start by characterizing the tumor microenvironment: evaluate natural killer cell functional activity, quantify T-cell exhaustion markers, and assess the immunosuppressive role of B cells. Then, broaden your analysis to the overall immune response by examining macrophage activation, investigating interferon-gamma signaling, and determining any evidence of genomic instability. Conclude by compiling a detailed report that interprets these findings and discusses their potential impact on the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"Based on processed mRNA TPM data reflecting the tumor immune microenvironment of a male patient diagnosed with bladder urothelial carcinoma (BLCA), who is White and has a tumor mutational burden of 35.0 (FMOne mutation burden per MB), could you assess whether this patient is likely to be a responder or non-responder to Atezolizumab therapy? Please include the supporting reasoning behind your conclusion.","Based on processed mRNA TPM data reflecting the tumor immune microenvironment of a male patient diagnosed with bladder urothelial carcinoma (BLCA), who is White and has a tumor mutational burden of 35.0 (FMOne mutation burden per MB), could you assess whether this patient is likely to be a responder or non-responder to Atezolizumab therapy? Please include the supporting reasoning behind your conclusion. Please use the COMPASS platform to perform a transcriptomic analysis of the patient's tumor. Begin by characterizing the tumor microenvironment: assess the functional activity of natural killer cells, measure markers of T-cell exhaustion, and evaluate the immunosuppressive role of B cells. Next, examine the broader immune response by analyzing macrophage activation, investigating interferon-gamma signaling, and identifying any signs of genomic instability. Finally, compile a comprehensive report that interprets these findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"For a male, white patient diagnosed with bladder urothelial carcinoma (BLCA) localized to the kidney and a tumor mutational burden of 5.0 mutations/MB, how does the mRNA TPM data of the tumor's immune microenvironment inform the predicted response to Atezolizumab? Please classify the patient as a responder or non-responder and explain the rationale behind your determination.","For a male, white patient diagnosed with bladder urothelial carcinoma (BLCA) localized to the kidney and a tumor mutational burden of 5.0 mutations/MB, how does the mRNA TPM data of the tumor's immune microenvironment inform the predicted response to Atezolizumab? Please classify the patient as a responder or non-responder and explain the rationale behind your determination. Using the COMPASS platform, perform a transcriptomic analysis of the patient's tumor as follows:

1. Start by characterizing the tumor microenvironment. Specifically:
   • Assess the functional activity of natural killer (NK) cells.
   • Quantify markers associated with T-cell exhaustion.
   • Evaluate the immunosuppressive influence of B cells.

2. Next, extend the analysis to the broader immune response by:
   • Investigating macrophage activation.
   • Analyzing interferon-gamma signaling pathways.
   • Identifying any evidence of genomic instability.

3. Finally, prepare a detailed report that interprets these findings and outlines their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"Given the patient's tumor immune microenvironment mRNA TPM data for bladder urothelial carcinoma (BLCA) with the following attributes—male, white, bladder tissue, and a tumor mutational burden of 5.0 FMOne mutations per MB—can you assess the likelihood that this patient will respond to Atezolizumab? Please provide your reasoning and conclusion regarding whether the patient is classified as a responder or non-responder.","Given the patient's tumor immune microenvironment mRNA TPM data for bladder urothelial carcinoma (BLCA) with the following attributes—male, white, bladder tissue, and a tumor mutational burden of 5.0 FMOne mutations per MB—can you assess the likelihood that this patient will respond to Atezolizumab? Please provide your reasoning and conclusion regarding whether the patient is classified as a responder or non-responder. Using the COMPASS platform, please perform a transcriptomic analysis of this patient's tumor according to the following steps:

1. Begin by evaluating the tumor microenvironment:
 • Determine the functional activity of natural killer (NK) cells.
 • Measure the expression levels of markers related to T-cell exhaustion.
 • Assess the immunosuppressive effects exerted by B cells.

2. Next, broaden the analysis to the overall immune response:
 • Examine the activation status of macrophages.
 • Analyze the pathways involved in interferon-gamma signaling.
 • Look for any indications of genomic instability.

3. Finally, compile a comprehensive report that interprets these findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"A patient with bladder urothelial carcinoma (BLCA) has been evaluated using mRNA TPM data to characterize their tumor immune microenvironment. The patient is a 16.0 FMOne mutation burden per MB, white male with tumor tissue from the bladder. Based on these parameters, can you assess whether the patient is likely to respond to atezolizumab and explain the reasoning behind your conclusion?","A patient with bladder urothelial carcinoma (BLCA) has been evaluated using mRNA TPM data to characterize their tumor immune microenvironment. The patient is a 16.0 FMOne mutation burden per MB, white male with tumor tissue from the bladder. Based on these parameters, can you assess whether the patient is likely to respond to atezolizumab and explain the reasoning behind your conclusion? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient’s tumor. Follow these steps:

1. First, assess the tumor microenvironment by:
 • Evaluating the functional activity of natural killer (NK) cells.
 • Quantifying the expression of T-cell exhaustion markers.
 • Investigating the immunosuppressive role of B cells.

2. Then, extend your evaluation to the broader immune response by:
 • Assessing the activation state of macrophages.
 • Analyzing pathways associated with interferon-gamma signaling.
 • Checking for signs of genomic instability.

3. Finally, prepare a comprehensive report that interprets these findings and examines their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"A patient with bladder urothelial carcinoma (BLCA) presents with the following characteristics: male, race identified as ""OTHER,"" bladder tissue involvement, and a tumor mutational burden of 8.0 mutations per MB (FMOne measurement). Given the mRNA TPM data reflecting this patient's tumor immune microenvironment, what is the predicted response to atezolizumab, and what is the supporting rationale for classifying the patient as a responder or non-responder?","A patient with bladder urothelial carcinoma (BLCA) presents with the following characteristics: male, race identified as ""OTHER,"" bladder tissue involvement, and a tumor mutational burden of 8.0 mutations per MB (FMOne measurement). Given the mRNA TPM data reflecting this patient's tumor immune microenvironment, what is the predicted response to atezolizumab, and what is the supporting rationale for classifying the patient as a responder or non-responder? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient’s tumor. Begin by examining the tumor microenvironment, specifically by:

• Assessing the functional activity of natural killer (NK) cells.
• Quantifying the expression of markers indicative of T-cell exhaustion.
• Investigating the immunosuppressive functions of B cells.

Next, broaden your analysis to include the systemic immune response by:

• Evaluating the activation status of macrophages.
• Analyzing key pathways associated with interferon-gamma signaling.
• Identifying any evidence of genomic instability.

Conclude by preparing a detailed report that interprets your findings and discusses their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"Based on a patient's mRNA TPM data representing the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can we assess their predicted response to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Please provide a conclusion regarding potential responsiveness along with the supporting rationale.","Based on a patient's mRNA TPM data representing the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can we assess their predicted response to Atezolizumab? The patient is a white male with bladder tissue involvement and a tumor mutational burden of 5.0 mutations per megabase. Please provide a conclusion regarding potential responsiveness along with the supporting rationale. Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the patient’s tumor tissue. Start by evaluating the tumor microenvironment, focusing on the following:

• Measure the functional activity of natural killer (NK) cells.
• Determine the expression levels of markers that indicate T‐cell exhaustion.
• Examine the immunosuppressive functions of B cells.

Next, assess the systemic immune response by:

• Evaluating the activation status of macrophages.
• Analyzing key pathways related to interferon-gamma signaling.
• Investigating any signs of genomic instability.

Finally, compile your findings into a detailed report that interprets these results and assesses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"For a female, White patient with Bladder Urothelial Carcinoma who has a tumor mutational burden of 5.0 mutations per megabase and tumor samples derived from kidney tissue, can we determine whether she is likely to respond to atezolizumab based on her processed mRNA TPM data of the tumor immune microenvironment? Please provide your conclusion along with the supporting rationale.","For a female, White patient with Bladder Urothelial Carcinoma who has a tumor mutational burden of 5.0 mutations per megabase and tumor samples derived from kidney tissue, can we determine whether she is likely to respond to atezolizumab based on her processed mRNA TPM data of the tumor immune microenvironment? Please provide your conclusion along with the supporting rationale. Please utilize the COMPASS platform to carry out a detailed transcriptomic analysis of the patient’s tumor tissue. Start by assessing the tumor microenvironment with a focus on:

• Quantifying the functional activity of natural killer (NK) cells.
• Assessing the expression levels of markers indicative of T‐cell exhaustion.
• Evaluating the immunosuppressive activity of B cells.

Subsequently, evaluate the systemic immune response by:

• Determining the activation status of macrophages.
• Analyzing key interferon‐gamma signaling pathways.
• Investigating potential signs of genomic instability.

Finally, prepare a comprehensive report that interprets these findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a white female with a bladder tumor and a tumor mutational burden of 7.0 mutations per megabase. Could you evaluate her likely response to atezolizumab and explain the reasoning behind classifying her as a responder or non-responder?,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a white female with a bladder tumor and a tumor mutational burden of 7.0 mutations per megabase. Could you evaluate her likely response to atezolizumab and explain the reasoning behind classifying her as a responder or non-responder? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient’s tumor tissue. Begin by evaluating the tumor microenvironment to:

• Quantify the functional activity of natural killer (NK) cells.
• Measure the expression of T‐cell exhaustion markers.
• Assess the immunosuppressive effects of B cells.

Next, analyze the systemic immune response by:

• Determining the activation status of macrophages.
• Examining key interferon‐gamma signaling pathways.
• Identifying any evidence of genomic instability.

Finally, prepare a detailed report that interprets these findings and outlines their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"Based on the mRNA TPM data of this patient's tumor immune microenvironment for bladder urothelial carcinoma, can you determine whether the patient is likely to respond to Atezolizumab? The patient is a white male with bladder tissue involvement, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Please provide your conclusion along with the reasoning behind your assessment.","Based on the mRNA TPM data of this patient's tumor immune microenvironment for bladder urothelial carcinoma, can you determine whether the patient is likely to respond to Atezolizumab? The patient is a white male with bladder tissue involvement, and the tumor mutational burden (FMOne mutation burden per MB) is not available. Please provide your conclusion along with the reasoning behind your assessment. Please use the COMPASS platform to perform an in‐depth transcriptomic analysis of the patient’s tumor tissue. Start by assessing the tumor microenvironment through the following steps:

• Quantify the functional activity of natural killer (NK) cells.
• Measure the expression levels of T‐cell exhaustion markers.
• Evaluate the immunosuppressive role of B cells.

Next, shift your focus to the systemic immune response by:

• Determining the activation status of macrophages.
• Examining critical interferon‐gamma signaling pathways.
• Investigating any signs of genomic instability.

Finally, prepare a detailed report that interprets these findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"Based on an mRNA TPM dataset representing a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and considering the following characteristics—Male, White, bladder tissue involved, BLCA diagnosis, and a tumor mutational burden of 9 mutations per MB—could you provide your assessment on the likelihood of this patient responding to Atezolizumab? Please include your reasoning in the conclusion.","Based on an mRNA TPM dataset representing a patient's tumor immune microenvironment in bladder urothelial carcinoma (BLCA) and considering the following characteristics—Male, White, bladder tissue involved, BLCA diagnosis, and a tumor mutational burden of 9 mutations per MB—could you provide your assessment on the likelihood of this patient responding to Atezolizumab? Please include your reasoning in the conclusion. Using the COMPASS platform, conduct a comprehensive transcriptomic evaluation of the patient’s tumor tissue. Begin with an analysis of the tumor microenvironment by:

• Assessing the functional activity of natural killer (NK) cells.
• Quantifying the expression of T-cell exhaustion markers.
• Investigating the immunosuppressive role of B cells.

Then, evaluate the systemic immune response by:

• Determining macrophage activation status.
• Analyzing key interferon-gamma signaling pathways.
• Looking for indications of genomic instability.

After completing these assessments, compile a detailed report that interprets the results and explains their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"Based on processed mRNA TPM data evaluating the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and considering the patient characteristics (female, White, bladder tissue, tumor mutational burden of 20 mutations/MB), could you provide an assessment on whether the patient is likely to respond to Atezolizumab, along with the supporting rationale?","Based on processed mRNA TPM data evaluating the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), and considering the patient characteristics (female, White, bladder tissue, tumor mutational burden of 20 mutations/MB), could you provide an assessment on whether the patient is likely to respond to Atezolizumab, along with the supporting rationale? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the patient’s tumor tissue. Begin by characterizing the tumor microenvironment: evaluate the functional activity of natural killer cells, measure the expression levels of T-cell exhaustion markers, and assess the immunosuppressive role of B cells. Next, examine the systemic immune response by determining the activation status of macrophages, analyzing key interferon-gamma signaling pathways, and identifying any evidence of genomic instability. Once these analyses are completed, prepare a comprehensive report that interprets the findings and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"For a female white patient with Bladder Urothelial Carcinoma (BLCA) who presents with lymph node involvement and a Tumor Mutational Burden of 10.0 mutations per megabase, how would you determine her likelihood of responding to Atezolizumab? Please provide a classification (responder or non-responder) along with your supporting rationale.","For a female white patient with Bladder Urothelial Carcinoma (BLCA) who presents with lymph node involvement and a Tumor Mutational Burden of 10.0 mutations per megabase, how would you determine her likelihood of responding to Atezolizumab? Please provide a classification (responder or non-responder) along with your supporting rationale. Please use the COMPASS platform to conduct a comprehensive transcriptomic evaluation of the patient's tumor tissue. Start by analyzing the tumor microenvironment: assess the functional activity of natural killer cells, quantify the expression of T-cell exhaustion markers, and evaluate the immunosuppressive role of B cells. Then, investigate the systemic immune response by determining macrophage activation status, analyzing key interferon-gamma signaling pathways, and identifying any signs of genomic instability. Once these analyses are complete, compile a detailed report that interprets the data and outlines its potential impact on the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"Based on the mRNA TPM data of the tumor immune microenvironment and the following clinical details—male, White, bladder tissue involved, diagnosed with Bladder Urothelial Carcinoma, and a tumor mutational burden of 35 mutations per MB—can you determine whether this patient is likely to respond to Atezolizumab, and provide your reasoning?","Based on the mRNA TPM data of the tumor immune microenvironment and the following clinical details—male, White, bladder tissue involved, diagnosed with Bladder Urothelial Carcinoma, and a tumor mutational burden of 35 mutations per MB—can you determine whether this patient is likely to respond to Atezolizumab, and provide your reasoning? Utilize the COMPASS platform to perform a thorough transcriptomic analysis of the patient’s tumor tissue. Begin by examining the tumor microenvironment: assess the functional activity of natural killer cells, measure the expression levels of T-cell exhaustion markers, and evaluate the immunosuppressive effects mediated by B cells. Then, evaluate the systemic immune response by determining macrophage activation status, examining key interferon-gamma signaling pathways, and identifying any evidence of genomic instability. Finally, compile a comprehensive report that interprets these findings and discusses how they might influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"For a female patient with Bladder Urothelial Carcinoma (BLCA) characterized by a tumor mutational burden of 6 mutations/MB, and based on evaluated mRNA TPM data of the tumor immune microenvironment from bladder tissue, would you consider her likely to respond to Atezolizumab therapy? Please include the rationale for your conclusion.","For a female patient with Bladder Urothelial Carcinoma (BLCA) characterized by a tumor mutational burden of 6 mutations/MB, and based on evaluated mRNA TPM data of the tumor immune microenvironment from bladder tissue, would you consider her likely to respond to Atezolizumab therapy? Please include the rationale for your conclusion. Please use the COMPASS platform to conduct a detailed transcriptomic study of the patient’s tumor tissue. Start by analyzing the tumor microenvironment by assessing natural killer cell functionality, quantifying the expression of T-cell exhaustion markers, and evaluating the immunosuppressive effects of B cells. Next, investigate the systemic immune response by determining macrophage activation, analyzing key interferon-gamma signaling pathways, and identifying any signs of genomic instability. Once these evaluations are complete, compile a comprehensive report that interprets the findings and outlines their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a female, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 3.0 mutations per megabase. Based on these findings, could you provide an assessment of the patient's likelihood of responding to Atezolizumab, including the clinical rationale for classifying her as a responder or non-responder?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a female, White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 3.0 mutations per megabase. Based on these findings, could you provide an assessment of the patient's likelihood of responding to Atezolizumab, including the clinical rationale for classifying her as a responder or non-responder? Utilize the COMPASS platform to perform an extensive transcriptomic analysis of the patient's tumor tissue. Begin by examining the tumor microenvironment: evaluate natural killer cell functionality, measure the expression levels of T-cell exhaustion markers, and assess the immunosuppressive activity of B cells. Then, assess the systemic immune response by determining macrophage activation, investigating key interferon-gamma signaling pathways, and detecting any indicators of genomic instability. Once your analyses are complete, prepare a detailed report that interprets these findings and discusses their potential implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"Based on the processed mRNA TPM data depicting the tumor immune microenvironment of a male, white patient with Bladder Urothelial Carcinoma (BLCA), and considering a tumor mutational burden of 5.0 mutations/Mb, could you please determine whether this patient is most likely to respond to Atezolizumab? Please provide a conclusion along with the rationale supporting your prediction.","Based on the processed mRNA TPM data depicting the tumor immune microenvironment of a male, white patient with Bladder Urothelial Carcinoma (BLCA), and considering a tumor mutational burden of 5.0 mutations/Mb, could you please determine whether this patient is most likely to respond to Atezolizumab? Please provide a conclusion along with the rationale supporting your prediction. Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient's tumor tissue. Start by analyzing the tumor microenvironment: assess the functionality of natural killer cells, quantify the expression levels of T-cell exhaustion markers, and evaluate the immunosuppressive activity of B cells. Next, investigate the systemic immune response by checking for macrophage activation, analyzing key interferon-gamma signaling pathways, and screening for signs of genomic instability. Once these analyses are complete, compile a comprehensive report that interprets the findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"Based on mRNA TPM data reflecting the tumor immune microenvironment in a male patient with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations per MB, can you determine whether this patient is likely to respond to Atezolizumab? Please include your rationale for the classification as responder or non-responder.","Based on mRNA TPM data reflecting the tumor immune microenvironment in a male patient with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 5.0 mutations per MB, can you determine whether this patient is likely to respond to Atezolizumab? Please include your rationale for the classification as responder or non-responder. Please use the COMPASS platform for a comprehensive transcriptomic evaluation of the patient's tumor tissue. Begin by examining the tumor microenvironment: assess the activity of natural killer cells, quantify T-cell exhaustion markers, and evaluate the immunosuppressive functions of B cells. Then, analyze the systemic immune response by examining macrophage activation, key interferon-gamma signaling pathways, and markers of genomic instability. Finally, prepare a detailed report that interprets these findings and discusses their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"I have compiled mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 5-mutational burden per MB, White male with a primary bladder tumor. Could you please evaluate the likelihood of a response to Atezolizumab and explain your reasoning?","I have compiled mRNA TPM data reflecting the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient is a 5-mutational burden per MB, White male with a primary bladder tumor. Could you please evaluate the likelihood of a response to Atezolizumab and explain your reasoning? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the patient's tumor tissue. Start by evaluating the tumor microenvironment: assess the activity of natural killer cells, measure markers indicative of T-cell exhaustion, and evaluate the immunosuppressive role of B cells. Next, examine the systemic immune response by analyzing macrophage activation, investigating key interferon-gamma signaling pathways, and assessing markers of genomic instability. Finally, compile a comprehensive report that interprets these findings and outlines their potential implications for the treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,Based on the processed mRNA TPM data for a patient diagnosed with Bladder Urothelial Carcinoma—who is a white male with a primary tumor component in the kidney and a tumor mutational burden of 5.0 mutations per megabase—could you please evaluate the likelihood of a positive response to Atezolizumab? Please include your rationale in the assessment.,"Based on the processed mRNA TPM data for a patient diagnosed with Bladder Urothelial Carcinoma—who is a white male with a primary tumor component in the kidney and a tumor mutational burden of 5.0 mutations per megabase—could you please evaluate the likelihood of a positive response to Atezolizumab? Please include your rationale in the assessment. Please utilize the COMPASS platform to carry out an in‐depth transcriptomic evaluation of the patient's tumor tissue. Begin by investigating the tumor microenvironment: assess the activity of natural killer cells, quantify markers of T‐cell exhaustion, and evaluate the immunosuppressive functions of B cells. Then, scrutinize the systemic immune response by analyzing macrophage activation, exploring key interferon-gamma signaling pathways, and assessing markers indicative of genomic instability. Conclude by preparing a comprehensive report that interprets these findings and discusses their potential implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"I have processed the patient's mRNA TPM data, which characterizes the tumor immune microenvironment in a case of bladder urothelial carcinoma. The patient is a white male, with bladder tissue sampled, and the tumor mutational burden is reported as ""nan."" Based on these data, could you please determine whether the patient is predicted to be a responder or non-responder to Atezolizumab, and explain the rationale behind your assessment?","I have processed the patient's mRNA TPM data, which characterizes the tumor immune microenvironment in a case of bladder urothelial carcinoma. The patient is a white male, with bladder tissue sampled, and the tumor mutational burden is reported as ""nan."" Based on these data, could you please determine whether the patient is predicted to be a responder or non-responder to Atezolizumab, and explain the rationale behind your assessment? Use the COMPASS platform to perform a detailed transcriptomic analysis of the patient's tumor tissue. Begin by examining the tumor microenvironment: evaluate natural killer cell activity, quantify markers of T‐cell exhaustion, and assess the immunosuppressive roles of B cells. Next, investigate the systemic immune response by determining macrophage activation, analyzing key interferon-gamma signaling pathways, and measuring markers that indicate genomic instability. Finally, compile a comprehensive report that interprets these findings and explains their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by a male gender, non-Caucasian background, bladder tissue involvement, and a tumor mutational burden of 3.0 mutations per megabase, how would you assess the predicted responsiveness to Atezolizumab? Please provide your determination as either responder or non-responder, along with the rationale behind your conclusion.","For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by a male gender, non-Caucasian background, bladder tissue involvement, and a tumor mutational burden of 3.0 mutations per megabase, how would you assess the predicted responsiveness to Atezolizumab? Please provide your determination as either responder or non-responder, along with the rationale behind your conclusion. Utilize the COMPASS platform to conduct a comprehensive transcriptomic evaluation of the patient’s tumor tissue. Start by analyzing the tumor microenvironment: assess natural killer cell activity, quantify markers of T‐cell exhaustion, and evaluate the immunosuppressive functions of B cells. Then, examine the systemic immune response by measuring macrophage activation, scrutinizing key interferon-gamma signaling pathways, and assessing markers indicative of genomic instability. Finally, prepare a detailed report summarizing these findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma. The patient is a 10 mutation/MB TMB, male, identified as White, and the tissue sample is from the ureter. Based on these parameters, can you determine whether the patient is likely to respond to Atezolizumab and provide the supporting clinical rationale for your conclusion?","I have analyzed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma. The patient is a 10 mutation/MB TMB, male, identified as White, and the tissue sample is from the ureter. Based on these parameters, can you determine whether the patient is likely to respond to Atezolizumab and provide the supporting clinical rationale for your conclusion? Please use the COMPASS platform to perform an in-depth transcriptomic analysis of the patient's tumor tissue. Start by examining the tumor microenvironment: assess natural killer cell activity, quantify markers of T‐cell exhaustion, and evaluate the immunosuppressive functions of B cells. Next, evaluate the systemic immune response by measuring macrophage activation, reviewing key interferon-gamma signaling pathways, and assessing markers of genomic instability. Finally, compile a detailed report that summarizes your findings and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"Given the patient's processed mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma, along with the following clinical details: male, white, lymph node tissue sample, and tumor mutational burden of 3.0 mutations/MB, can you determine whether this patient is likely to respond to Atezolizumab? Please include your conclusion and the supporting rationale.","Given the patient's processed mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma, along with the following clinical details: male, white, lymph node tissue sample, and tumor mutational burden of 3.0 mutations/MB, can you determine whether this patient is likely to respond to Atezolizumab? Please include your conclusion and the supporting rationale. Utilize the COMPASS platform to conduct a comprehensive transcriptomic evaluation of the patient’s tumor tissue. Begin by analyzing the tumor microenvironment: assess natural killer cell activity, measure markers indicating T-cell exhaustion, and evaluate the immunosuppressive functions of B cells. Then, move on to assessing the systemic immune response by quantifying macrophage activation, examining key interferon-gamma signaling pathways, and determining markers of genomic instability. Conclude your analysis by preparing a detailed report that summarizes your findings and discusses their potential impact on the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"We have mRNA TPM data characterizing the tumor immune microenvironment of a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 3.0 mutations/Mb. Based on this information, could you assess whether this patient is likely to respond to Atezolizumab and provide the reasoning behind your conclusion?","We have mRNA TPM data characterizing the tumor immune microenvironment of a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 3.0 mutations/Mb. Based on this information, could you assess whether this patient is likely to respond to Atezolizumab and provide the reasoning behind your conclusion? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the patient's tumor sample. Start by studying the tumor microenvironment: evaluate natural killer cell function, assess indicators of T-cell exhaustion, and examine the immunosuppressive role of B cells. Next, analyze the systemic immune response by measuring macrophage activation levels, investigating key interferon-gamma signaling pathways, and identifying markers of genomic instability. Finally, compile a comprehensive report that summarizes your findings and explains their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"A patient with Bladder Urothelial Carcinoma (BLCA) has been profiled using mRNA TPM data to characterize the tumor immune microenvironment. The patient’s clinical details are as follows: Female, Black or African American, tissue sampled from the lung, and a tumor mutational burden of 11.0 mutations per MB. Based on these attributes, could you please assess whether the patient is more likely to be responsive or non-responsive to Atezolizumab, and provide the rationale for your conclusion?","A patient with Bladder Urothelial Carcinoma (BLCA) has been profiled using mRNA TPM data to characterize the tumor immune microenvironment. The patient’s clinical details are as follows: Female, Black or African American, tissue sampled from the lung, and a tumor mutational burden of 11.0 mutations per MB. Based on these attributes, could you please assess whether the patient is more likely to be responsive or non-responsive to Atezolizumab, and provide the rationale for your conclusion? Use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient's tumor sample. Begin by evaluating the tumor microenvironment: analyze natural killer cell activity, assess markers of T-cell exhaustion, and investigate the immunosuppressive role of B cells. Next, assess the systemic immune response by measuring macrophage activation, examining key interferon-gamma signaling pathways, and identifying indicators of genomic instability. Conclude by preparing a detailed report that summarizes your findings and discusses their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"I have mRNA TPM gene expression data reflecting the tumor immune microenvironment from a lymph node biopsy in a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The tumor mutational burden (FMO mutation burden per MB) is unavailable. Based on this information, could you provide your clinical assessment on whether this patient is likely to respond to Atezolizumab and explain the rationale behind your determination?","I have mRNA TPM gene expression data reflecting the tumor immune microenvironment from a lymph node biopsy in a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The tumor mutational burden (FMO mutation burden per MB) is unavailable. Based on this information, could you provide your clinical assessment on whether this patient is likely to respond to Atezolizumab and explain the rationale behind your determination? Please use the COMPASS platform to carry out an in-depth transcriptomic analysis of the patient's tumor sample. Start by evaluating the tumor microenvironment: examine natural killer cell activity, assess markers indicative of T-cell exhaustion, and evaluate the immunosuppressive properties of B cells. Then, assess the systemic immune response by measuring macrophage activation, analyzing key interferon-gamma signaling pathways, and identifying signs of genomic instability. Finally, prepare a comprehensive report detailing your findings and discussing their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"In a patient with bladder urothelial carcinoma where we have mRNA TPM data characterizing the tumor immune microenvironment from a liver tissue sample, the patient is a  male of White race and has an unavailable tumor mutational burden (FMOne mutation burden per MB is NaN). Based on these details, does the available data suggest that the patient is likely a responder or non-responder to Atezolizumab? Please provide your rationale for this assessment.","In a patient with bladder urothelial carcinoma where we have mRNA TPM data characterizing the tumor immune microenvironment from a liver tissue sample, the patient is a  male of White race and has an unavailable tumor mutational burden (FMOne mutation burden per MB is NaN). Based on these details, does the available data suggest that the patient is likely a responder or non-responder to Atezolizumab? Please provide your rationale for this assessment. Please use the COMPASS platform to perform a comprehensive transcriptomic analysis on the patient’s tumor sample. Begin by thoroughly evaluating the tumor microenvironment through an assessment of natural killer cell activity, examination of T-cell exhaustion markers, and analysis of the immunosuppressive characteristics of B cells. Next, analyze the systemic immune response by measuring macrophage activation, investigating key interferon-gamma signaling pathways, and detecting any indicators of genomic instability. Conclude by compiling a detailed report that outlines your findings and discusses potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"I have mRNA TPM data evaluating the tumor immune microenvironment of a white female patient with Bladder Urothelial Carcinoma (BLCA) and a high tumor mutational burden (FMOne mutation burden: 26.0 per MB), with the tumor located in the ureter. Based on these data, could you assess whether this patient is likely to respond to Atezolizumab, and provide the reasoning supporting your conclusion?","I have mRNA TPM data evaluating the tumor immune microenvironment of a white female patient with Bladder Urothelial Carcinoma (BLCA) and a high tumor mutational burden (FMOne mutation burden: 26.0 per MB), with the tumor located in the ureter. Based on these data, could you assess whether this patient is likely to respond to Atezolizumab, and provide the reasoning supporting your conclusion? Please use the COMPASS platform to conduct a thorough transcriptomic analysis of the patient’s tumor sample. Begin by evaluating the tumor microenvironment, specifically by assessing natural killer cell activity, examining markers of T-cell exhaustion, and analyzing the immunosuppressive features of B cells. Next, measure the systemic immune response through analysis of macrophage activation, investigation of key interferon-gamma signaling pathways, and assessment of genomic instability. Finally, prepare a detailed report summarizing your findings and their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"In a patient diagnosed with bladder urothelial carcinoma, we have mRNA TPM data representing the tumor immune microenvironment. The patient is a white male with a bladder tissue sample, and his tumor mutational burden is 14.0 mutations per megabase. Based on these data, could you provide an assessment of his likely response to Atezolizumab along with a detailed explanation supporting your conclusion?","In a patient diagnosed with bladder urothelial carcinoma, we have mRNA TPM data representing the tumor immune microenvironment. The patient is a white male with a bladder tissue sample, and his tumor mutational burden is 14.0 mutations per megabase. Based on these data, could you provide an assessment of his likely response to Atezolizumab along with a detailed explanation supporting your conclusion? Please use the COMPASS platform to perform a comprehensive transcriptomic evaluation of the patient’s tumor sample. Begin by characterizing the tumor microenvironment: assess the activity of natural killer cells, identify markers indicative of T-cell exhaustion, and evaluate any immunosuppressive traits in B cells. Then, analyze the systemic immune response by examining macrophage activation, key components of interferon-gamma signaling, and indicators of genomic instability. Conclude by preparing a detailed report that outlines your findings and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with lung tissue involvement, and the tumor mutational burden is not available. Based on these data, can you assess whether the patient is likely to respond to Atezolizumab and provide your reasoning for this prediction?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a white male with lung tissue involvement, and the tumor mutational burden is not available. Based on these data, can you assess whether the patient is likely to respond to Atezolizumab and provide your reasoning for this prediction? Using the COMPASS platform, please conduct a thorough transcriptomic analysis of the patient’s tumor sample. Begin by evaluating the tumor microenvironment: quantify natural killer cell activity, determine the presence of T-cell exhaustion markers, and assess any immunosuppressive characteristics in B cells. Next, investigate the systemic immune response by examining macrophage activation status, key elements of interferon-gamma signaling, and signs of genomic instability. Finally, compile a detailed report that summarizes your findings and outlines their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"Based on the analysis of mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA), could you determine if the patient is likely to respond to Atezolizumab? The patient details include: female sex, white race, tumor tissue located in the ureter, and a tumor mutational burden of 4.0 mutations per megabase. Please provide your conclusion on whether this patient is classified as a responder or non-responder, along with the supporting reasoning.","Based on the analysis of mRNA TPM data from the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA), could you determine if the patient is likely to respond to Atezolizumab? The patient details include: female sex, white race, tumor tissue located in the ureter, and a tumor mutational burden of 4.0 mutations per megabase. Please provide your conclusion on whether this patient is classified as a responder or non-responder, along with the supporting reasoning. Please use the COMPASS platform to perform a detailed transcriptomic analysis of the patient's tumor sample. Start by evaluating the tumor microenvironment: quantify natural killer cell activity, check for T-cell exhaustion markers, and assess any immunosuppressive features in B cells. Then, review the systemic immune response by examining macrophage activation, key components of interferon-gamma signaling, and any indicators of genomic instability. Finally, generate a comprehensive report summarizing your findings and discussing their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a male, Caucasian patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 3.0 mutations per MB. Based on this information, could you provide an assessment of the patient's predicted responsiveness to Atezolizumab, including the rationale for the determination as a responder or non-responder?","I have analyzed mRNA TPM data reflecting the tumor immune microenvironment of a male, Caucasian patient diagnosed with Bladder Urothelial Carcinoma (BLCA), with a tumor mutational burden of 3.0 mutations per MB. Based on this information, could you provide an assessment of the patient's predicted responsiveness to Atezolizumab, including the rationale for the determination as a responder or non-responder? Utilize the COMPASS platform for an in-depth transcriptomic investigation of the patient’s tumor sample. Begin by analyzing the tumor microenvironment: measure natural killer cell activity, screen for markers of T-cell exhaustion, and evaluate any immunosuppressive characteristics in B cells. Next, assess the systemic immune response by investigating macrophage activation, examining key elements of interferon-gamma signaling, and identifying signs of genomic instability. Conclude by compiling a detailed report of your findings and discussing their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"I have comprehensive mRNA TPM data profiling the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a 22.0 mutations/MB TMB, White male with bladder tissue involvement. Based on this information, could you evaluate whether this patient is likely to respond to Atezolizumab treatment and explain the underlying rationale?","I have comprehensive mRNA TPM data profiling the tumor immune microenvironment of a patient with bladder urothelial carcinoma (BLCA). The patient is a 22.0 mutations/MB TMB, White male with bladder tissue involvement. Based on this information, could you evaluate whether this patient is likely to respond to Atezolizumab treatment and explain the underlying rationale? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the patient's tumor sample. Begin by examining the tumor microenvironment: assess natural killer cell activity, identify markers indicative of T-cell exhaustion, and evaluate any immunosuppressive traits present in B cells. Then, investigate the systemic immune response by evaluating macrophage activation, analyzing key aspects of interferon-gamma signaling, and detecting evidence of genomic instability. Finally, compile a detailed report of your observations and discuss how these findings might influence the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"I have mRNA TPM data characterizing the tumor immune microenvironment for a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The available data include tissue from the bladder and a reported tumor mutational burden (FMOne mutation burden per MB) of ""nan"". Could you please provide an assessment of the patient's predicted response to Atezolizumab, indicating whether he would likely be classified as a responder or non-responder, along with your supporting rationale?","I have mRNA TPM data characterizing the tumor immune microenvironment for a male, white patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The available data include tissue from the bladder and a reported tumor mutational burden (FMOne mutation burden per MB) of ""nan"". Could you please provide an assessment of the patient's predicted response to Atezolizumab, indicating whether he would likely be classified as a responder or non-responder, along with your supporting rationale? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the patient's tumor sample. Begin by analyzing the tumor microenvironment, specifically: evaluate natural killer cell activity, identify markers indicative of T-cell exhaustion, and assess any immunosuppressive features in B cells. Next, examine the systemic immune response by reviewing macrophage activation, key aspects of interferon-gamma signaling, and signs of genomic instability. Once your analysis is complete, prepare a comprehensive report outlining your observations and discuss how these findings may affect the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"Based on the patient's mRNA TPM data from the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you evaluate the predicted responsiveness to Atezolizumab? The patient is a  female of white race, with lymph node tissue involvement, and has a tumor mutational burden of 3.0 mutations per MB. Please provide your assessment on whether she is more likely to be a responder or non-responder, including your supporting rationale.","Based on the patient's mRNA TPM data from the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), can you evaluate the predicted responsiveness to Atezolizumab? The patient is a  female of white race, with lymph node tissue involvement, and has a tumor mutational burden of 3.0 mutations per MB. Please provide your assessment on whether she is more likely to be a responder or non-responder, including your supporting rationale. Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the patient's tumor sample. Begin by evaluating the tumor microenvironment: specifically, assess natural killer cell activity, identify indicators of T-cell exhaustion, and evaluate any immunosuppressive characteristics within the B-cell population. Next, examine the systemic immune response by analyzing macrophage activation, key elements of interferon-gamma signaling, and signs of genomic instability. After completing your analysis, compile a detailed report that outlines your findings and discusses their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"I have processed mRNA TPM data assessing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA) who also presents with a high tumor mutational burden of 62.0 mutations/Mb. The patient is a White male, and the tissue sample analyzed is from the kidney. Based on these clinical and molecular parameters, can we determine whether this patient is likely to respond to Atezolizumab? Please provide your evaluation along with the supporting rationale.","I have processed mRNA TPM data assessing the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA) who also presents with a high tumor mutational burden of 62.0 mutations/Mb. The patient is a White male, and the tissue sample analyzed is from the kidney. Based on these clinical and molecular parameters, can we determine whether this patient is likely to respond to Atezolizumab? Please provide your evaluation along with the supporting rationale. Please use the COMPASS platform to perform a full transcriptomic analysis on the patient's tumor sample. Begin by assessing the tumor microenvironment: evaluate natural killer cell activity, look for evidence of T-cell exhaustion, and determine if there are any immunosuppressive features in the B-cell population. Next, analyze the systemic immune response by examining macrophage activation, critical aspects of interferon-gamma signaling, and any signs of genomic instability. Once your analysis is complete, prepare a detailed report that summarizes your findings and explains their potential implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"I have processed mRNA TPM data to assess the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient’s details are as follows: male, self-identified as Other for race, tissue classified as “other”, and a tumor mutational burden of 14.0 mutations per megabase. Based on these data points, can you determine whether this patient is likely to respond to atezolizumab, and please provide the reasoning behind your assessment?","I have processed mRNA TPM data to assess the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA). The patient’s details are as follows: male, self-identified as Other for race, tissue classified as “other”, and a tumor mutational burden of 14.0 mutations per megabase. Based on these data points, can you determine whether this patient is likely to respond to atezolizumab, and please provide the reasoning behind your assessment? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the patient's tumor sample. Begin by characterizing the tumor microenvironment: assess natural killer cell activity, identify any indications of T-cell exhaustion, and evaluate for immunosuppressive characteristics within the B-cell compartment. Then, investigate the systemic immune response by analyzing macrophage activation, key aspects of interferon-gamma signaling, and any markers of genomic instability. After completing your analysis, compile a detailed report that summarizes your findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"Given a male, white patient with bladder urothelial carcinoma (BLCA) involving lymph node tissue and a tumor mutational burden of 7.0 mutations per megabase, can you use the processed mRNA TPM data to predict this patient’s response to Atezolizumab? Please provide a conclusion regarding whether he is likely to be a responder or non-responder, along with your supporting rationale.","Given a male, white patient with bladder urothelial carcinoma (BLCA) involving lymph node tissue and a tumor mutational burden of 7.0 mutations per megabase, can you use the processed mRNA TPM data to predict this patient’s response to Atezolizumab? Please provide a conclusion regarding whether he is likely to be a responder or non-responder, along with your supporting rationale. Using the COMPASS platform, conduct a thorough transcriptomic analysis of the patient's tumor specimen. Begin by assessing the tumor microenvironment: evaluate natural killer cell activity, detect any evidence of T-cell exhaustion, and analyze the B-cell compartment for signs of immunosuppressive behavior. Next, characterize the systemic immune response by examining macrophage activation, critical aspects of interferon-gamma signaling, and indicators of genomic instability. Finally, compile a comprehensive report detailing your findings and their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"I have analyzed the mRNA TPM data of a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) with the following attributes: male sex, race unknown, bladder tissue, BLCA diagnosis, and a tumor mutational burden of 15.0 mutations per megabase. Based on this information, what is your assessment of the patient's likely responsiveness to Atezolizumab, and what is the rationale supporting your conclusion?","I have analyzed the mRNA TPM data of a patient's tumor immune microenvironment for Bladder Urothelial Carcinoma (BLCA) with the following attributes: male sex, race unknown, bladder tissue, BLCA diagnosis, and a tumor mutational burden of 15.0 mutations per megabase. Based on this information, what is your assessment of the patient's likely responsiveness to Atezolizumab, and what is the rationale supporting your conclusion? Please use the COMPASS platform to perform an in-depth transcriptomic analysis of the patient’s tumor specimen. Start by evaluating the tumor microenvironment, specifically assessing natural killer cell activity, identifying any markers of T-cell exhaustion, and examining the B-cell compartment for signs of immunosuppressive activity. Then, analyze the systemic immune response by investigating macrophage activation, key elements of interferon-gamma signaling, and any indicators of genomic instability. Once the analysis is complete, prepare a detailed report that summarizes your findings and discusses their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"I have processed mRNA TPM data from a patient with bladder urothelial carcinoma. The patient is a white male with a kidney tissue sample and a tumor mutational burden of 5.0 mutations per megabase. Based on these factors, could you provide your assessment of whether this patient is likely to respond to Atezolizumab, including the reasoning behind your conclusion?","I have processed mRNA TPM data from a patient with bladder urothelial carcinoma. The patient is a white male with a kidney tissue sample and a tumor mutational burden of 5.0 mutations per megabase. Based on these factors, could you provide your assessment of whether this patient is likely to respond to Atezolizumab, including the reasoning behind your conclusion? Using the COMPASS platform, please conduct a comprehensive transcriptomic analysis of the patient’s tumor tissue. Begin by assessing the tumor microenvironment: evaluate natural killer cell activity, look for markers that indicate T-cell exhaustion, and review the B-cell compartment for signs of immunosuppressive behavior. Next, analyze the systemic immune response by examining macrophage activation, key elements of interferon-gamma signaling, and any evidence of genomic instability. Once completed, compile a detailed report that summarizes your findings and discusses how these insights might inform the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"For a male Caucasian patient with bladder urothelial carcinoma (BLCA) and available mRNA TPM data assessing the tumor immune microenvironment (noting that the tumor mutational burden is unavailable), can you provide an assessment of the patient’s predicted response to Atezolizumab? Please include a conclusion on responder versus non-responder status along with supporting rationale.","For a male Caucasian patient with bladder urothelial carcinoma (BLCA) and available mRNA TPM data assessing the tumor immune microenvironment (noting that the tumor mutational burden is unavailable), can you provide an assessment of the patient’s predicted response to Atezolizumab? Please include a conclusion on responder versus non-responder status along with supporting rationale. Please use the COMPASS platform to perform an in-depth transcriptomic analysis on the patient’s tumor tissue. Start by evaluating the tumor microenvironment: assess natural killer cell activity, identify markers indicative of T-cell exhaustion, and examine the B-cell compartment for any evidence of immunosuppressive behavior. Then, review the systemic immune response by analyzing macrophage activation, key components of interferon-gamma signaling, and signs of genomic instability. Once your analysis is complete, prepare a detailed report summarizing your findings and discussing their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"I have processed mRNA TPM data that characterize the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white female with a primary tumor in the ureter and, based on current records, her tumor mutational burden (FMOne mutations per MB) is not available. Could you please evaluate her predicted response to Atezolizumab and provide your rationale for classifying her as a responder or non-responder?","I have processed mRNA TPM data that characterize the tumor immune microenvironment for a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white female with a primary tumor in the ureter and, based on current records, her tumor mutational burden (FMOne mutations per MB) is not available. Could you please evaluate her predicted response to Atezolizumab and provide your rationale for classifying her as a responder or non-responder? Please access the COMPASS platform to conduct a detailed transcriptomic analysis of the patient’s tumor tissue. Begin by characterizing the tumor microenvironment, including an evaluation of natural killer cell function, identification of markers of T-cell exhaustion, and an assessment of the B-cell compartment for any signs of immunosuppressive activity. Next, assess the systemic immune response by examining macrophage activation, elements of the interferon-gamma signaling pathway, and any indications of genomic instability. After completing your analysis, compile a comprehensive report that outlines your findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"I have processed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) with the following attributes: male, White, bladder tissue, and an FMOne mutation burden of 24.0 per MB. Based on these findings, could you assess the predicted responsiveness of this patient to Atezolizumab and provide your reasoning for classifying the patient as a potential responder or non-responder?","I have processed mRNA TPM data representing the tumor immune microenvironment for a patient diagnosed with Bladder Urothelial Carcinoma (BLCA) with the following attributes: male, White, bladder tissue, and an FMOne mutation burden of 24.0 per MB. Based on these findings, could you assess the predicted responsiveness of this patient to Atezolizumab and provide your reasoning for classifying the patient as a potential responder or non-responder? Please log into the COMPASS platform and perform a comprehensive transcriptomic analysis on the patient's tumor tissue. Start by evaluating the tumor microenvironment: analyze natural killer cell activity, identify markers indicating T-cell exhaustion, and review the B-cell compartment for signs of immunosuppressive behavior. Then, examine the systemic immune response by assessing macrophage activation, components of the interferon-gamma signaling pathway, and any evidence of genomic instability. Once you have completed these analyses, prepare a detailed report summarizing your findings and discussing their potential impact on the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"I have analyzed mRNA TPM data representing a patient's tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA) and am evaluating the likelihood of a response to Atezolizumab. The patient’s profile includes a male sex, White race, bladder tissue involvement, and an unavailable tumor mutational burden (FMOne mutation burden per MB recorded as nan). Based on the available data, could you provide an assessment of whether this patient would be classified as a responder or non-responder to Atezolizumab, along with the rationale behind your conclusion?","I have analyzed mRNA TPM data representing a patient's tumor immune microenvironment in the context of bladder urothelial carcinoma (BLCA) and am evaluating the likelihood of a response to Atezolizumab. The patient’s profile includes a male sex, White race, bladder tissue involvement, and an unavailable tumor mutational burden (FMOne mutation burden per MB recorded as nan). Based on the available data, could you provide an assessment of whether this patient would be classified as a responder or non-responder to Atezolizumab, along with the rationale behind your conclusion? Please log into the COMPASS platform and perform a thorough transcriptomic analysis of the patient's tumor tissue. Begin by assessing the tumor microenvironment: evaluate the activity of natural killer cells, identify markers of T-cell exhaustion, and examine the B-cell compartment for any indicators of immunosuppressive behavior. Next, analyze the systemic immune response by reviewing macrophage activation, the components of the interferon-gamma signaling pathway, and any evidence of genomic instability. Once your analysis is complete, compile a detailed report summarizing your findings and outlining their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"Based on mRNA TPM data from this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you assess the likelihood of a favorable response to Atezolizumab? The patient is a white male with tissue sampled from the ureter and a tumor mutational burden of 8.0 mutations per megabase. Please provide your conclusion regarding responder status along with the rationale.","Based on mRNA TPM data from this patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you assess the likelihood of a favorable response to Atezolizumab? The patient is a white male with tissue sampled from the ureter and a tumor mutational burden of 8.0 mutations per megabase. Please provide your conclusion regarding responder status along with the rationale. Please access the COMPASS platform and conduct a comprehensive transcriptomic analysis on the patient's tumor tissue. Start by evaluating the tumor microenvironment: assess natural killer cell activity, screen for markers indicating T-cell exhaustion, and inspect the B-cell compartment for any signs of immunosuppressive behavior. Then, shift your focus to the systemic immune response by investigating macrophage activation levels, examining the components of the interferon-gamma signaling pathway, and identifying any evidence of genomic instability. After completing your analysis, please prepare a detailed report that summarizes your findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"Given a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor immune microenvironment has been profiled using mRNA TPM data, and considering the following attributes: male, white, kidney tissue involvement, and a tumor mutational burden of 4.0 mutations/MB, what is the assessment of this patient’s likely responsiveness to Atezolizumab? Please provide both the classification (responder or non-responder) and the supporting clinical rationale.","Given a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor immune microenvironment has been profiled using mRNA TPM data, and considering the following attributes: male, white, kidney tissue involvement, and a tumor mutational burden of 4.0 mutations/MB, what is the assessment of this patient’s likely responsiveness to Atezolizumab? Please provide both the classification (responder or non-responder) and the supporting clinical rationale. Please log into the COMPASS platform and perform a thorough transcriptomic evaluation of the tumor sample. Begin by analyzing the tumor microenvironment: measure natural killer cell activity, look for indicators of T-cell exhaustion, and assess the B-cell compartment for any immunosuppressive characteristics. Next, evaluate the systemic immune response by determining macrophage activation status, analyzing the interferon-gamma signaling pathway components, and checking for signs of genomic instability. Once your analysis is complete, compile a detailed report summarizing your findings and discussing their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by the following attributes—male, White, bladder tissue, a tumor mutational burden of 14.0 (FMOne mutation burden per MB)—and mRNA TPM data for their tumor immune microenvironment, based on current research, would you classify this patient as a likely responder or non-responder to Atezolizumab? Please provide the conclusion with supporting evidence or reasoning.","For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by the following attributes—male, White, bladder tissue, a tumor mutational burden of 14.0 (FMOne mutation burden per MB)—and mRNA TPM data for their tumor immune microenvironment, based on current research, would you classify this patient as a likely responder or non-responder to Atezolizumab? Please provide the conclusion with supporting evidence or reasoning. Please access the COMPASS platform and conduct a comprehensive transcriptomic analysis of the tumor sample. Begin by evaluating the tumor microenvironment: quantify natural killer cell activity, assess T-cell exhaustion markers, and examine the B-cell compartment for any immunosuppressive features. Then, assess the systemic immune response by determining the activation status of macrophages, evaluating components of the interferon-gamma signaling pathway, and identifying indicators of genomic instability. After completing your analysis, please prepare a detailed report summarizing your findings and discussing their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"Based on mRNA TPM data profiling the tumor immune microenvironment in a male, White patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0 mutations per MB, how should we interpret the predicted response to Atezolizumab? Please classify the patient as a responder or non-responder and provide the clinical rationale for this determination.","Based on mRNA TPM data profiling the tumor immune microenvironment in a male, White patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0 mutations per MB, how should we interpret the predicted response to Atezolizumab? Please classify the patient as a responder or non-responder and provide the clinical rationale for this determination. Access the COMPASS platform to perform a detailed transcriptomic analysis of the tumor sample. First, evaluate the tumor microenvironment by quantifying natural killer cell activity, assessing markers of T-cell exhaustion, and examining the B-cell compartment for signs of immunosuppression. Next, assess the systemic immune response by determining the activation state of macrophages, evaluating key components of the interferon-gamma signaling pathway, and identifying markers of genomic instability. After completing these analyses, compile a comprehensive report that summarizes your findings and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"I have mRNA TPM data reflecting the tumor immune microenvironment for a 68-year-old white male patient diagnosed with Bladder Urothelial Carcinoma, with a reported tumor mutational burden of 10 mutations per MB. Based on these findings, how would you assess his likelihood of responding to Atezolizumab? Please provide a conclusion regarding his responder status along with the rationale behind your assessment.","I have mRNA TPM data reflecting the tumor immune microenvironment for a 68-year-old white male patient diagnosed with Bladder Urothelial Carcinoma, with a reported tumor mutational burden of 10 mutations per MB. Based on these findings, how would you assess his likelihood of responding to Atezolizumab? Please provide a conclusion regarding his responder status along with the rationale behind your assessment. Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample. Begin by analyzing the tumor microenvironment, specifically by measuring natural killer cell activity, evaluating T-cell exhaustion markers, and reviewing the B-cell compartment for any evidence of immunosuppression. Then, evaluate the systemic immune response by assessing macrophage activation, key elements of the interferon-gamma signaling pathway, and markers of genomic instability. Finally, prepare a detailed report that summarizes your results and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"Can you evaluate, based on processed mRNA TPM data of a tumor immune microenvironment, whether a patient with Bladder Urothelial Carcinoma (BLCA) is likely to respond to Atezolizumab treatment? The patient is a White male with kidney tissue involvement and no available tumor mutational burden data. Please provide your conclusion regarding responder status along with the supporting rationale.","Can you evaluate, based on processed mRNA TPM data of a tumor immune microenvironment, whether a patient with Bladder Urothelial Carcinoma (BLCA) is likely to respond to Atezolizumab treatment? The patient is a White male with kidney tissue involvement and no available tumor mutational burden data. Please provide your conclusion regarding responder status along with the supporting rationale. Utilize the COMPASS platform to conduct a detailed transcriptomic evaluation of the tumor sample. Start by thoroughly assessing the tumor microenvironment: quantify natural killer cell activity, determine the presence of T-cell exhaustion markers, and examine the B-cell compartment for signs of immunosuppression. Next, investigate the systemic immune response by evaluating macrophage activation, key components of the interferon-gamma signaling pathway, and indicators of genomic instability. Finally, compile a comprehensive report outlining your findings and discussing their potential implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"Based on the patient's tumor immune microenvironment mRNA TPM data for bladder urothelial carcinoma, could you assess their likely response to Atezolizumab treatment? The patient is a white male with lymph node tissue involvement and an unavailable tumor mutational burden value. Please provide your conclusion on whether he is likely to be a responder or non-responder, along with the reasoning behind your assessment.","Based on the patient's tumor immune microenvironment mRNA TPM data for bladder urothelial carcinoma, could you assess their likely response to Atezolizumab treatment? The patient is a white male with lymph node tissue involvement and an unavailable tumor mutational burden value. Please provide your conclusion on whether he is likely to be a responder or non-responder, along with the reasoning behind your assessment. Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor specimen. Begin by examining the tumor microenvironment: measure natural killer cell activity, evaluate the expression of T-cell exhaustion markers, and assess the B-cell compartment for any evidence of immunosuppression. Then, study the systemic immune response by analyzing macrophage activation, key elements in the interferon-gamma signaling pathway, and markers of genomic instability. Conclude by compiling a comprehensive report that summarizes your findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"A patient with bladder urothelial carcinoma (BLCA) has been profiled using mRNA TPM data of the tumor immune microenvironment and exhibits a tumor mutational burden of 19.0 FMOne mutations per megabase. The patient is male and self-identifies as white, with bladder tissue affected. Based on these clinical and molecular findings, could you please assess whether this patient is likely to be a responder or a non-responder to Atezolizumab, and explain your rationale?","A patient with bladder urothelial carcinoma (BLCA) has been profiled using mRNA TPM data of the tumor immune microenvironment and exhibits a tumor mutational burden of 19.0 FMOne mutations per megabase. The patient is male and self-identifies as white, with bladder tissue affected. Based on these clinical and molecular findings, could you please assess whether this patient is likely to be a responder or a non-responder to Atezolizumab, and explain your rationale? Utilize the COMPASS platform to conduct an in‐depth transcriptomic analysis of the tumor sample. Start by investigating the tumor microenvironment: quantify natural killer cell activity, assess T‐cell exhaustion marker expression, and evaluate the B‐cell compartment for signs of immunosuppression. Next, analyze the systemic immune response by examining macrophage activation, key components of the interferon‐gamma signaling pathway, and indicators of genomic instability. Finally, prepare a detailed report summarizing your findings and discussing how they may influence the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"Given a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor originates from the ureter, who is female and of an unclassified race category (""OTHER""), and with a tumor mutational burden of 5.0 mutations per MB, how should we predict her response to Atezolizumab based on mRNA TPM data characterizing the tumor immune microenvironment? Could you also provide the rationale for classifying her as a responder or non-responder?","Given a patient with Bladder Urothelial Carcinoma (BLCA) whose tumor originates from the ureter, who is female and of an unclassified race category (""OTHER""), and with a tumor mutational burden of 5.0 mutations per MB, how should we predict her response to Atezolizumab based on mRNA TPM data characterizing the tumor immune microenvironment? Could you also provide the rationale for classifying her as a responder or non-responder? Use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor specimen. First, focus on the tumor microenvironment by quantifying natural killer (NK) cell activity, measuring markers of T-cell exhaustion, and examining the B-cell compartment for signs of immunosuppressive activity. Then, evaluate the systemic immune response by analyzing macrophage activation, components of the interferon-gamma signaling pathway, and markers indicative of genomic instability. Finally, compile a detailed report that summarizes your findings and discusses potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"Using processed mRNA TPM data from a female patient of White race diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 2.0 mutations/MB, how would you classify her predicted response to Atezolizumab therapy—as a responder or non-responder—and what is the supporting rationale for this assessment?","Using processed mRNA TPM data from a female patient of White race diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 2.0 mutations/MB, how would you classify her predicted response to Atezolizumab therapy—as a responder or non-responder—and what is the supporting rationale for this assessment? Please use the COMPASS platform for an in-depth transcriptomic analysis of the tumor sample. Begin by assessing the tumor microenvironment: quantify natural killer (NK) cell activity, evaluate markers of T-cell exhaustion, and review the B-cell population for indicators of immunosuppression. Next, analyze the systemic immune response by examining macrophage activation, components of the interferon-gamma signaling pathway, and markers of genomic instability. Finally, prepare a detailed report summarizing your findings and discussing their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by the following parameters: male, white, bladder tissue involvement, and a tumor mutational burden of 14.0 mutations per MB, could you provide an assessment of the likelihood of a favorable response to Atezolizumab, including the supporting rationale?","For a patient with Bladder Urothelial Carcinoma (BLCA) characterized by the following parameters: male, white, bladder tissue involvement, and a tumor mutational burden of 14.0 mutations per MB, could you provide an assessment of the likelihood of a favorable response to Atezolizumab, including the supporting rationale? Please utilize the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample. Begin by evaluating the tumor microenvironment: determine the level of natural killer (NK) cell activity, assess markers indicative of T-cell exhaustion, and analyze the B-cell population for any signs of immunosuppressive activity. Then, shift your focus to the systemic immune response by reviewing macrophage activation, components of the interferon-gamma signaling pathway, and any markers of genomic instability. Once these analyses are completed, compile a detailed report that summarizes your findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"We have processed mRNA TPM data reflecting the tumor immune microenvironment for a female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 17.0 mutations per megabase. Given these data, could you please assess whether this patient is likely to respond to Atezolizumab, and provide your reasoning behind this conclusion?","We have processed mRNA TPM data reflecting the tumor immune microenvironment for a female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 17.0 mutations per megabase. Given these data, could you please assess whether this patient is likely to respond to Atezolizumab, and provide your reasoning behind this conclusion? Please use the COMPASS platform to conduct a full transcriptomic analysis of the tumor specimen. Start by assessing the tumor microenvironment: quantify natural killer (NK) cell activity, evaluate markers associated with T-cell exhaustion, and examine the B-cell population for any indications of immunosuppressive activity. Next, assess the systemic immune response by evaluating macrophage activation, key components of the interferon-gamma signaling pathway, and detecting any markers of genomic instability. Finally, prepare a detailed report summarizing your findings and discussing their possible implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"I have analyzed mRNA TPM data of the tumor immune microenvironment from a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male with tumor tissue derived from the bladder, and the tumor mutational burden data (FMO mutation burden per MB) is not available. Based on this information, what is the predicted response to Atezolizumab, and what rationale supports classifying this patient as a responder or non-responder?","I have analyzed mRNA TPM data of the tumor immune microenvironment from a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male with tumor tissue derived from the bladder, and the tumor mutational burden data (FMO mutation burden per MB) is not available. Based on this information, what is the predicted response to Atezolizumab, and what rationale supports classifying this patient as a responder or non-responder? Use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor specimen. Begin by examining the tumor microenvironment: quantify natural killer (NK) cell activity, assess markers indicative of T-cell exhaustion, and analyze the B-cell profile for signs of immunosuppressive behavior. Next, evaluate the systemic immune response by measuring macrophage activation, investigating key components of the interferon-gamma signaling pathway, and screening for markers of genomic instability. Finally, compile a detailed report that summarizes your findings and discusses their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"Given mRNA TPM data for a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), with the following characteristics—
• Sex: Male
• Race: White
• Tissue: Bladder
• Tumor Mutational Burden: 6.0 mutations per megabase

—could you evaluate whether this patient is predicted to respond to Atezolizumab? Please include your reasoning for the classification as responder or non-responder.","Given mRNA TPM data for a patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), with the following characteristics—
• Sex: Male
• Race: White
• Tissue: Bladder
• Tumor Mutational Burden: 6.0 mutations per megabase

—could you evaluate whether this patient is predicted to respond to Atezolizumab? Please include your reasoning for the classification as responder or non-responder. Please utilize the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor specimen. Begin by assessing the tumor microenvironment: quantify the activity of natural killer (NK) cells, evaluate markers associated with T-cell exhaustion, and examine the B-cell profile for evidence of immunosuppressive activity. Then, assess the systemic immune response by measuring macrophage activation, analyzing key components of the interferon-gamma signaling pathway, and screening for markers of genomic instability. Finally, prepare a comprehensive report that summarizes your findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"A patient with bladder urothelial carcinoma (BLCA) has mRNA TPM data from her tumor immune microenvironment available. She is a White female with a tumor mutational burden of 9 mutations/MB. Based on this information, how would you predict her responsiveness to Atezolizumab, and what is the rationale for classifying her as a responder or non-responder?","A patient with bladder urothelial carcinoma (BLCA) has mRNA TPM data from her tumor immune microenvironment available. She is a White female with a tumor mutational burden of 9 mutations/MB. Based on this information, how would you predict her responsiveness to Atezolizumab, and what is the rationale for classifying her as a responder or non-responder? Please use the COMPASS platform to conduct a comprehensive transcriptomic assessment of the tumor specimen. Start by analyzing the tumor microenvironment: quantify natural killer (NK) cell function, assess markers indicative of T-cell exhaustion, and evaluate the B-cell profile for signs of immunosuppressive activity. Next, evaluate the systemic immune response by measuring macrophage activation, analyzing key elements of the interferon-gamma signaling pathway, and screening for indicators of genomic instability. Finally, compile a detailed report summarizing your findings and discussing their potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"Based on the mRNA TPM data analyzing the patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), which includes the following attributes—Sex: Female, Race: White, Tissue: Kidney, and a Tumor Mutational Burden of 5.0 mutations per MB—could you please evaluate whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Based on the mRNA TPM data analyzing the patient's tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), which includes the following attributes—Sex: Female, Race: White, Tissue: Kidney, and a Tumor Mutational Burden of 5.0 mutations per MB—could you please evaluate whether this patient is likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Use the COMPASS platform to perform an in-depth transcriptomic analysis of the tumor specimen. Begin by characterizing the tumor microenvironment: quantify natural killer cell activity, evaluate markers of T-cell exhaustion, and assess the B-cell profile for indications of immunosuppressive behavior. Then, investigate the systemic immune response by measuring macrophage activation, examining critical components of the interferon-gamma signaling pathway, and screening for signs of genomic instability. Finally, compile a comprehensive report detailing your findings and discussing their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA), we have processed mRNA TPM data of the tumor immune microenvironment. The patient's details are: male, white, with a liver tissue sample, a diagnosis of BLCA, and a tumor mutational burden of 5.0 mutations per megabase. Based on these data, could you please assess the likelihood of a positive response to Atezolizumab and explain your rationale?","For a patient with Bladder Urothelial Carcinoma (BLCA), we have processed mRNA TPM data of the tumor immune microenvironment. The patient's details are: male, white, with a liver tissue sample, a diagnosis of BLCA, and a tumor mutational burden of 5.0 mutations per megabase. Based on these data, could you please assess the likelihood of a positive response to Atezolizumab and explain your rationale? Use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor sample. Start by examining the tumor microenvironment, including quantification of natural killer cell activity, evaluation of T-cell exhaustion markers, and assessment of the B-cell profile for any signs of immunosuppressive activity. Next, assess the systemic immune response by measuring macrophage activation, analyzing key elements of the interferon-gamma signaling pathway, and screening for evidence of genomic instability. Conclude by preparing a detailed report that summarizes your findings and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"I have analyzed mRNA TPM data from the tumor immune microenvironment of a male patient diagnosed with Bladder Urothelial Carcinoma, and I am evaluating his potential response to Atezolizumab. Notably, the tumor mutational burden is not available (recorded as 'nan'). Based on these data, could you assess whether this patient is likely to be a responder or non-responder to Atezolizumab, and please explain your reasoning?","I have analyzed mRNA TPM data from the tumor immune microenvironment of a male patient diagnosed with Bladder Urothelial Carcinoma, and I am evaluating his potential response to Atezolizumab. Notably, the tumor mutational burden is not available (recorded as 'nan'). Based on these data, could you assess whether this patient is likely to be a responder or non-responder to Atezolizumab, and please explain your reasoning? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis on the tumor sample. Begin by assessing the tumor microenvironment, which should include quantification of natural killer cell activity, evaluation of T-cell exhaustion markers, and analysis of the B-cell profile for any signs of immunosuppressive activity. Next, investigate the systemic immune response by measuring macrophage activation, examining key components of the interferon‑gamma signaling pathway, and screening for genomic instability. Finally, compile a detailed report summarizing your findings, including a discussion on how these results might influence the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e71235-ar-e712352.pkl. "
BLCA,,,,NR,"Based on mRNA TPM data representing the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA) with the following patient details—male, white, kidney tissue sample, and an unavailable tumor mutational burden—how would you assess the likelihood of response to Atezolizumab? Please indicate whether the patient is predicted to be a responder or non-responder and provide the rationale behind your conclusion.","Based on mRNA TPM data representing the tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA) with the following patient details—male, white, kidney tissue sample, and an unavailable tumor mutational burden—how would you assess the likelihood of response to Atezolizumab? Please indicate whether the patient is predicted to be a responder or non-responder and provide the rationale behind your conclusion. Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor sample. Start by evaluating the tumor microenvironment through quantification of natural killer cell activity, assessment of T-cell exhaustion markers, and examination of the B-cell profile for any immunosuppressive characteristics. Then, analyze the systemic immune response by measuring macrophage activation, investigating critical elements of the interferon‑gamma signaling pathway, and screening for genomic instability. Finally, prepare a comprehensive report that summarizes your findings and discusses the potential implications for the patient's treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"I have analyzed mRNA TPM data from a patient with bladder urothelial carcinoma to assess their tumor immune microenvironment and to predict responsiveness to Atezolizumab. The patient is a 7.0 TMB (mutations per megabase) white male with kidney tissue involvement. Could you please evaluate whether, based on these clinical and molecular characteristics, the patient is more likely to be a responder or a non-responder to Atezolizumab, and explain your reasoning?","I have analyzed mRNA TPM data from a patient with bladder urothelial carcinoma to assess their tumor immune microenvironment and to predict responsiveness to Atezolizumab. The patient is a 7.0 TMB (mutations per megabase) white male with kidney tissue involvement. Could you please evaluate whether, based on these clinical and molecular characteristics, the patient is more likely to be a responder or a non-responder to Atezolizumab, and explain your reasoning? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample. Begin by assessing the tumor microenvironment: quantify natural killer cell activity, evaluate markers of T-cell exhaustion, and review the B-cell profile for signs of immunosuppression. Next, examine the systemic immune response by measuring macrophage activation, probing key aspects of the interferon‑gamma signaling pathway, and screening for genomic instability. Lastly, compile your findings into a thorough report that outlines the results and discusses their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"I have analyzed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male, white individual with bladder tissue involvement and a tumor mutational burden of 1.0 mutations per megabase. Based on these data, can you provide a determination of whether the patient is predicted to be a responder or non-responder to Atezolizumab, along with a detailed rationale for the classification?","I have analyzed mRNA TPM data of the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient is a  male, white individual with bladder tissue involvement and a tumor mutational burden of 1.0 mutations per megabase. Based on these data, can you provide a determination of whether the patient is predicted to be a responder or non-responder to Atezolizumab, along with a detailed rationale for the classification? Please use the COMPASS platform to conduct a detailed transcriptomic evaluation of the tumor sample. Start by analyzing the tumor microenvironment: measure the activity of natural killer cells, assess the status of T-cell exhaustion markers, and evaluate the B-cell profile for indications of immunosuppression. Then, evaluate the systemic immune response by determining macrophage activation levels, examining key components of the interferon‑gamma signaling pathway, and assessing for genomic instability. Finally, prepare a comprehensive report that details your findings and discusses how these results might influence the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"I have mRNA TPM data profiling the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient's details are as follows:

• Sex: Male  
• Race: White  
• Tissue: Bladder  
• Disease: Bladder Urothelial Carcinoma (BLCA)  
• Tumor Mutational Burden (FMOne mutation burden per MB): Not available

Could you please assess whether this patient is likely to respond to Atezolizumab and provide a detailed explanation for the classification?","I have mRNA TPM data profiling the tumor immune microenvironment of a patient diagnosed with Bladder Urothelial Carcinoma (BLCA). The patient's details are as follows:

• Sex: Male  
• Race: White  
• Tissue: Bladder  
• Disease: Bladder Urothelial Carcinoma (BLCA)  
• Tumor Mutational Burden (FMOne mutation burden per MB): Not available

Could you please assess whether this patient is likely to respond to Atezolizumab and provide a detailed explanation for the classification? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis on the tumor sample. Begin by examining the tumor microenvironment: quantify natural killer cell activity, evaluate markers indicative of T-cell exhaustion, and profile B-cells to identify any signs of immunosuppression. Next, assess the systemic immune response by measuring macrophage activation, analyzing key components of the interferon‑gamma signaling pathway, and checking for evidence of genomic instability. Finally, compile a detailed report that outlines your findings and discusses the potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"Based on a processed mRNA TPM analysis of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (male, white, bladder tissue involvement, and a tumor mutational burden of 6.0 mutations per MB), could you determine whether this patient is more likely to respond to Atezolizumab? Please provide a conclusion (responder or non-responder) along with the supporting clinical rationale.","Based on a processed mRNA TPM analysis of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (male, white, bladder tissue involvement, and a tumor mutational burden of 6.0 mutations per MB), could you determine whether this patient is more likely to respond to Atezolizumab? Please provide a conclusion (responder or non-responder) along with the supporting clinical rationale. Using the COMPASS platform, please conduct a comprehensive transcriptomic analysis of the tumor sample. First, evaluate the tumor microenvironment by quantifying natural killer cell activity, assessing markers of T-cell exhaustion, and profiling B-cells to detect any signs of immunosuppression. Next, analyze the systemic immune response by measuring macrophage activation, investigating key components of the interferon‑gamma signaling pathway, and identifying evidence of genomic instability. Finally, prepare a detailed report that summarizes your findings and discusses their potential implications for the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"Given the processed mRNA TPM data profiling the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), what is the predicted response to Atezolizumab therapy? The patient is a white female with bladder tissue involvement and a tumor mutational burden of 3.0 mutations/MB. Based on these details, would you classify this patient as a responder or non-responder to Atezolizumab, and what is the rationale behind your assessment?","Given the processed mRNA TPM data profiling the tumor immune microenvironment in a patient with bladder urothelial carcinoma (BLCA), what is the predicted response to Atezolizumab therapy? The patient is a white female with bladder tissue involvement and a tumor mutational burden of 3.0 mutations/MB. Based on these details, would you classify this patient as a responder or non-responder to Atezolizumab, and what is the rationale behind your assessment? Please utilize the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample. Begin by assessing the tumor microenvironment: quantify natural killer cell activity, evaluate markers indicative of T-cell exhaustion, and profile B-cell populations to determine if immunosuppression is present. Next, examine the systemic immune response by measuring macrophage activation, assessing key components of the interferon‑gamma signaling pathway, and looking for signs of genomic instability. Finally, compile a detailed report summarizing your findings and discussing their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"Based on a patient's processed mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you assess whether this patient is likely to respond to Atezolizumab? The patient's key clinical details are as follows: male, White, bladder tissue sample, and a tumor mutational burden of 7.0 mutations per megabase. Please include the rationale behind your assessment.","Based on a patient's processed mRNA TPM data for the tumor immune microenvironment in Bladder Urothelial Carcinoma (BLCA), could you assess whether this patient is likely to respond to Atezolizumab? The patient's key clinical details are as follows: male, White, bladder tissue sample, and a tumor mutational burden of 7.0 mutations per megabase. Please include the rationale behind your assessment. Please use the COMPASS platform to conduct a thorough transcriptomic analysis of the tumor sample. Start by evaluating the tumor microenvironment: measure natural killer cell activity, quantify markers associated with T-cell exhaustion, and characterize B-cell populations to assess potential immunosuppression. Then, assess the systemic immune response by evaluating macrophage activation, analyzing key components of the interferon‑gamma signaling pathway, and screening for genomic instability. Finally, prepare a comprehensive report that summarizes your findings and discusses their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The patient's details are as follows: male, white, bladder tissue, with a tumor mutational burden of 14.0 FMOne mutation burden per MB. Based on these parameters, could you provide an assessment of the patient's likely responsiveness to Atezolizumab and detail the reasoning behind this prediction?","I have analyzed mRNA TPM data from a patient's tumor immune microenvironment in a case of Bladder Urothelial Carcinoma (BLCA). The patient's details are as follows: male, white, bladder tissue, with a tumor mutational burden of 14.0 FMOne mutation burden per MB. Based on these parameters, could you provide an assessment of the patient's likely responsiveness to Atezolizumab and detail the reasoning behind this prediction? Please use the COMPASS platform to perform a comprehensive transcriptomic evaluation of the tumor sample. Begin by analyzing the tumor microenvironment: assess natural killer cell activity, quantify markers indicative of T-cell exhaustion, and delineate B-cell populations to evaluate any immunosuppressive conditions. Next, evaluate the systemic immune response by determining macrophage activation status, analyzing key components of the interferon‑gamma signaling pathway, and screening for genomic instability. Finally, compile a detailed report summarizing your findings and explaining their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"Based on the mRNA TPM data of a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA) and given the following attributes (male, White, kidney tissue, tumor mutational burden of 2.0 mutations/MB), could you assess whether this patient is likely to respond to Atezolizumab? Please include the clinical rationale behind your conclusion.","Based on the mRNA TPM data of a patient's tumor immune microenvironment for bladder urothelial carcinoma (BLCA) and given the following attributes (male, White, kidney tissue, tumor mutational burden of 2.0 mutations/MB), could you assess whether this patient is likely to respond to Atezolizumab? Please include the clinical rationale behind your conclusion. Please use the COMPASS platform to conduct a detailed transcriptomic evaluation of the tumor sample. Start by examining the tumor microenvironment: assess natural killer cell activity, measure markers of T-cell exhaustion, and profile B-cell populations to identify any immunosuppressive characteristics. Then, evaluate the systemic immune response by determining macrophage activation status, analyzing key components of the interferon‑gamma signaling pathway, and screening for genomic instability. Finally, compile a thorough report that summarizes these findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"Given the processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA)—a male, White individual with bladder tissue involvement and an undetermined tumor mutational burden—can you provide an assessment of the patient's likelihood to respond to Atezolizumab? Please include the rationale supporting your conclusion.","Given the processed mRNA TPM data representing the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA)—a male, White individual with bladder tissue involvement and an undetermined tumor mutational burden—can you provide an assessment of the patient's likelihood to respond to Atezolizumab? Please include the rationale supporting your conclusion. Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample. Begin by assessing the tumor microenvironment: examine natural killer cell activity, evaluate markers of T-cell exhaustion, and characterize B-cell populations to identify any immunosuppressive features. Next, evaluate the systemic immune response by determining the activation status of macrophages, analyzing key elements of the interferon‑gamma signaling pathway, and screening for signs of genomic instability. Finally, prepare a detailed report summarizing these results and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma. The patient is a white male with lymph node involvement, and the tumor mutational burden is reported as not available (NaN). Could you please evaluate the likelihood of response to Atezolizumab, providing your assessment on whether the patient is predicted to be a responder or non-responder along with the supporting rationale?","I have processed mRNA TPM data reflecting the tumor immune microenvironment in a patient diagnosed with bladder urothelial carcinoma. The patient is a white male with lymph node involvement, and the tumor mutational burden is reported as not available (NaN). Could you please evaluate the likelihood of response to Atezolizumab, providing your assessment on whether the patient is predicted to be a responder or non-responder along with the supporting rationale? Utilize the COMPASS platform to conduct an extensive transcriptomic evaluation of the tumor sample. Start by analyzing the tumor microenvironment: assess natural killer cell activity, measure markers indicative of T-cell exhaustion, and profile B-cell populations to detect any immunosuppressive characteristics. Then, evaluate the patient's systemic immune response by determining the activation state of macrophages, analyzing critical components of the interferon‑gamma signaling pathway, and checking for signs of genomic instability. Conclude by compiling a detailed report that summarizes these findings and discusses their potential impact on the patient's treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"For a patient with Bladder Urothelial Carcinoma (BLCA), we have processed mRNA TPM data reflecting the tumor immune microenvironment. The patient is a white male with a lung tissue sample and a Tumor Mutational Burden of 1.0 FMOne mutation burden per MB. Could you assess whether, based on this data, the patient is likely to respond to Atezolizumab, and explain the reasoning behind your conclusion?","For a patient with Bladder Urothelial Carcinoma (BLCA), we have processed mRNA TPM data reflecting the tumor immune microenvironment. The patient is a white male with a lung tissue sample and a Tumor Mutational Burden of 1.0 FMOne mutation burden per MB. Could you assess whether, based on this data, the patient is likely to respond to Atezolizumab, and explain the reasoning behind your conclusion? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample as follows:

1. Begin by examining the tumor microenvironment. Specifically, assess the activity of natural killer cells, quantify markers of T-cell exhaustion, and analyze B-cell populations to identify any immunosuppressive features.

2. Next, evaluate the patient’s overall immune response. This should include determining the activation status of macrophages, investigating key elements of the interferon‑gamma signaling pathway, and screening for indications of genomic instability.

3. Finally, prepare a detailed report that summarizes your findings and explains how these results may influence the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"Considering the processed mRNA TPM data of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you assess whether this patient is predicted to respond to Atezolizumab? The patient's details are as follows: Male, White, tumor tissue from the ureter, BLCA diagnosis, and a Tumor Mutational Burden of 14.0 mutations per MB. Please provide your conclusion on responder status along with the rationale behind your assessment.","Considering the processed mRNA TPM data of the tumor immune microenvironment in a patient with Bladder Urothelial Carcinoma (BLCA), could you assess whether this patient is predicted to respond to Atezolizumab? The patient's details are as follows: Male, White, tumor tissue from the ureter, BLCA diagnosis, and a Tumor Mutational Burden of 14.0 mutations per MB. Please provide your conclusion on responder status along with the rationale behind your assessment. Please use the COMPASS platform to conduct a detailed transcriptomic evaluation of the tumor sample with the following steps:

1. Start by assessing the tumor microenvironment. This includes measuring natural killer cell activity, quantifying markers of T-cell exhaustion, and evaluating B-cell populations to identify any immunosuppressive characteristics.

2. Then, evaluate the overall immune response by determining the activation status of macrophages, analyzing key components of the interferon‑gamma signaling pathway, and screening for signs of genomic instability.

3. Finally, prepare a comprehensive report that summarizes your observations and discusses how these findings might impact the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"Given mRNA TPM data reflecting a patient’s tumor immune microenvironment, could you assess the likelihood of response to Atezolizumab in this case? The patient is a male, white individual with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 14 mutations per megabase, with tissue sampled from the kidney. Please provide your conclusion on whether the patient should be classified as a responder or non-responder, including your evidence-based reasoning.","Given mRNA TPM data reflecting a patient’s tumor immune microenvironment, could you assess the likelihood of response to Atezolizumab in this case? The patient is a male, white individual with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 14 mutations per megabase, with tissue sampled from the kidney. Please provide your conclusion on whether the patient should be classified as a responder or non-responder, including your evidence-based reasoning. Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor sample. Begin by characterizing the tumor microenvironment, which should include an assessment of natural killer cell activity, quantification of T-cell exhaustion markers, and evaluation of B-cell populations for any immunosuppressive features. Next, analyze the overall immune response by determining macrophage activation status, assessing key components of the interferon‑gamma signaling pathway, and screening for indicators of genomic instability. Finally, compile a detailed report summarizing your findings and discussing their potential impact on the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"I have processed mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma. The patient is a male, Black or African American, with bladder tissue involvement and a tumor mutational burden of 9 mutations per MB. Could you please assess whether this patient is likely to respond to Atezolizumab, providing a conclusion along with the underlying rationale?","I have processed mRNA TPM data from the tumor immune microenvironment of a patient with Bladder Urothelial Carcinoma. The patient is a male, Black or African American, with bladder tissue involvement and a tumor mutational burden of 9 mutations per MB. Could you please assess whether this patient is likely to respond to Atezolizumab, providing a conclusion along with the underlying rationale? Please use the COMPASS platform to conduct a detailed transcriptomic evaluation of the tumor sample. Start by examining the tumor microenvironment: assess natural killer cell activity, quantify markers of T-cell exhaustion, and evaluate B-cell populations for any immunosuppressive characteristics. Then, analyze the broader immune response by determining the status of macrophage activation, assessing key elements of the interferon‑gamma signaling pathway, and screening for indicators of genomic instability. Finally, compile a comprehensive report summarizing your observations and discussing how these findings might impact the patient’s treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"Based on the patient's mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma, along with the following details—Sex: Male; Race: White; Tissue: Bladder; Tumor Mutational Burden: 8.0 mutations/Mb—could you please determine whether this patient is more likely to respond to Atezolizumab and provide the supportive reasoning behind your conclusion?","Based on the patient's mRNA TPM data reflecting the tumor immune microenvironment in bladder urothelial carcinoma, along with the following details—Sex: Male; Race: White; Tissue: Bladder; Tumor Mutational Burden: 8.0 mutations/Mb—could you please determine whether this patient is more likely to respond to Atezolizumab and provide the supportive reasoning behind your conclusion? Using the COMPASS platform, please perform a comprehensive transcriptomic analysis of the tumor sample. Begin by characterizing the tumor microenvironment: assess natural killer cell activity, quantify markers indicative of T-cell exhaustion, and evaluate B-cell populations for any immunosuppressive properties. Next, expand your analysis to the broader immune response by determining the activation status of macrophages, examining key components of the interferon‑gamma signaling pathway, and screening for signs of genomic instability. After completing these assessments, prepare a detailed report that summarizes your findings and discusses the potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient’s details are: Female, White, bladder tissue specimen, a diagnosis of BLCA, and a tumor mutational burden of 7.0 mutations per megabase. Based on these attributes, could you please provide an assessment as to whether the patient is likely to respond to Atezolizumab, including the scientific rationale for your conclusion?","I have processed mRNA TPM data reflecting the tumor immune microenvironment for a patient with Bladder Urothelial Carcinoma (BLCA). The patient’s details are: Female, White, bladder tissue specimen, a diagnosis of BLCA, and a tumor mutational burden of 7.0 mutations per megabase. Based on these attributes, could you please provide an assessment as to whether the patient is likely to respond to Atezolizumab, including the scientific rationale for your conclusion? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor sample. Start by evaluating the tumor microenvironment: measure natural killer cell activity, quantify markers associated with T-cell exhaustion, and assess B-cell populations for any immunosuppressive traits. Then, extend your analysis to the broader immune response by assessing macrophage activation, examining key elements of the interferon‑gamma signaling pathway, and checking for genomic instability. Finally, compile a comprehensive report that summarizes your findings and outlines their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"I have processed mRNA TPM data from a patient with bladder urothelial carcinoma and would like to evaluate the predicted responsiveness to Atezolizumab. The patient is a 4.0 mutations/MB TMB, female of Asian descent, with a tumor located in the kidney and a confirmed diagnosis of BLCA. Based on this data, can you determine whether the patient is likely to be classified as a responder or non-responder to Atezolizumab, and provide the rationale for your conclusion?","I have processed mRNA TPM data from a patient with bladder urothelial carcinoma and would like to evaluate the predicted responsiveness to Atezolizumab. The patient is a 4.0 mutations/MB TMB, female of Asian descent, with a tumor located in the kidney and a confirmed diagnosis of BLCA. Based on this data, can you determine whether the patient is likely to be classified as a responder or non-responder to Atezolizumab, and provide the rationale for your conclusion? Kindly use the COMPASS platform to perform an in-depth transcriptomic analysis on the provided tumor sample. Begin by evaluating the tumor microenvironment: determine natural killer cell activity, quantify markers indicative of T-cell exhaustion, and assess B-cell populations for immunosuppressive characteristics. Next, broaden your assessment to include the overall immune response by examining macrophage activation, analyzing significant aspects of interferon‑gamma signaling, and detecting any signs of genomic instability. Please consolidate your findings into a comprehensive report that details these observations and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"I have analyzed mRNA TPM expression data profiling the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male, with the tumor sampled from the kidney, and exhibits a Tumor Mutational Burden of 7.0 mutations per megabase. Based on these details, how should we interpret his potential response to Atezolizumab, and what evidence supports classifying him as a likely responder or non-responder?","I have analyzed mRNA TPM expression data profiling the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male, with the tumor sampled from the kidney, and exhibits a Tumor Mutational Burden of 7.0 mutations per megabase. Based on these details, how should we interpret his potential response to Atezolizumab, and what evidence supports classifying him as a likely responder or non-responder? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the provided tumor sample. Start by examining the tumor microenvironment: assess natural killer cell function, quantify markers associated with T-cell exhaustion, and characterize the B-cell populations for signs of immunosuppressive behavior. Then, evaluate the overall immune response by analyzing macrophage activation, reviewing key aspects of interferon‑gamma signaling, and identifying any indicators of genomic instability. Finally, consolidate your results into a detailed report that outlines these observations and discusses their potential implications for the patient’s treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"Based on processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma, could you determine whether this patient—a white male with bladder tissue involvement and an unreported tumor mutational burden—is more likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale.","Based on processed mRNA TPM data from a patient with Bladder Urothelial Carcinoma, could you determine whether this patient—a white male with bladder tissue involvement and an unreported tumor mutational burden—is more likely to respond to Atezolizumab? Please provide your conclusion along with the supporting rationale. Using the COMPASS platform, please perform a detailed transcriptomic analysis of the provided tumor sample. Begin with an assessment of the tumor microenvironment: evaluate natural killer cell activity, measure markers of T-cell exhaustion, and analyze B-cell populations for any immunosuppressive traits. Next, assess the overall immune response by examining macrophage activation, key components of interferon‑gamma signaling, and any signs of genomic instability. Finally, compile your findings into a comprehensive report that outlines these observations and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male, with tumor tissue from the bladder, and exhibits a tumor mutational burden of 5.0 mutations per megabase. Could you please evaluate whether this patient is likely to respond to Atezolizumab, and explain the reasoning behind your assessment?","I have processed mRNA TPM data reflecting the tumor immune microenvironment of a patient diagnosed with bladder urothelial carcinoma (BLCA). The patient is a white male, with tumor tissue from the bladder, and exhibits a tumor mutational burden of 5.0 mutations per megabase. Could you please evaluate whether this patient is likely to respond to Atezolizumab, and explain the reasoning behind your assessment? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the provided tumor sample. Start by evaluating the tumor microenvironment: assess natural killer cell activity, quantify markers of T-cell exhaustion, and analyze B-cell populations for potential immunosuppressive features. Next, examine the overall immune response by evaluating macrophage activation, key elements of the interferon‑gamma signaling pathway, and any evidence of genomic instability. Finally, compile your results into a detailed report that discusses these findings and their possible implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"For a patient with bladder urothelial carcinoma whose mRNA TPM data indicate specific characteristics of the tumor immune microenvironment (Sex: F, Race: WHITE, Tissue: bladder, Tumor Mutational Burden: 7.0 mutations/MB), could you evaluate the likelihood of response to Atezolizumab and provide a rationale based on these parameters?","For a patient with bladder urothelial carcinoma whose mRNA TPM data indicate specific characteristics of the tumor immune microenvironment (Sex: F, Race: WHITE, Tissue: bladder, Tumor Mutational Burden: 7.0 mutations/MB), could you evaluate the likelihood of response to Atezolizumab and provide a rationale based on these parameters? Use the COMPASS platform to perform a comprehensive examination of the transcriptome from the tumor sample provided. Begin by assessing the tumor microenvironment: evaluate natural killer cell activity, quantify markers that indicate T-cell exhaustion, and analyze B-cell populations to identify any features of immunosuppression. Next, assess the overall immune response by examining macrophage activation and key components of the interferon‑gamma signaling pathway, as well as any signs of genomic instability. Conclude your analysis by preparing a detailed report that summarizes these findings and discusses their potential impact on the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"How might the patient's tumor immune microenvironment, as reflected by processed mRNA TPM data, inform the predicted response to Atezolizumab in the context of Bladder Urothelial Carcinoma? The patient's details are as follows: male, White, tissue type specified as ""other,"" with a tumor mutational burden of 10 mutations per megabase. Based on these attributes, could you determine whether the patient is more likely to respond to Atezolizumab, and please explain the reasoning behind this assessment?","How might the patient's tumor immune microenvironment, as reflected by processed mRNA TPM data, inform the predicted response to Atezolizumab in the context of Bladder Urothelial Carcinoma? The patient's details are as follows: male, White, tissue type specified as ""other,"" with a tumor mutational burden of 10 mutations per megabase. Based on these attributes, could you determine whether the patient is more likely to respond to Atezolizumab, and please explain the reasoning behind this assessment? Please use the COMPASS platform to conduct an in‐depth transcriptomic analysis of the provided tumor sample. Start by examining the tumor microenvironment by evaluating natural killer cell activity, quantifying markers of T‐cell exhaustion, and analyzing B‐cell populations for signs of immunosuppression. Then, assess the broader immune response by examining macrophage activation, key elements of the interferon‑gamma signaling pathway, and any evidence of genomic instability. Finally, prepare a detailed report summarizing your findings and discussing their potential implications for the patient’s treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ffa5c7-ar-ffa5c7c.pkl. "
